

Georgina V. Long AO

Melanoma Institute Australia and The University of Sydney
40 Rocklands Road, North Sydney NSW 2060
+61 2 9911 7336 | georgina.long@sydney.edu.au

PROFILE

Professor Georgina Long AO, BSc (Hons1, UM) PhD MBBS (Hons) FRACP FAHMS, is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance. In recognition of her ground-breaking research and work, Professor Long was recognized with the Australian Academy of Health and Medical Sciences Outstanding Female Research Medal 2021 and was appointed as an Officer of the Order of Australia (2020) and has received numerous awards, including Sydney Local Health District/Sydney Research 2022 Research Excellence Award (2022) the prestigious Ramaciotti Medal for Biomedical Research (2021), Vice Chancellor's Award for Excellence Award for Outstanding Research (2021), Research Australia GSK Research Excellence Award (2018) and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016). She has a number of CINSW Premiers Awards, including; the Outstanding Cancer Researcher (2018), the Excellence in Translational Cancer Research Award (2017), the Wildfire Award for the most highly-cited, original, peer-reviewed article published (2011, 2014, 2016, 2017, 2018, 2019 & 2020), and in 2013 she was named the Outstanding Cancer Research Fellow. She is also Clarivate highly-cited Researcher for 2017-2022. Her H index is 127 and in February 2023 she was ranked the world's 1st melanoma expert in all fields and discipline (<http://expertscape.com/ex/melanoma>)

Professor Long is the author of over 458 peer-reviewed publications in clinical and translational research in melanoma, including the New England Journal of Medicine, Lancet, Lancet Oncology, Science, Nature, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 200 occasions. She is Past President for the prestigious international Society for Melanoma Research (2018-2020), is a member and Chair of the ASCO (2015-2017) and ESMO (2017-2020) Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, and is member of both the ASCO Plenary Series and ASCO AGM Education committees (2021-2024) she is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.

AWARDS AND DISTINCTIONS

The Australian Newspaper – Research Magazine's Top 250 researchers – Oncology	2022
Clarivate Analytics 2022 – Highly Cited Researcher – Clinical Medicine	2022
Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2019	2022
Gide TN, Quek C (Awardee Tuba Nur Gide – 1 st Author) et al, Cancer Cell 2019, 35 238-255	
Sydney Local Health District/Sydney Research 2022 Research Excellence Award	2022
Co-awardees Professor Richard Scolyer & Assoc Professor Alexander Menzies in recognition	

of the best publication in a high impact journal for “Menziess, A.M., et al. Nat Med 27, 301–309 (2021)

Ramaciotti Medal for Excellence in Biomedical Research	2021
Vice Chancellor’s Award for Excellence Award for Outstanding Research, University of Sydney	2021
Co-awardee Professor Richard Scolyer	
Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2018	2021
Long GV, Scolyer RA, Menziess AM, et al, Lancet Oncology 2018, (5):672–to 681	
The Australian Newspaper – Research Magazine’s Top 250 researchers – Oncology	2021
AAHMS 2021 Medal for Outstanding Female Researcher	2021
Clarivate Analytics 2021 – Highly Cited Researcher – Clinical Medicine	2021
Clarivate Analytics 2020 – Highly Cited Researcher – Clinical Medicine	2020
Order of Australia	2020
Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2017	2020
Hayward NK, Wilmott JW (Awardee J Wilmott – snr author) et al, Nature 2017, 545(7653):175-180	
The Australian Newspaper – 2019 Research Magazine Named as Field Leader (Oncology)	2019
Clarivate Analytics 2019 Highly Cited Researcher – Clinical Medicine	2019
Australian Financial Review – 100 Women of Influence Award Finalist	2019
Clarivate Analytics 2018 Highly Cited Researcher – Clinical Medicine	2018
GSK Award for Research Excellence, Research Australia Health & Medical Research Awards	2018
Co-awardee Professor Richard Scolyer	
Cancer Institute NSW Premiers Awards: Outstanding Cancer Researcher of the Year	2018
Clarivate Analytics 2017 Highly Cited Researcher – Clinical Medicine	2017
Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2014	2017
Rizos H, Long GV (Awardee H Rizos – senior author) et al, Clinical Cancer Res 2014, 20(7): 1965–1977	
Cancer Institute NSW Premiers Awards: Excellence in Translational Cancer Research Award	2017
Co-awardees Professor Richard Scolyer and the Melanoma Institute Australia Translational Team	
Fellowship of the Australian Academy of Health and Medical Sciences	2017
Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2013	2016
Long GV, Wilmott JS (Awardee JSW - shared 1 st authorship) et al, Am J Surg Pathol 2013, 37:61.	
Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research	2016
For extensive contributions to the field of melanoma research and clinical services	
Society for Melanoma Research, Young Investigator Award	2016
Society for Melanoma Research 2015 International Congress, 18-21 November, San Francisco, USA	
Amgen Australia, Award for the Best Consultant Poster, Medical Oncology Group of	2015
Australia’s Annual Scientific Meeting in Hobart	
Thomson Reuters Citation and Innovation Award for Outstanding Research	2015
For research in BRAF-mutated melanoma. Co-awardees Professor Richard Scolyer, Professor Richard Kefford, Professor Grant McArthur	

INSTYLE award for Women in Science and Technology	2015
Finalist, Pride of Australia Award for contribution to the community (Telegraph Newspaper)	2015
Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2011	2014
Long GV et al J Clin Oncol 2011, 29:1239-46	
Top 5 most highly cited article 2012 for Clinical Cancer Research (IF 7.837)	2014
Long GV, Wilmott J (shared first authorship) Clin Can Res, 2012, 18:1386-94	
Top 50 most highly cited article 2011 for Journal Clinical Oncology (IF18.97)	2013
Long GV et al J Clin Oncol 2011, 29:1239-46	
Cancer Institute NSW Premiers award for Outstanding Cancer Research Fellow	2013
Nominated for Australian of the Year 2013	2013
Sir Roy McCaughey Fellowship, RACP	2013
Melanoma Research Alliance Young Investigator	2013-2016
Marjorie Hooper Scholarship, RACP	2012
Best published manuscript, Westmead Millennium Institute	2011
Development Fellowship, Cancer Institute NSW	2011
Career Development Grant, Cancer Institute NSW	2011
Australia Post Melanoma Fellowship, Cancer Institute NSW	2010
Cancer Institute NSW, Conference Grant	2010
ANZATAX, Advanced Trainee Travel Grant	2007
Amgen Australia, Advanced Trainee Grant, for best oral presentation MOGA	2006
DK Baird Bicentennial Travelling Fellowship, Royal Prince Alfred Hospital	2006
Esma May Harris Scholarship, Sydney University	1998, 1999
J B Watt Travelling Scholarship, Sydney University	1996, 1997
C G and R J W Le Fevre Postgraduate Student Lecture, Sydney University	1995
George Harris Postgraduate Prize, Sydney University	1995
James Kentley Memorial Scholarship, Sydney University	1994
G H S and I R Lightoller Scholarship, Sydney University	1994
R J W Le Fevre Travelling Scholarship, Sydney University	1994
Henry Bertie Florence Mable Gritton Postgraduate Scholarship	1993-1996
Australian Post Graduate Research Award, Sydney University	1993
University Medal for Organic Chemistry, Sydney University	1992
Janet Elspeth Crawford Prize, Chemistry, Sydney University	1992
Inglis Hudson Scholarship (major), Chemistry, Sydney University	1991
Vacation Scholarship, Research School of Chemistry, ANU,	1991-1992
Prof. D Evans – Molecular Dynamics	

MAJOR GRANTS AWARDED

Funding	Project title	Role	Start	End	Amount (AUD)
NHMRC Ideas Grant APP2020569	Liver metastases: a niche of resistance and of therapeutic opportunities for all cancers	AI	01.01.2023	31.12.2026	\$852,280.00
NHMRC Clinical Trials and Cohorts Studies Grant APP2023996	A Phase II, open label, single arm clinical trial of neoadjuvant nivolumab and ipilimumab in stage I to III resectable merkel cell carcinoma	CI	01.01.2023	31.12.2028	\$2,053,040.00
NHMRC MRFF Early to Mid-Career Researchers Grant APP2022808	Unveiling organ-specific mechanisms of resistance to standard immunotherapy in melanoma and matching optimal drug therapy for these resistant patients	AI	01.01.2023	31.12.2025	\$783,935.00
Sydney Cancer Partners	Identifying the immune populations driving response to immune checkpoint blockade therapies	CI	15.04.2023	15.04.2024	\$116,000.00
Department of Defense W81XWH-22-1-0732	Multimodal Precision Liquid Biopsy to Predict Risk of Melanoma Recurrence	PI	01.09.2022	30.09.2025	\$769,864.00 (USD)
The University of Sydney Equipment Grant	PAVONE - transformative, automated high-throughput testing platform for nanomedicine, mechanopharmacology, mechanobiology, and precision medicine		01.06.2022	31.12.2022	\$217,115.00
NHMRC Ideas Grant APP2012860	Restoring Anti-Tumour Immunity in Melanoma	AI	01.01.2022	31.12.2025	\$1,134,001.00
Cancer Institute NSW APP2021/TPG2114	Personalised Immunotherapy Program - Precision immunotherapies for multiple solid tumours using a biomarker driven adaptive enrichment clinical trials platform	CI	01.01.2022	31.12.2026	\$3,748,551.00
Cancer Institute NSW Premiers Award	Wildfire Award, most cited article published in 2018		01.01.2021	31.12.2021	\$10,000.00
NHMRC Investigator Grant APP2007839	Towards Zero Deaths from Melanoma Innovative Clinical Trials with -Multi-omics Analysis	CI	01.01.2022	31.12.2026	\$3,927,015.00

Funding	Project title	Role	Start	End	Amount (AUD)
NHMRC Project Grant APP2009057	Integrated Multimodel precision liquid biopsy to enhance melanoma and NSCLC Treatment (IMPLEMENT)	CID	01.06.2021	31.05.2025	\$2,031,178.80
NHMRC Project Grant APP2007157	NADINA Phase 3 trial comparing response driven neo-adjuvant combination of ipilimumab + nivolumab versus adjuvant nivolumab	CIA	01.06.2021	31.05.2025	\$2,023,376.40
NHMRC Project Grant APP2006415	Anti-PD 1 Brain Collaboration + Radiotherapy Extension: The ABC-X Study	CIA	01.07.2021	30.06.2026	\$1,010,141.60
Friends of the Mater Foundation		CI	01.01.2021	31.12.2021	\$80,000.00
Investigator-led trial grant NCT04207086	Merck Sharpe & Dohme A Phase II study of Neoadjuvant Pembrolizumab & Lenvatinib for resectable Stage III Melanoma (NeoPele)	CI	01.01.2020	31.12.2025	\$635,937.60
MRFF International Clinical Trial Collaborations grant program 2019 MRFF MRF1192497	Circulating Tumours DNA guided therapy for Stage IIB/C BRAF mutant positive melanoma after surgical resection (Detection)	CI	01.06.2020	30.11.2025	\$3,230,670.00
USYD & NHMRC Equipment Grant	Economic and versatile singe-cell preparation system for shared use, in the Multi-Disciplinary Sydney Cytometry Faculty, from Cancer to COVID-19	CI	01.01.2020	31.12.2020	\$55,000.00
Tour de Cure	Improving survival in melanoma by matching optimal drug therapy for individual patients	CI	01.01.2019	31.12.2019	\$199,526.00
Bristol-Myers Squibb Investigator-led Trial Grant	Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X)	CI	01.01.2019	31.12.2024	\$2,400,000
Cancer Institute NSW Premiers Awards	Outstanding Cancer Researcher of the Year	CI	01.01.2018	31.12.2018	\$60,000.00
NHMRC Project Grant	A randomized Phase III study of the duration of the Anti PD-1 – therapy in metastatic melanoma (STOP-GAP)	CI	01.01.2018	31.12.2023	\$2,276,726.60

Funding	Project title	Role	Start	End	Amount (AUD)
The Council of the Queensland Institute of Medical Research	Overcoming resistance to cancer immunotherapy by targeting MET-signalling in Neutrophils		01.01.2018	31.12.2020	\$447,375.00
The Council of the Queensland Institute of Medical Research	Immunotherapy in cancer and virus infection		01.01.2018	31.12.2022	\$9,312,735.00
GSK Award	GSK Award for Research Excellence (co-awardee Richard Scolyer)	CI	01.01.2018	31.12.2018	\$80,000.00
NHMRC Program Grant	Melanotransferrin: A “missing link” and a novel pharmacological target for treatment		01.01.2018	31.12.2022	\$613,848.00
NHMRC Project Grant	Acquired resistance to PD1 inhibition in melanoma		01.01.2017	31.12.2021	\$986,348.00
Cancer Institute NSW Premiers Award	Wildfire Award, most cited article published in 2014		01.01.2017	31.12.2017	\$20,000.00
NHMRC	Centre of Research Excellence in Melanoma: person, tumour and system-focused knowledge to drive better outcomes in melanoma		01.11.2017	31.10.2022	\$2,486,945.00
Merck Sharpe Dohme Investigator-led Trial Grant	Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF mutant resectable Stage III Melanoma (NeoTrio)	CI	01.01.2017	31.12.2022	\$1,301,730.00
USYD & NHRMC Equipment Grant	Dolomite Bio Single Cell RNAseq system	CI	01.01.2017	31.12.2022	\$138,000.00
The Council of the Queensland Institute of Medical Research	Towards better treatments for acral melanoma through function genomics	CI	01.01.2017	31.12.2020	\$1,456,823.00
NHMRC Practitioner Fellowship Grant	Development of systemic therapies to improve response and prevent resistance in the treatment of Melanoma	CI	01.01.2017	31.12.2021	\$569,219.00
NHMRC Project Grant	Determinants of response to immune checkpoint inhibitors in melanoma	CI	01.01.2017	31.12.2020	\$1,021,486.50
	The combination of CDK4 and MAPK-ERK pathway inhibitor therapy in Melanoma: defining		01.01.2016	31.12.2019	\$824,288.00

Funding	Project title	Role	Start	End	Amount (AUD)
	melanoma cell intrinsic and immune mediated responses				
NHMRC Program Grant	Molecular determinants of risk, progression and treatment response in melanoma	Co-PI	01.01.2016	31.12.2021	\$14,663,120.00
Sir Zelman Cowan Universities Fund Prize for Discovery in Medical Research	Prize for Discovery in Medical Research		01.01.2006	31.12.2006	\$20,000.00
NHMRC Equipment Grant	NanoString Counter SPRINT Profiler System for Shared Use in the Open Access, Multi-User, Bosch Molecular Biology Facility		2016		\$199,000.00
NHMRC Project Grant	Alpha-actinin-4 as an ocogenic driver and therapeutic target in melanoma		01.01.2016	31.12.2019	\$401,786.40
CINSW Equipment Grant	Biacore T200 Molecular interaction analysis system for the open access, multi-disciplinary Sydney Cancer Research Core Facility		01.01.2015	31.12.2017	\$354,048.00
NHMRC Project Grant	Significance of soluble PD-L1 in melanoma patients	CI	01.03.2015	28.02.2019	\$542,974.00
Cancer Research Institute Clinical Trial Team Grant	Targeting adenosine in the tumour microenvironment	CI	01.01.2015	31.12.2015	\$15,050.00
CINSW Research Infrastructure Grant	Advanced Technical Support for the open access, multi-disciplinary Sydney Cancer Research Core Facility		01.01.2016	31.12.2018	\$272,876.00
NSW Government Health, Office for Health and Medical Research Genomics Collaborative Grants Program	Genetic factors in outcome of new therapies for metastatic melanoma	CI	01.01.2015	31.12.2015	\$811,150.00
Society for Melanoma Research	Young Investigator Award		01.01.2015	31.12.2015	\$5,000.00
USYD Collaborative Research Equipment Grant	Automated high throughput hypoxic live cell imaging system for shared use in open access, multi-user Bosch, Blackburn Molecular Biology Facility	AI	01.01.2014	31.12.2014	\$170,573.00

Funding	Project title	Role	Start	End	Amount (AUD)
Novartis – Investigator-led trial grant	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 Mutation positive melanoma: a single arm, open label single-centre phase 2 trial (Neocombi)	CI	01.01.2014		\$981,755.00
Cancer Institute NSW Premier's Award	Wildfire Award		01.01.2014	31.12.2014	\$20,000.00
Bristol-Myers Squibb Investigator-led Trial Grant	Anti-PD1 Brain Collaboration for patients with Melanoma Brain Metastases (ABC)	CI	01.01.2014		\$1,876,980.00
NHMRC	MAPK reactivation drives melanoma resistance to MAPK inhibition		01.01.2014	31.12.2016	\$720,558.00
Melanoma Research Alliance Award	Targeting BRAF-mutant melanoma brain metastases		01.06.2013	31.05.2018	USD\$900,000.00
Cancer Institute NSW	Premier's award for Outstanding Cancer Research Fellow		01.01.2013	31.12.2013	\$20,000.00
Sir Roy McCaughey Fellowship RACP	Enhancing response to MAP kinase inhibition in melanoma		01.01.2013	31.12.2013	\$75,000.00
Marjorie Hooper Scholarship RACP	Mechanisms of Response and Resistance to Targeted Drugs in Melanoma		01.01.2012	31.12.2012	\$20,000.00
Cancer Institute NSW, Career Development Grant	Determining mechanisms of resistance and heterogeneity of response to novel targeted drugs in metastatic melanoma to improve survival and prevent metastatic disease		01.01.2011	31.12.2014	\$599,895.00
ACRF	Completion and expansion of the ACRF Melanoma Research Laboratories at Westmead Millennium Institute for Cancer Research		01.01.2011	31.12.2011	\$5,000,000.00
NHMRC Project Grant	Manipulating the MAPK pathway in Melanoma		01.01.2011	31.12.2013	\$543,390.00
NHMRC Project Grant	Manipulating the B-RAF/MEK pathway in the genesis and treatment of melanoma		01.01.2011	31.12.2013	\$652,815.75

Funding	Project title	Role	Start	End	Amount (AUD)
Cancer Institute NSW	Clinical and biomarker correlates of melanoma chemosensitivity		01.01.2009	31.12.2009	\$174,852.00
Australia Post, Medical Research Fellowship RACP	Clinical and biomarker correlates of melanoma chemosensitivity and epidemiological studies of outcomes in Stage IV melanoma		01.01.2009	30.12.2010	\$100,000.00
Scripps Research Institute	Fulbright Postdoctoral Fellow Award		01.01.1996	31.12.1996	\$25,000.00
British Ramsay Fellowship	Offer declined		01.01.1995	31.12.1998	
Australian Postgraduate Research Award			01.01.1993	31.12.1996	\$60,000.00

PUBLICATIONS (Key Contributions to Field Bolded)

- Reijers ILM*, Rao D*, Versluis JM, Menzies AM, Dimitriadis P, Wouters MW, Spillane AJ, Klop WMC, Broeks A, Bosch LJW, Lopez-Yurda M, van Houdt WJ, Rawson RV, Griepink-Ongering LG, Gonzalez M, Cornelissen S, Bouwman J, Sanders J, Plasmeijer E, Elshot YS, Scolyer RA, van de Wiel BA, Peeper DS, van Akkooi ACJ, **Long GV**, Blank CU, IFN- γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma, *J Exp Med*. **2023 May 1**; 220(5):e20221952. doi: 10.1084/jem.20221952. Epub 2023 Mar 15. PMID 36920329
- Hoefsmit, E. P., Vollmy, F., Rozeman, E. A., Reijers, I. L. M., Versluis, J. M., Hoekman, L., van Akkooi, A.C. J., **Long, G. V.**, Schadendorf, D., Dummer, R., Altelaar, M., Blank, C. U., Systemic LRG1 expression in melanoma is associated with disease progression and recurrence, *Cancer Res Commun*. **2023 Apr 20**;3(4):672-683. doi: 10.1158/2767-9764.CRC-23-0015. eCollection 2023 Apr. PMID 37089863
- Mao, Y., Gide, T. N., Adegoke, N. A., Quek, C., Maher, N., Potter, A., Patrick, E., Saw, R. P. M., Thompson, J. F., Spillane, A. J., Shannon, K. F., Carlino, M. S., Lo, S. N., Menzies, A. M., da Silva, I. P., **Long, G. V.**, Scolyer, R. A., Wilmott, J. S., Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach, *J Transl Med*. **2023 Apr 13**;21(1):257. doi: 10.1186/s12967-023-04092-9. PMID 37055772
- Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, Eriksson H, Klop WMC, Ch'ng S, van Thienen JV, Mallo H, Gonzalez M, Torres Acosta A, Griepink-Ongering LG, van der Wal A, Bruining A, van de Wiel BA, Scolyer RA, Haanen JBAG, Schumacher TN, van Akkooi ACJ, **Long GV**, Blank CU, Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials, *Ann Oncol*. **2023 Apr**;34(4):420-430. doi: 10.1016/j.annonc.2023.01.004. Epub 2023 Jan 18. PMID 36681299
- Lai-Kwon, J., Jacques, S., Carlino, M., Benannoune, N., Robert, C., Allayous, C., Baroudjian, B., Lebbe, C., Zimmer, L., Eroglu, Z., Topcu, T. O., Dimitriou, F., Haydon, A., Lo, S. N., Menzies, A. M., **Long, G. V.**, Efficacy of ipilimumab 3mg/kg following progression on low dose ipilimumab in metastatic melanoma, *Eur J Cancer*. **2023 Mar 11**;186:12-21. doi: 10.1016/j.ejca.2023.03.006. Online ahead of print. PMID 37018924
- Lim, S. Y., Shklovskaya, E., Lee, J. H., Pedersen, B., Stewart, A., Ming, Z., Irvine, M., Shivalingam, B., Saw, R. P. M., Menzies, A. M., Carlino, M. S., Scolyer, R. A., **Long, G. V.**, Rizos, H., The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma, *Nat Commun*. **2023 Mar 18**;14(1):1516. doi: 10.1038/s41467-023-36979-y. PMID 36934113

7. Park, B. C., Narayanan, S., Gavraldis, A., Ye, F., Fan, R., Sullivan, R. J., Boland, G., Reynolds, K. L., Balko, J. M., Carlino, M. S., **Long, G. V.**, Zubiri, L., Menzies, A. M., Johnson, D. B., Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations, *Oncoimmunology*. **2023 Mar 8**;12(1):2188719. doi: 10.1080/2162402X.2023.2188719. eCollection 2023. PMID 36926262
8. Ascierto, P. A., Lipson, E. J., Dummer, R., Larkin, J., **Long, G. V.**, Sanborn, R. E., Chiarion-Sileni, V., Dreno, B., Dalle, S., Schadendorf, D., Callahan, M. K., Nyakas, M., Atkinson, V., Gomez-Roca, C. A., Yamazaki, N., Tawbi, H. A., Sarkis, N., Warad, D., Dolfi, S., Mitra, P., Suryawanshi, S., Grob, J. J., Nivolumab and Relatlimab In Patients With Advanced Melanoma Who Had Prior Pd-1/Pd-L1 Therapy: Results From The Phase 1/2 Relativity-020 Trial, *J Clin Oncol*. **2023 Feb 13**;jco2202072. doi: 10.1200/JCO.22.02072. Online ahead of print. PMID 36780608
9. Wilmott, J. S., Tawbi, H., Engh, J. A., Amankulor, N. M., Shivalingam, B., Banerjee, H., Vergara, I. A., Lee, H., Johansson, P. A., Ferguson, P. M., Saiag, P., Robert, C., Grob, J. J., Butterfield, L. H., Scolyer, R. A., Kirkwood, J. M., **Long, G. V.**, Davies, M. A., Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases, *Clin Cancer Res*. **2023 Feb 1**;29(3):521-531. doi: 10.1158/1078-0432.CCR-22-2581, PMID 36477181
10. Wepler, A. M., Da Meda, L., Pires da Silva, I., Xu, W., Grignani, G., Menzies, A. M., Carlino, M. S., **Long, G. V.**, Lo, S. N., Nordman, I., Steer, C. B., Lyle, M., Trojaniello, C., Ascierto, P. A., Lebbe, C., Sandhu, S., Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation, *Eur J Cancer*. **2023 Jan 30**;183:109-118. doi: 10.1016/j.ejca.2023.01.016. Online ahead of print. PMID 36842413
11. Sandhu, S., Atkinson, V., Cao, M. G., Medina, T., Rivas, A. S., Menzies, A. M., Caro, I., Roberts, L., Song, Y., Yan, Y., Guo, Y., Xue, C., **Long, G. V.**, Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy, *Eur J Cancer*. **2023 Jan**;17 8:180-190. doi: 10.1016/j.ejca.2022.10.019. Epub 2022 Nov 2. PMID 36455412
12. Vergara, I. A., Aivazian, K., Carlino, M. S., Guminski, A. D., Maher, N. G., Shannon, K. F., Ch'ng, S., Saw, R. P. M., **Long, G. V.**, Wilmott, J. S., Scolyer, R. A., Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets, *Mod Pathol*. **2023 Jan 10**;36(4):100099. doi: 10.1016/j.modpat.2023.100099. Online ahead of print. PMID 36788083
13. Wong, S. K., Blum, S. M., Sun, X., Da Silva, I. P., Zubiri, L., Ye, F., Bai, K., Zhang, K., Ugurel, S., Zimmer L., Livingstone, E., Schadendorf, D., Serra-Bellver, P., Munoz-Couselo, E., Ortiz, C., Lostes, J., Huertas, R. M., Arance, A., Pickering, L., **Long, G. V.**, Carlino, M. S., Buchbinder, E. I., Vazquez-Cortes, L., Jara-Casas, D., Marquez-Rodas, I., Gonzalez-Espinoza, I. R., Balko, J. M., Menzies, A. M., Sullivan, R. J., Johnson, D. B., Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma, *Eur J Cancer*. **2022 Dec 27**;181:188-197. doi: 10.1016/j.ejca.2022.12.013. Online ahead of print. PMID 36680880
14. Smith, J. L., Menzies, A. M., Cohen, J. V., Mut-Lloret, M., Ozgun, A., Spain, L., Park, J., Quach, H. T., Pallan L., McQuade, J., Feng, S., Sandhu, S., Atkinson, V., Tsai, K., **Long, G. V.**, Larkin, J., Eroglu, Z., Johnson, D. B., Sullivan, R., Herkes, G. K., Henderson, A., Carlino, M. S., Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series, *Melanoma Res*. **2022 Dec 1**; 32(6):451-459. doi: 10.1097/CMR.0000000000000825. Epub 2022 Sep 23. PMID 36164923
15. Lai-Kwon, J., Kelly, B., Lane, S., Biviano, R., Bartula, I., Brennan, F., Kivikoski, I., Thompson, J., Dhillon, H. M., Menzies, A., **Long, G. V.**, Feasibility, acceptability and utility of a pilot nurse-led survivorship program for people with metastatic melanoma (MELCARE), *Support Care Cancer*. **2022 Nov**;30 (11):9587-9596. doi: 10.1007/s00520-022-07360-4. Epub 2022 Sep 22. PMID 36136246
16. Conway, J. W., Braden, J., Wilmott, J. S., Scolyer, R. A., **Long, G. V.**, Pires da Silva, I., The effect of organ-specific tumor microenvironments on response patterns to immunotherapy, *Front Immunol*. **2022 Nov 17**; 13:1030147. doi: 10.3389/fimmu.2022.1030147. eCollection 2022. PMID 36466910
17. Lee, J., Ahmed, T., Maurichi, A., Di Guardo, L., Stagno, A. M., Warburton, L., Taylor, A. M., Livingstone, E., Rehman, S., Khattak, A., Kahler, K. C., Vanella, V., Atkinson, V., Millward, M., Schadendorf, D., Johnson, D. B., Ascierto, P. A., Hauschild, A., Lo, S. N., **Long, G. V.**, Menzies, A. M., Carlino, M. S., BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-

- term outcomes, *Eur J Cancer*. **2022 Nov 12**; 179:87-97. doi: 10.1016/j.ejca.2022.11.009. Online ahead of print. PMID 35609002
18. Paver, E., Aivazian, K., Maclean, F., **Long, G. V.**, Spillane, A. J., Wilmott, J. S., Scolyer, R. A., Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma, *Pathology*. **2022 Oct 29**; S0031-3025(22)00277-X. doi: 10.1016/j.pathol.2022.08.011. Online ahead of print. PMID 36400594
 19. Meric-Bernstam, F., Sweis, R. F., Kasper, S., Hamid, O., Bhatia, S., Dummer, R., Stradella, A., **Long, G. V.**, Spreafico, A., Shimizu, T., Steeghs, N., Luke, J. J., McWhirter, S. M., Muller, T., Nair, N., Lewis, N., Chen, X., Bean, A., Kattenhorn, L., Pelletier, M., Sandhu, S., Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study, *Clin Cancer Res*. **2022 Oct 25**; CCR-22-2235. doi: 10.1158/1078-0432.CCR-22-2235. Online ahead of print. PMID 36285874
 20. Serra-Bellver, P., Versluis, J. M., Oberoi, H. K., Zhou, C., Slattery, T. D., Khan, Y., Patrinely, J. R., Pires da Silva, I., Martinez-Vila, C., Cook, N., Graham, D. M., Carlino, M. S., Menzies, A. M., Arance, A. M., Johnson, D. B., **Long, G. V.**, Pickering, L., Larkin, J. M. G., Blank, C. U., Lorigan, P., Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study, *Eur J Cancer*. **2022 Oct 7**; 176:121-132. doi: 10.1016/j.ejca.2022.09.004. Online ahead of print. PMID 36215945
 21. Shteinman, E. R., Wilmott, J. S., da Silva, I. P., **Long, G. V.**, Scolyer, R. A., Vergara, I. A., Causes, consequences and clinical significance of aneuploidy across melanoma subtypes, *Front Oncol*. **2022 Oct 6**; 12:988691. doi: 10.3389/fonc.2022.988691. eCollection 2022. PMID 36276131
 22. Moschos, S. J., Sandhu, S., Lewis, K. D., Sullivan, R. J., Puzanov, I., Johnson, D. B., Henary, H. A., Wong, H., Upreti, V. V., **Long, G. V.**, Flaherty, K. T., Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study, *Invest New Drugs*. **2022 Oct**; 40(5):1051-1065. doi: 10.1007/s10637-022-01253-3. Epub 2022 May 30. PMID 35635631
 23. Shklovskaya, E., Pedersen, B., Stewart, A., Simpson, J. O. G., Ming, Z., Irvine, M., Scolyer, R. A., **Long, G. V.**, Rizos, H. Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers, *Cancers (Basel)*. **2022 Oct 3**; 14(19):4830. doi: 10.3390/cancers14194830, PMID 36230753
 24. Khattak, M. A., Luke, J. J., **Long, G. V.**, Ascierto, P. A., Rutkowski, P., Schadendorf, D., Robert, C., Grob, J. J., de la Cruz Merino, L., Del Vecchio, M., Spagnolo, F., Mackiewicz, J., Chiarion-Sileni, V., Carlino, M. S., Mohr, P., De Galitiis, F., Ross, M. I., Eroglu, Z., Chen, K., Jiang, R., Fukunaga-Kalabis, M., Krepler, C., Eggermont, A. M. M., Kirkwood, J. M., Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study, *Eur J Cancer*. **2022 Oct 3**; S0959-8049(22)00477-4. doi: 10.1016/j.ejca.2022.08.004. Online ahead of print. PMID 36202690
 25. Smith, A. L., Watts, C. G., Henderson, M., **Long, G. V.**, Rapport, F., Saw, R. P. M., Scolyer, R. A., Spillane, A. J., Thompson, J. F., Cust, A. E., Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework *Implement Sci Commun*. **2022 Oct 1**; 3(1):103. doi: 10.1186/s43058-022-00351-w. PMID 36183121
 26. Nahar, K. J., Marsh-Wakefield, F., Rawson, R. V., Gide, T. N., Ferguson, A. L., Allen, R. O., Quek, C., Pires da Silva, I., Tattersall, S., Kiely, C. J., Sandanayake, N., Carlino, M. S., McCaughan, G., Wilmott, J. S., Scolyer, R. A., **Long, G. V.**, Menzies, A. M., Palendira, U., Distinct pre-treatment innate immune landscape and post-treatment T cell responses underlie immunotherapy-induced colitis, *JCI Insight*. **2022 Sep 29**; e157839. doi: 10.1172/jci.insight.157839. Online ahead of print. PMID 36173679
 27. Weber, J. S., Schadendorf, D., Del Vecchio, M., Larkin, J., Atkinson, V., Schenker, M., Pigozzo, J., Gogas, H., Dalle, S., Meyer, N., Ascierto, P. A., Sandhu, S., Eigentler, T., Gutzmer, R., Hassel, J. C., Robert, C., Carlino, M. S., Di Giacomo, A. M., Butler, M. O., Munoz-Couselo, E., Brown, M. P., Rutkowski, P., Haydon, A., Grob, J. J., Schachter, J., Queirolo, P., de la Cruz-Merino, L., van der Westhuizen, A., Menzies, A. M., Re, S., Bas, T., de Pril, V., Braverman, J., Tenney, D. J., Tang, H., **Long, G. V.**, Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915), *J Clin Oncol*. **2022 Sep 26**; JCO2200533. doi: 10.1200/JCO.22.00533. PMID 36162037

28. Simpson, R. C., Shanahan, E. R., Batten, M., Reijers, I. L. M., Read, M., Silva, I. P., Versluis, J. M., Ribeiro, R., Angelatos, A. S., Tan, J., Adhikari, C., Menzies, A. M., Saw, R. P. M., Gonzalez, M., Shannon, K. F., Spillane, A. J., Velickovic, R., Lazar, A. J., Damania, A. V., Mishra, A. K., Chelvanambi, M., Banerjee, A., Ajami, N. J., Wargo, J. A., Macia, L., Holmes, A. J., Wilmott, J. S., Blank, C. U., Scolyer, R. A., **Long, G. V.**, Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome, *Nat Med.* **2022 Sep 22**. doi: 10.1038/s41591-022-01965-2. Online ahead of print. PMID 36138151
29. Muller-Jensen, L., Zierold, S., Versluis, J. M., Boehmerle, W., Huehnchen, P., Endres, M., Mohr, R., Compter, A., Blank, C. U., Hagenacker, T., Meier, F., Reinhardt, L., Gesierich, A., Salzmann, M., Hassel, J. C., Ugurel, S., Zimmer, L., Banks, P., Spain, L., Soon, J. A., Enokida, T., Tahara, M., Kahler, K. C., Seggewiss-Bernhardt, R., Harvey, C., **Long, G. V.**, Schoberl, F., von Baumgarten, L., Hundsberger, T., Schlaak, M., French, L. E., Knauss, S., Heinzerling, L. M., Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study, *Eur J Cancer.* **2022 Sep 22**; 175:224-235. doi: 10.1016/j.ejca.2022.08.009. Online ahead of print. PMID 36155116
30. Newell, F., Johansson, P. A., Wilmott, J. S., Nones, K., Lakis, V., Pritchard, A. L., Lo, S. N., Rawson, R. V., Kazakoff, S. H., Colebatch, A. J., Koufariotis, L. T., Ferguson, P. M., Wood, S., Leonard, C., Law, M. H., Brooks, K. M., Broit, N., Palmer, J. M., Coutts, K. L., Vergara, I. A., **Long, G. V.**, Barbour, A. P., Nieweg, O. E., Shivalingam, B., Robinson, W. A., Stretch, J. R., Spillane, A. J., Saw, R. P. M., Shannon, K. F., Thompson, J. F., Mann, G. J., Pearson, J. V., Scolyer, R. A., Waddell, N., Hayward, N. K., Comparative genomics provides etiological and biological insights into melanoma subtypes, *Cancer Discov.* **2022 Sep 13**; CD-22-0603. doi: 10.1158/2159-8290.CD-22-0603. Online ahead of print. PMID 36098958
31. Conway, J. W., Rawson, R. V., Lo, S., Ahmed, T., Vergara, I. A., Gide, T. N., Attrill, G. H., Carlino, M. S., Saw R. P. M., Thompson, J. F., Spillane, A. J., Shannon, K. F., Shivalingam, B., Menzies, A. M., Wilmott, J. S., **Long, G. V.**, Scolyer, R. A., Pires da Silva, I., Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites, *J Immunother Cancer.* **2022 Sep**;10(9):e004884. doi: 10.1136/jitc-2022-004884. PMID 36096531
32. Alexander MM Eggermont, Michal Kicinski, Christian U Blank, Mario Mandala, **Georgina V Long**, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James Larkin, MD, , Susana Puig, MD, Paolo A Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus JM van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Paul Lorigan, Dmitri Grebennik, Nageatte Ibrahim, Sandrine Marreaud, Stefan Suciu, Caroline Robert, Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma, *NEJM Evidence*, **Sept 10 2022**, <https://doi.org/10.1056/EVIDoA2200214>
33. Seviiri, M., Scolyer, R. A., Bishop, D. T., Newton-Bishop, J. A., Iles, M. M., Lo, S. N., Stretch, J. R., Saw, R. P. M., Nieweg, O. E., Shannon, K. F., Spillane, A. J., Gordon, S. D., Olsen, C. M., Whiteman, D. C., Landi, M. T., Thompson, J. F., **Long, G. V.**, MacGregor, S., Law, M. H., Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting, *J Transl Med.* **2022 Sep 5**;20(1):403. doi: 10.1186/s12967-022-03613-2, PMID 36064556
34. **Long, G. V.**, Ferrucci, P. F., Khattak, A., Meniawy, T. M., Ott, P. A., Chisamore, M., Trolle, T., Hyseni, A., Heegaard, E., KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma, *Future Oncol.* **2022 Sep 1**. doi: 10.2217/fo-2022-0694. Online ahead of print. PMID 36047545
35. Chesney, J. A., Ribas, A., **Long, G. V.**, Kirkwood, J. M., Dummer, R., Puzanov, I., Hoeller, C., Gajewski, T. F., Gutzmer, R., Rutkowski, P., Demidov, L., Arenberger, P., Shin, S. J., Ferrucci, P. F., Haydon, A., Hyngstrom, J., van Thienen, J. V., Haferkamp, S., Guiler, J. M., Rapoport, B. L., VanderWalde, A., Dieder, S. J., Anderson, J. R., Treichel, S., Chan, E. L., Bhatta, S., Gansert, J., Hodi, F. S., Gogas, H., Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma, *J Clin Oncol.* **2022 Aug 23**; JCO2200343. doi: 10.1200/JCO.22.00343. Online ahead of print. PMID 35998300
36. Larkin, J., Weber, J., Del Vecchio, M., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J. J., Chiarion-Sileni, V., Marquez-Rodas, I., Butler, M. O., Di Giacomo, A. M., Middleton, M. R., De la Cruz-Merino, L., Arenberger, P., Atkinson, V., Hill, A., Fecher, L. A., Millward, M.,

- Khushalani, N. I., Queirolo, P., **Long, G. V.**, Lobo, M., Askelson, M., Ascierto, P. A., Mandala M., Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C/IV melanoma: reassessment of 4 year CheckMate 238 efficacy outcomes per AJCC-8 staging criteria, *EJC*, June 26 2022, accepted for publication *Eur J Cancer*. **2022 Aug 11** ;173:285-296. doi: 10.1016/j.ejca.2022.06.041. Online ahead of print. PMID 35964471
37. Attrill, G. H., Lee, H., Tasker, A. T., Adegoke, N. A., Ferguson, A. L., da Silva, I. P., Saw, R. P. M., Thompson, J. F., Palendira, U., **Long, G. V.**, Ferguson, P. M., Scolyer, R. A., Wilmott, J. S., Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome, *Front Immunol*. **2022 Aug 8**; 13:979993. doi: 10.3389/fimmu.2022.979993. eCollection 2022. PMID 36003398
 38. Arance, A., de la Cruz-Merino, L., Petrella, T. M., Jamal, R., Ny, L., Carneiro, A., Berrocal, A., Marquez-Rodas, I., Spreafico, A., Atkinson, V., Costa Svedman, F., Mant, A., Khattak, M. A., Mihalcioiu, C., Jang, S., Cowey, C. L., Smith, A. D., Hawk, N., Chen, K., Diede, S. J., Krepler, C., **Long, G. V.**, Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination, *J Clin Oncol*, **2022 Jul 22**; JCO2200221. doi: 10.1200/JCO.22.00221. Online ahead of print.
 39. Rawson RV, Shteinman ER, Ansar S, Vergara IA, Thompson JF, **Long GV**, Rcolyer RA, Wilmott JS, Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics, *Pathology*. **2022 Jul 31**; S0031-3025(22)00215-X. doi: 10.1016/j.pathol.2022.05.012. Online ahead of print. PMID 35987723
 40. Bhave, P., Ahmed, T., Lo, S. N., Shoushtari, A., Zaremba, A., Versluis, J. M., Mangana, J., Weichenthal, M., Si, L., Lesimple, T., Robert, C., Trojanello, C., Wicky, A., Heywood, R., Tran, L., Batty, K., Dimitriou, F., Stansfeld, A., Allayous, C., Schwarze, J. K., Mooradian, M. J., Klein, O., Mehmi, I., Roberts-Thomson, R., Maurichi, A., Yeoh, H. L., Khattak, A., Zimmer, L., Blank, C. U., Ramelyte, E., Kahler, K. C., Roy, S., Ascierto, P. A., Michielin, O., Lorigan, P. C., Johnson, D. B., Plummer, R., Lebbe, C., Neyns, B., Sullivan, R., Hamid, O., Santinami, M., McArthur, G. A., Haydon, A. M., **Long, G. V.**, Menzies, A. M., Carlino, M. S., Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma, *J Immunother Cancer*. **2022 Jul 10** (7):e004668. doi: 10.1136/jitc-2022-004668, PMID 35793872
 41. Holmberg, C. J., Ny, L., Hieken, T. J., Block, M. S., Carr, M. J., Sondak, V. K., Ortenwall, C., Katsarelias, D., Dimitriou, F., Menzies, A. M., Saw, R. P., Rogiers, A., Straker, R. J., 3rd, Karakousis, G., Applewaite, R., Pallan, L., Han, D., Vetto, J. T., Gyorki, E., Tie, E. N., Vitale, M. G., Ascierto, P. A., Dummer, R., Cohen, J., Hui, J. Y., Schachter, J., Asher, N., Helgadottir, H., Chai, H., Kroon, H., Coventry, B., Rothermel, L. D., Sun, J., Carlino, M. S., Duncan, Z., Broman, K., Weber, J., Lee, A. Y., Berman, R. S., Teras, J., Ollila, D. W., **Long, G. V.**, Zager, J. S., van Akkooi, A., Olofsson Bagge, R., The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study, *Eur J Cancer*. **2022 Jul;16** 9:210-222. doi: 10.1016/j.ejca.2022.03.041. Epub 2022 May 26. PMID 35644725
 42. Pires da Silva, I., Zakria, D., Ahmed, T., Trojanello, C., Dimitriou, F., Allayous, C., Gerard, C., Zimmer, L., Lo, S., Michielin, O., Lebbe, C., Mangana, J., Ascierto, P. A., Johnson, D. B., Carlino, M., Menzies, A., **Long, GV.**, Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma, *J Immunother Cancer*. **2022 Jul;10** (7):e004610. doi: 10.1136/jitc-2022-004610. PMID 35798536
 43. Reijers, I. L. M., Menzies, A. M., van Akkooi, A. C. J., Versluis, J. M., van den Heuvel, N. M. J., Saw, R. P. M., Pennington, T. E., Kapiteijn, E., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., Hospers, G. A. P., Rozeman, E. A., Klop, W. M. C., van Houdt, W. J., Sikorska, K., van der Hage, J. A., Grunhagen, D. J., Wouters, M. W., Witkamp, A. J., Zuur, C. L., Lijnsvelt, J. M., Torres Acosta, A., Griepink-Ongering, L. G., Gonzalez, M., Jozwiak, K., Bierman, C., Shannon, K. F., Ch'ng, S., Colebatch, A. J., Spillane, A. J., Haanen, Jbag, Rawson, R. V., van de Wiel, B. A., van de Poll-Franse, L. V., Scolyer, R. A., Boekhout, A. H., **Long, G. V.**, Blank, C. U., Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial, *Nat Med*. **2022 Jun;28** (6):1178-1188. doi: 10.1038/s41591-022-01851-x. Epub 2022 Jun 5. PMID 35661157
 44. Garbe, C., Keim, U., Amaral, T., Berking, C., Eigentler, T. K., Flatz, L., Gesierich, A., Leiter, U., Stadler, R., Sunderkotter, C., Tuting, T., Utikal, J., Wollina, U., Zimmer, L., Zouboulis, C. C., Ascierto, P. A., Eggermont, A. M. M., Grob, J. J., Hauschild, A., Sekulovic, L. K., **Long, G. V.**, Luke, J. J., Michielin,

- O., Peris, K., Schadendorf, D., Kirkwood, J. M., Lorigan, P. C., Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment, *J Clin Oncol.* **2022 Jun 16** ;jco2200202. doi: 10.1200/JCO.22.00202. Online ahead of print. PMID 35709414
45. Dimitriou, F., Namikawa, K., Reijers, I. L. M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhawe, P., Farid, M., Kahler, K. C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C. J., Zaman, F., Haydon, A., Carvajal, R. D., Hamid, O., Dummer, R., Hauschild, A., Carlino, M. S., Mandala, M., Robert, C., Lebbe, C., Guo, J., Johnson, D. B., Ascierto, P. A., Shoushtari, A. N., Sullivan, R. J., Cybulska-Stopa, B., Rutkowski, P., Zimmer, L., Sandhu, S., Blank, C. U., Lo, S. N., Menzies, A. M., **Long, G. V.**, Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study, *Ann Oncol.* **2022 Jun 16**; S0923-7534(22)01731-8. doi: 10.1016/j.annonc.2022.06.004. Online ahead of print, PMID 35716907
 46. Tawbi, H. A., Robert, C., Brase, J. C., Gusenleitner, D., Gasal, E., Garrett, J., Savchenko, A., Gorgun, G., Flaherty, K. T., Ribas, A., Dummer, R., Schadendorf, D., **Long, G. V.**, Nathan, P. D., Ascierto, P. A., Spaltalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i), *J Immunother Cancer.* **2022 Jun;10** (6):e004226. doi: 10.1136/jitc-2021-004226. PMID 35728875
 47. Attrill, G. H., Owen, C. N., Ahmed, T., Vergara, I. A., Colebatch, A. J., Conway, J. W., Nahar, K. J., Thompson, J. F., Pires da Silva, I., Carlino, M. S., Menzies, A. M., Lo, S., Palendira, U., Scolyer, R. A., **Long, G. V.**, Wilmott, J. S., Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy, *J Immunother Cancer.* **2022 Jun;10** (6):e004771. doi: 10.1136/jitc-2022-004771. PMID 35688560
 48. Vellano, C. P., White, M. G., Andrews, M. C., Chelvanambi, M., Witt, R. G., Daniele, J. R., Titus, M., McQuade, J. L., Conforti, F., Burton, E. M., Lastrapes, M. J., Ologun, G., Cogdill, A. P., Morad, G., Prieto, P., Lazar, A. J., Chu, Y., Han, G., Khan, M. A. W., Helmink, B., Davies, M. A., Amaria, R. N., Kovacs, J. J., Woodman, S. E., Patel, S., Hwu, P., Peoples, M., Lee, J. E., Cooper, Z. A., Zhu, H., Gao, G., Banerjee, H., Lau, M., Gershenwald, J. E., Lucci, A., Keung, E. Z., Ross, M. I., Pala, L., Pagan, E., Segura, R. L., Liu, Q., Borthwick, M. S., Lau, E., Yates, M. S., Westin, S. N., Wani, K., Tetzlaff, M. T., Haydu, L. E., Mahendra, M., Ma, X., Logothetis, C., Kulstad, Z., Johnson, S., Hudgens, C. W., Feng, N., Federico, L., **Long, G. V.**, Futreal, P. A., Arur, S., Tawbi, H. A., Moran, A. E., Wang, L., Heffernan, T. P., Marszalek, J. R., Wargo, J. A., Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy, *Nature.* **2022 Jun 6** 06(7915):797-803. doi: 10.1038/s41586-022-04833-8. Epub 2022 Jun 15. PMID 35705814
 49. Schwartz, R. J., Ho, G., Smith, A., Collgros, H., Regio Pereira, A., Gouveia, B., **Long, G. V.**, Menzies, A. M., Potter, A. J., Paver, E., Star, P., Scolyer, R. A., Martin, L. K., Successful treatment of eruptive keratoacanthomas with actitreten for patients on checkpoint inhibitor immunotherapy, *J Eur Acad Dermatol Venereol.* **2022 Jun;36**(6):e445-e448. doi: 10.1111/jdv.17940. Epub 2022 Jan 28 PMID 35043483
 50. Yaseen, Z., Gide, T. N., Conway, J. W., Potter, A. J., Quek, C., Hong, A. M., **Long, G. V.**, Scolyer, R. A., Wilmott, J. S., Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma, *Front Mol Biosci.* **2022 May 19**; 9:810858. doi: 10.3389/fmolb.2022.810858. eCollection 2022.
 51. Li, A. T., Miin Yip, J., Choksi, H., London, K., Potter, A. J., Lo, S. N., Saw, R. P. M., Shannon, K. F., Pires da Silva, I., Valey, A. H. R., Menzies, A. M., **Long, G. V.**, Shivalingam, B., Scolyer, R. A., Thompson, J. F., Ch'ng, S., Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread, *Melanoma Res.* **2022 May 13**. doi: 10.1097/CMR.0000000000000827. Online ahead of print. PMID 35579680
 52. Ascierto, P. A., Warner, A. B., Blank, C., Caraco, C., Demaria, S., Gershenwald, J. E., Khushalani, N. I., **Long, G. V.**, Luke, J. J., Mehnert, J. M., Robert, C., Rutkowski, P., Tawbi, H. A., Osman, I., Puzanov, I. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021, *J Transl Med.* **2022 May 10** ;20(1):200. doi: 10.1186/s12967-022-03406-7. PMID 35538491
 53. Luke, J. J., Rutkowski, P., Queirolo, P., Del Vecchio, M., Mackiewicz, J., Chiarion-Sileni, V., de la Cruz, Merino, L., Khattak, M. A., Schadendorf, D., **Long, G. V.**, Ascierto, P. A., Mandala, M., De Galitiis, F.,

- Haydon, A., Dummer, R., Grob, J. J., Robert, C., Carlino, M. S., Mohr, P., Poklepovic, A., Sondak, V. K., Scolyer, R. A., Kirkwood, J. M., Chen, K., Diede, S. J., Ahsan, S., Ibrahim, N., Eggermont, A. M. M., Keynote- Investigators, Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial, *Lancet*, **2022 Apr 30**; 399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1. PMID 35367007
54. Jobson, D., Roffey, B., Arnold, C., Azzi, A., Button-Sloan, A., Dawson, T., Fernandez-Penas, P., Fishburn, P., Gyorki, D. E., Hiscutt, E. L., Jakrot, V., Lilleyman, A., Lochhead, A., **Long, G. V.**, Mailer, S., Mann, G., McCormack, C. J., Muir, J., Pratt, G. F., Scolyer, R. A., Shackelton, M., Shumack, S., Soyer, H. P., Tan, C. G., Webb, A., Zalcberg, J., Morton, R., Mar, V., Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study, *Australas J Dermatol*. **2022 Apr 29**. doi: 10.1111/ajd.13848. Online ahead of print.
 55. Kaptein, P., Jacobberger-Foissac, C., Dimitriadis, P., Voabil, P., de Bruijn, M., Brokamp, S., Reijers, I., Versluis, J., Nallan, G., Triscott, H., McDonald, E., Tay, J., **Long, G. V.**, Blank, C. U., Thommen, D. S., Teng, M. W. L., Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade, *Sci Transl Med*. **2022 Apr 27** ;14(642):eabj9779. doi: 10.1126/scitranslmed.abj9779. Epub 2022 Apr 27 PMID 35476594
 56. Eggermont, A. M. M., Hamid, O., **Long, G. V.**, Luke, J. J., Optimal systemic therapy for high-risk resectable melanoma, *Nat Rev Clin Oncol*. **2022 Apr 25**. doi: 10.1038/s41571-022-00630-4. Online ahead of print. PMID 35468949
 57. Colebatch, A. J., Adhikari, C., Diefenbach, R. J., Rawson, R. V., Ferguson, P. M., Rizos, H., **Long, G. V.**, McCarthy, S. W., Thompson, J. F., Wilmott, J. S., Scolyer, R. A., Comprehensive clinical, histopathological and molecular analysis and long-term follow-up of patients with nodal blue nevi, *Am J Surg Pathol*, **2022 Apr 20**. doi: 10.1097/PAS.0000000000001902. Online ahead of print. PMID35439782
 58. Hanna S, Marinos E, Bryan D, Ahmed T, Lo SN, Carlino MS, Smith A, Cairns G, Shannon K, **Long GV**, Scolyer RA, Saw RPM, Effect of the SunSafe Training Program on the attitudes, knowledge, and behaviour of Australian high school students towards sun safety: a prospective study. *Clin Exp Dermatol*. **2022 Apr 18**. doi: 10.1111/ced.15220. Online ahead of print. PMID: 35434843
 59. Diefenbach, R. J., Lee, J. H., Stewart, A., Menzies, A. M., Carlino, M. S., Saw, R. P. M., Stretch, J. R., **Long, G. V.**, Scolyer, R. A., Rizos, H., Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA, *Front Oncol*. **2022 Apr 12**;12:820510. doi: 10.3389/fonc.2022.820510. eCollection 2022. PMID 35494035
 60. Wang, M., Zadeh, S., Pizzolla, A., Thia, K., Gyorki, D. E., McArthur, G. A., Scolyer, R. A., **Long, G.**, Wilmott, J. S., Andrews, M. C., Au-Yeung, G., Wepler, A., Sandhu, S., Trapani, J. A., Davis, M. J., Neeson, P. J., Characterization of the treatment-naïve immune microenvironment in melanoma with BRAF mutation, *J Immunother Cancer*. **2022 Apr;10** (4):e004095. doi: 10.1136/jitc-2021-004095, PMID 35383113
 61. Weiss, J. M., Hunter, M. V., Cruz, N. M., Baggolini, A., Tagore, M., Ma, Y., Misale, S., Marasco, M., Simon-Vermot, T., Campbell, N. R., Newell, F., Wilmott, J. S., Johansson, P. A., Thompson, J. F., **Long, G. V.**, Pearson, J. V., Mann, G. J., Scolyer, R. A., Waddell, N., Montal, E. D., Huang, T. H., Jonsson, P., Donoghue, M. T. A., Harris, C. C., Taylor, B. S., Xu, T., Chaligne, R., Shliaha, P. V., Hendrickson, R., Jungbluth, A. A., Lezcano, C., Koche, R., Studer, L., Ariyan, C. E., Solit, D. B., Wolchok, J. D., Merghoub, T., Rosen, N., Hayward, N. K., White, R. M., Anatomic position determines oncogenic specificity in melanoma, *Nature*. **2022 Apr 6**, 04(7905):354-361. doi: 10.1038/s41586-022-04584-6. Epub 2022 Mar 30. PMID 35355015
 62. Luke, J. J., Rutkowski, P., Queirolo, P., Del Vecchio, M., Mackiewicz, J., Chiarion-Sileni, V., de la Cruz Merino, L., Khattak, M. A., Schadendorf, D., **Long, G. V.**, Ascierto, P. A., Mandala, M., De Galitiis, F., Haydon, A., Dummer, R., Grob, J. J., Robert, C., Carlino, M. S., Mohr, P., Poklepovic, A., Sondak, V. K., Scolyer, R. A., Kirkwood, J. M., Chen, K., Diede, S. J., Ahsan, S., Ibrahim, N., Eggermont, A. M. M., Keynote- Investigators, Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial, *Lancet*. **2022 Apr 30**;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1. PMID 35367007
 63. Star, P., Jakkett, L. A., Cheung, K., Wilmott, J. S., Ho, G., Smith, A., **Long, G. V.**, Scolyer, R. A., Martin, L. K., Multiple eruptive squamoproliferative lesions during immunotherapy for metastatic melanoma:

- an exploration of pathogenesis with immunohistochemical analysis, *Dermatol Ther.* **2022 Mar 29** ;e15472. doi: 10.1111/dth.15472. Online ahead of print. PMID 35347815
64. Bai, X., Shoushtari, A. N., Betof Warner, A., Si, L., Tang, B., Cui, C., Yang, X., Wei, X., Quach, H. T., Cann, C. G., Zhang, M. Z., Pallan, L., Harvey, C., Kim, M. S., Kasumova, G., Sharova, T., Cohen, J. V., Lawrence, D. P., Freedman, C., Fadden, R. M., Rubin, K. M., Frederick, D. T., Flaherty, K. T., **Long, G. V.**, Menzies, A. M., Sullivan, R. J., Boland, G. M., Johnson, D. B., Guo, J., Benefit and Toxicity to PD-1 Blockade Varies by Ethnicity in Patients with Advanced Melanoma: An International Multicenter Observational Study, *Br J Dermatol.* **2022 Mar 16**. doi: 10.1111/bjd.21241. Online ahead of print. PMID 35293617
 65. Ho, G., Schwartz, R. J., Regio Pereira, A., Dimitrou, F., Paver, E., McKenzie, C., Saw, R. P. M., Scolyer, R. A., **Long, G. V.**, Guitera, P., Reflectance confocal microscopy as a non-invasive tool for monitoring systemic treatment response on a primary unresected scalp melanoma, *J Eur Acad Dermatol Venereol.* **2022 Mar 14**. doi: 10.1111/jdv.18076. Online ahead of print. PMID 35285090
 66. Potter, A. J., Colebatch, A. J., Rawson, R. V., Ferguson, P. M., Cooper, W. A., Gupta, R., O'Toole, S., Saw, R. P. M., Ch'ng, S., Menzies, A. M., **Long, G. V.**, Scolyer, R. A., Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre, *Pathology.* **2022 Mar 3** ;S0031-3025(22)00062-9. doi: 10.1016/j.pathol.2021.12.290. Online ahead of print.
 67. Colebatch, A. J., Paver, E. C., Vergara, I. A., Thompson, J. F., **Long, G. V.**, Wilmott, J. S., Scolyer, R. A., Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma, *Pathology.* **2022 Mar 2** ;S0031-3025(22)00061-7. doi: 10.1016/j.pathol.2021.12.289. Online ahead of print. PMID 35248370
 68. Kennedy, O. J., Kicinski, M., Valpione, S., Gandini, S., Suci, S., Blank, C. U., **Long, G. V.**, Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J. M., Grob, J. J., Gutzmer, R., Jamal, R., van Akkooi, A. C. J., Robert, C., Eggermont, A. M. M., Lorigan, P., Mandala, M., Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab vs placebo in resected high-risk stage III melanoma, *Eur J Cancer.* **2022 Feb 24** ;165:97-112. doi: 10.1016/j.ejca.2022.01.017. Online ahead of print. PMID 35220182
 69. Pennington, T. E., Zhao, C. Y., Colebatch, A. J., Fernandez-Penas, P., Guitera, P., Burke, H., Scolyer, R. A., Menzies, A. M., Carlino, M. S., Lo, S., **Long, G. V.**, Saw, R. P., Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma, *Australas J Dermatol.* **2022 Feb 21**. doi: 10.1111/ajd.13807. Online ahead of print. PMID 35188271
 70. Goldinger, S. M., Buder-Bakhaya, K., Lo, S. N., Forschner, A., McKean, M., Zimmer, L., Khoo, C., Dummer, R., Eroglu, Z., Buchbinder, E. I., Ascierto, P. A., Gutzmer, R., Rozeman, E. A., Hoeller, C., Johnson, D. B., Gesierich, A., Kolblinger, P., Bennannoune, N., Cohen, J. V., Kahler, K. C., Wilson, M. A., Cebon, J., Atkinson, V., Smith, J. L., Michielin, O., **Long, G. V.**, Hassel, J. C., Weide, B., Haydu, L. E., Schadendorf, D., McArthur, G., Ott, P. A., Blank, C., Robert, C., Sullivan, R., Hauschild, A., Carlino, M. S., Garbe, C., Davies, M. A., Menzies, A. M., Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis, *Eur J Cancer.* **2022 Feb;16** 2:22-33. doi: 10.1016/j.ejca.2021.11.022. Epub 2021 Dec 21. PMID 34952480
 71. Pires da Silva, I., Ahmed, T., McQuade, J. L., Nebhan, C. A., Park, J. J., Versluis, J. M., Serra-Bellver, P., Khan, Y., Slattery, T., Oberoi, H. K., Ugurel, S., Haydu, L. E., Herbst, R., Utikal, J., Pfohler, C., Terheyden, P., Weichenthal, M., Gutzmer, R., Mohr, P., Rai, R., Smith, J. L., Scolyer, R. A., Arance, A. M., Pickering, L., Larkin, J., Lorigan, P., Blank, C. U., Schadendorf, D., Davies, M. A., Carlino, M. S., Johnson, D. B., **Long, G. V.**, Lo, S. N., Menzies, A. M., Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma, *J Clin Oncol.* **2022 Feb 10** ;JCO2101701. doi: 10.1200/JCO.21.01701. Online ahead of print. PMID 35143285
 72. Reijers, I. L. M., Rawson, R. V., Colebatch, A. J., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Shannon, K. F., Wouters, M. W., Saw, R. P. M., van Houdt, W. J., Zuur, C. L., Nieweg, O. E., Ch'ng, S., Klop, W. M. C., Spillane, A. J., **Long, G. V.**, Scolyer, R. A., van de Wiel, B. A., Blank, C. U., Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma, *JAMA Surg.* **2022 Feb 9**. doi: 10.1001/jamasurg.2021.7554. Online ahead of print. PMID 35138335

73. **Long, G. V.**, Arance, A., Mortier, L., Lorigan, P., Blank, C., Mohr, P., Schachter, J., Grob, J. J., Lotem, M., Middleton, M. R., Neyns, B., Steven, N., Ribas, A., Walpole, E., Carlino, M. S., Lebbe, C., Sznol, M., Jensen, E., Leiby, M. A., Ibrahim, N., Robert, C., Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma Enrolled in KEYNOTE-006, *Ann Oncol.* **2022 Feb 3** 3(2):204-215 doi:10.1016/j.annonc.2021.10.010. Epub 2021 Oct 25. PMID 34710571
74. Muir, C. A., Wood, C. C. G., Clifton-Bligh, R. J., **Long, G. V.**, Scolyer, R. A., Carlino, M. S., Menzies, A. M., Tsang, V. H. M., Association of anti-thyroid antibodies in checkpoint inhibitor associated thyroid immune related adverse events, *J Clin Endocrinol Metab.* **2022 Feb 1**; dgac059. doi: 10.1210/clinem/dgac059. Online ahead of print, PMID 35104870
75. van Akkooi, A. C. J., Hieken, T. J., Burton, E. M., Ariyan, C., Ascierto, P. A., Asero, Svma, Blank, C. U., Block, M. S., Boland, G. M., Caraco, C., Chng, S., Davidson, B. S., Duprat Neto, J. P., Faries, M. B., Gershenwald, J. E., Grunhagen, D. J., Gyorki, D. E., Han, D., Hayes, A. J., van Houdt, W. J., Karakousis, G. C., Klop, W. M. C., **Long, G. V.**, Lowe, M. C., Menzies, A. M., Olofsson Bagge, R., Pennington, T. E., Rutkowski, P., Saw, R. P. M., Scolyer, R. A., Shannon, K. F., Sondak, V. K., Tawbi, H., Testori, A. A. E., Tetzlaff, M. T., Thompson, J. F., Zager, J. S., Zuur, C. L., Wargo, J. A., Spillane, A. J., Ross, M. I., International Neoadjuvant Melanoma Consortium, Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC), *Ann Surg Oncol.* **2022 Jan 28.** doi: 10.1245/s10434-021-11236-y. Online ahead of print. PMID 35089452
76. Eggermont, A. M., Ascierto, P. A., Khushalani, N. I., Schadendorf, D., Boland, G., Weber, J., Lewis, K. D., Johnson, D., Rivalland, G., Khattak, A., Majem, M., Gogas, H., **Long, G. V.**, Currie, S. L., Chien, D., Tagliaferri, M. A., Carlino, M. S., Diab, A., PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence, *Future Oncol.* **2022 Jan 25.** doi: 10.2217/fon-2021-1286. Online ahead of print, PMID 35073733
77. Dummer, R.*, **Long, G. V.***, Robert, C., Tawbi, H. A., Flaherty, K. T., Ascierto, P. A., Nathan, P. D., Rutkowski, P., Leonov, O., Dutriaux, C., Mandala, M., Lorigan, P., Ferrucci, P. F., Grob, J. J., Meyer, N., Gogas, H., Stroyakovskiy, D., Arance, A., Brase, J. C., Green, S., Haas, T., Masood, A., Gasal, E., Ribas, A., Schadendorf, D., Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma, *J Clin Oncol.* **2022 Jan 14**; JCO2101601. doi: 10.1200/JCO.21.01601. Online ahead of print. PMID 35030011
78. Newell, F., Pires da Silva, I., Johansson, P. A., Menzies, A. M., Wilmott, J. S., Addala, V., Carlino, M. S., Rizos, H., Nones, K., Edwards, J. J., Lakis, V., Kazakoff, S. H., Mukhopadhyay, P., Ferguson, P. M., Leonard, C., Koufariotis, L. T., Wood, S., Blank, C. U., Thompson, J. F., Spillane, A. J., Saw, R. P. M., Shannon, K. F., Pearson, J. V., Mann, G. J., Hayward, N. K., Scolyer, R. A., Waddell, N., **Long, G. V.**, Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance, *Cancer Cell.* **2022 Jan 10**;40(1):88-102.e7. doi: 10.1016/j.ccell.2021.11.012. Epub 2021 Dec 23. PMID34951955
79. Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutierrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., Dalle, S., Arance, A., Grob, J. J., Srivastava, S., Abaskharoun, M., Hamilton, M., Keidel, S., Simonsen, K. L., Sobiesk, A. M., Li, B., Hodi, F. S., **Long, G. V.**, Relativity- Investigators, Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma, *N Engl J Med.* **2022 Jan 6**; 386(1):24-34. doi: 10.1056/NEJMoa2109970, PMID 34986285
80. Dimitriou, F., Lo, S. N., Tan, A. C., Emmett, L., Kapoor, R., Carlino, M. S., **Long, G. V.**, Menzies, A. M., FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma, *Ann Oncol.* **2022 Jan 3**, 3(1):99-106. doi: 10.1016/j.annonc.2021.10.003. Epub 2021 Oct 21. PMID 34687894
81. Scolyer, R. A., Atkinson, V., Gyorki, D. E., Lambie, D., O'Toole, S., Saw, R. P. M., Amanuel, B., Angel, C. M., Button-Sloan, A. E., Carlino, M. S., Ch'ng, S., Colebatch, A. J., Daneshvar, D., Pires da Silva, I., Dawson, T., Ferguson, P. M., Foster-Smith, E., Fox, S. B., Gill, A. J., Gupta, R., Henderson, M. A., Hong, A. M., Howle, J. R., Jakkett, L. A., James, C., Lee, C. S., Lochhead, A., Loh, D., McArthur, G. A., McLean, C. A., Menzies, A. M., Nieweg, O. E., O'Brien, B. H., Pennington, T. E., Potter, A. J., Prakash, S., Rawson, R. V., Read, R. L., Rtshiladze, M. A., Shannon, K. F., Smithers, B. M., Spillane, A. J., Stretch, J. R., Thompson, J. F., Tucker, P., Varey, A. H. R., Vilain, R. E., Wood, B. A., **Long, G. V.**, BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance

- for the Australian setting, *Pathology*. **2021 Dec 19** ;S0031-3025(21)00533-X. doi: 10.1016/j.pathol.2021.11.002. Online ahead of print. PMID34937664
82. Choi, S., Hong, A., Wang, T., Lo, S., Chen, B., Silva, I., Kapoor, R., Hsiao, E., Fogarty, G. B., Carlino, M. S., Menzies, A. M., **Long, G. V.**, Shivalingam, B. S., Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location, *Strahlenther Onkol*. **2021 Dec;197**(12):1104-1112. doi: 10.1007/s00066-021-01798-x. Epub 2021 Jun 10. PMID 34114045
 83. Gallagher, S. J., Bailey, T., Rawson, R. V., Mahar, A. M., Thompson, J. F., **Long, G. V.**, Wilmott, J. S., Scolyer, R. A., Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis *Pathology*. **2021 Dec 5** 3(7):830-835. doi: 10.1016/j.pathol.2021.02.012. Epub 2021 Jun 2 PMID 34090666
 84. Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Butler, M. O., Hill, A., Marquez-Rodas, I., Haanen, Jbag, Guidoboni, M., Maio, M., Schoffski, P., Carlino, M. S., Lebbe, C., McArthur, G., Ascierto, P. A., Daniels, G. A., **Long, G. V.**, Bas, T., Ritchings, C., Larkin, J., Hodi, F. S., Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma, *J Clin Oncol*. **2021 Nov 24**;jco2102229. doi: 10.1200/JCO.21.02229. Online ahead of print. PMID 34818112
 85. Liyanage, U., MacGregor, S., Bishop, D. T., Shi, J., An, J., Ong, J. S., Han, X., Scolyer, R. A., Martin, N. G., Medland, S. E., Byrne, E. M., Green, A. C., Saw, R. P. M., Thompson, J. F., Stretch, J., Spillane, A., Jiang, Y., Tian, C., and Me Research, Team, Gordon, S. G., Duffy, D. L., Olsen, C. M., Whiteman, D. C., **Long, G. V.**, Iles, M. M., Landi, M. T., Law, M. H., Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma, *J Invest Dermatol*, **2021 Nov 20**; S0022-202X(21)02513-6. doi: 10.1016/j.jid.2021.08.449. Online ahead of print PMID 34813871
 86. Hamid, O., Robert, C., Daud, A., Carlino, M. S., Mitchell, T. C., Hersey, P., Schachter, J., **Long, G. V.**, Hodi, F. S., Wolchok, J. D., Arance, A., Grob, J. J., Joshua, A. M., Weber, J. S., Mortier, L., Jensen, E., Diede, S. J., Moreno, B. H., Ribas, A., Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006, *Eur J Cancer*, **2021 Nov;15** 7:391-402. doi: 10.1016/j.ejca.2021.08.013. Epub 2021 Sep 25. PMID 34571336
 87. Dimitriou F, Hogan S, Cheng PF, Menzies AMM, Dummer R, **Long GV**, Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy, *Eur J Cancer*, . **2021 Nov;15** 7:214-224. doi: 10.1016/j.ejca.2021.08.031. Epub 2021 Sep 15. PMID: 34536945
 88. Bai, X., Hu, J., Betof Warner, A., Quach, H. T., Cann, C. G., Zhang, M. Z., Si, L., Tang, B., Cui, C., Yang, X., Wei, X., Pallan, L., Harvey, C., Manos, M. P., Ouyang, O., Kim, M. S., Kasumova, G., Cohen, J. V., Lawrence, D. P., Freedman, C., Fadden, R. M., Rubin, K. M., Sharova, T., Frederick, D. T., Flaherty, K. T., Rahma, O. E., **Long, G. V.**, Menzies, A. M., Guo, J., Shoushtari N., , Johnson, D. B., Sullivan, R. J., Boland, G. M., Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy, *Clin Cancer Res*. **2021 Nov 1**; 27(21):5993-6000. doi: 10.1158/1078-0432.CCR-21-1283. Epub 2021 Aug 10. PMID 34376536
 89. Zaremba, A., Kramer, R., De Temple, V., Bertram, S., Salzmann, M., Gesierich, A., Reinhardt, L., Baroudjian, B., Sachse, M. M., Mechttersheimer, G., Johnson, D. B., Wepler, A. M., Spain, L., Loquai, C., Dudda, M., Pfohler, C., Hepner, A., **Long, G. V.**, Menzies, A. M., Carlino, M. S., Lebbe, C., Enokida, T., Tahara, M., Brockelmann, P. J., Eigentler, T., Kahler, K. C., Gutzmer, R., Berking, C., Ugurel, S., Stadtler, N., Sucker, A., Becker, J. C., Livingstone, E., Meier, F., Hassel, J. C., Schadendorf, D., Hanoun, M., Heinzerling, L., Zimmer, L., Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis, *Front Oncol*. **2021 Oct 21**; 11:765608. doi: 10.3389/fonc.2021.765608. eCollection 2021, PMID 34746007
 90. Srinivasan, M., Taylor, A. M., **Long, G. V.**, Herkes, G., King, G. G., Acute bilateral phrenic nerve neuropathy causing hypercapnic respiratory associated with checkpoint inhibitor immunotherapy, *Respir Med Case Rep*. **2021 Oct 21**; 34:101533. doi: 10.1016/j.rmcr.2021.101533. eCollection 2021. PMID 34745870
 91. Eggermont, A. M., Meshcheryakov, A., Atkinson, V., Blank, C. U., Mandala, M., **Long, G. V.**, Barrow, C., Di Giacomo, A. M., Fisher, R., Sandhu, S., Kudchadkar, R., Ortiz Romero, P. L., Svane, I. M., Larkin, J., Puig, S., Hersey, P., Quaglino, P., Stroyakovskiy, D., Bastholt, L., Mohr, P., Hernberg, M.,

- Chiarion-Sileni, V., Strother, M., Hauschild, A., Yamazaki, N., van Akkooi, A. C., Lorigan, P., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suci, S., Robert, C., Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma, *Eur J Cancer*. **2021 Oct 18**;158:156-168. doi: 10.1016/j.ejca.2021.09.023. Online ahead of print. PMID 34678677
92. Quek, C., Bai, X., **Long, G. V.**, Scolyer, R. A., Wilmott, J. S., High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy, *Genes (Basel)*. **2021 Oct 16**; 12(10):1629. doi: 10.3390/genes12101629. PMID 34681023
 93. Halle, B. R., Betof Warner, A., Zaman, F. Y., Haydon, A., Bhawe, P., Dewan, A. K., Ye, F., Irlmeier, R., Mehta, P., Kurtansky, N. R., Lacouture, M. E., Hassel, J. C., Choi, J. S., Sosman, J. A., Chandra, S., Otto, T. S., Sullivan, R., Mooradian, M. J., Chen, S. T., Dimitriou, F., **Long, G.**, Carlino, M., Menzies, A., Johnson, D. B., Rotemberg, V. M., Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy, *J Immunother Cancer*. **2021 Oct**;9(10):e003066. doi: 10.1136/jitc-2021-003066. PMID 34635495
 94. Cho, K. K., Cust, A. E., Foo, Y. M., **Long, G. V.**, Menzies, A. M., Eslick, G. D., Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis, *Melanoma Res*. **2021 Oct 1**; 31(5):482-486. doi: 10.1097/CMR.0000000000000764. PMID 34433196
 95. Waldstein C, Wanga W, Lo S, Shivalingam B, Fogarty GB, Carlino MS, Menzies AM, **Long GV**. Hong AM, Melanoma brain metastasis: The outcome of whole brain radiation therapy in the era of effective systemic therapy. *Therapeutic Radiology and Oncology*, **Sept 20 2021**, doi.org/10.21037/tro-21-6
 96. Dey, A, Rogiers A, **Long GV**, Schrieber L, Immunotherapy for Cancer and immune related-adverse events (irAEs), *Medicine Today*, **Sept 2021**
 97. A. Zaremba, A.M.M. Eggermont, C. Robert, R. Dummer, S. Ugure, L. Livingstone, P. Ascierto, **G. Long**, D. Schadendorf, L. Zimmer, The concepts of rechallenge and retreatment in melanoma treated with immune checkpoint blockade, *Eur J Cancer*. **2021 Sep 15** 5:268-280. doi: 10.1016/j.ejca.2021.07.002. Epub 2021 Aug 12. PMID 34392069
 98. Carlino, M. S., Larkin, J., **Long, G. V.**, Immune checkpoint inhibitors in melanoma, *Lancet*, **2021 Sep 11**; 398(10304):1002-1014. doi: 10.1016/S0140-6736(21)01206-X. PMID 34509219
 99. Livingstone, A, Dempsey, K, Stockler, M. R, Howard, K, **Long, G. V.**, Carlino, M. S, Menzies, A. M., Morton, R. L, Adjuvant immunotherapy recommendations for stage III melanoma: Physician and Nurse interviews, *BMC Cancer* **2021 Sep 10**; 21(1):1014. doi: 10.1186/s12885-021-08752-1. PMID 34507552
 100. Potter, A. J., Dimitriou, F., Karim, R. Z., Mahar, A., Chan, C., **Long, G. V.**, Scolyer, R. A., Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma, *Pathology*. **2021 Aug 19**; S0031-3025(21)00423-2. doi: 10.1016/j.pathol.2021.05.097. Online ahead of print. PMID 34420793
 101. Dearden, H., Au, L. Wang, D. Y., Zimmer, L., Eroglu, Z., Smith, J. L., Cuvietto, M., Khoo, C., Atkinson, V., Lo, S., **Long, G. V.**, Sandhu, S., Ascierto, P. A., Carlino, M. S., Johnson, D. B., Larkin, J., Menzies, A. M., Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy, *Eur J Cancer*, **2021 Aug**;15 3:168-178. doi: 10.1016/j.ejca.2021.04.045. Epub 2021 Jun 25. PMID 34182268
 102. Hodi, F. S., Wolchok, J. D., Schadendorf, D., Larkin, J., **Long, G. V.**, Qian, X., Saci, A., Young, T. C., Srinivasan, S., Chang, H., Tang, H., Wind-Rotolo, M., Rizzo, J. I., Jackson, D. G., Ascierto, P. A., TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma, *Cancer Immunol Res*, **2021 Aug 13**; canimm.0983.2020. doi: 10.1158/2326-6066.CIR-20-0983. Online ahead of print. PMID 34389558
 103. Li, A. T., Vakharia, K., Lo, S. N., Valey, A. H. R., Carlino, M. S., Saw, R. P. M., Shannon, K. F., Howle, J. R., Pennington, T. E., Stretch, J. R., Nieweg, O. E., Spillane, A. J., **Long, G. V.**, Menzies, A. M., Scolyer, R. A., Thompson, J. F., Ch'ng, S., Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma, *Ann Surg Oncol*. **2021 Aug 4**. doi: 10.1245/s10434-021-10489-x. Online ahead of print. PMID 34347220
 104. Schadendorf, D., Robert, C., Dummer, R., Flaherty, K. T., Tawbi, H. A., Menzies, A. M., Banerjee, H., Lau, M., **Long, G. V.**, Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in

- BRAF-mutant cancers, *Eur J Cancer*. **2021 Jul 2**; 153:234-241. doi: 10.1016/j.ejca.2021.05.005. Online ahead of print. PMID 34225229
105. Haas, L., Elewaut, A., Gerard, C. L., Umkehrer, C., Leiendecker, L., Pedersen, M., Krecioch, I., Hoffmann, D., Novatchkova, M., Kuttke, M., Neumann, T., da Silva, I. P., Witthock, H., Cuendet, M. A., Carotta, S., Harrington, K. J., Zuber, J., Scolyer, R. A., **Long, G. V.**, Wilmott, J. S., Michielin, O., Vanharanta, S., Wiesner, T., Obenauf, A. C., Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma *Nat Cancer*. **2021 Jul;2** (7):693-708. doi: 10.1038/s43018-021-00221-9. Epub 2021 Jul 15. PMID 35121945
 106. **Long, G. V.**, Robert, C., Butler, M. O., Couture, F., Carlino, M. S., O'Day, S., Atkinson, V., Cebon, J. S., Brown, M. P., Dalle, S., Hill, A. G., Gibney, G. T., McCune, S., Menzies, A. M., Niu, C., Ibrahim, N., Homet Moreno, B., Diab, A., Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules, *Clin Cancer Res*. **2021 Jul 1**; clincanres.0793.2021. doi: 10.1158/1078-0432.CCR-21-0793. Online ahead of print. PMID 34210681
 107. Hepner, A., Atkinson, V. G., Larkin, J., Burrell, R. A., Carlino, M. S., Johnson, D. B., Zimmer, L., Tsai, K. K., Klein, O., Lo, S. N., Haydon, A., Bhave, P., Lyle, M., Pallan, L., Pires da Silva, I., Gerard, C., Michielin, O., **Long, G. V.**, Menzies, A. M., Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy, *Eur J Cancer*, **2021 Jun 28**; 153:213-222. doi: 10.1016/j.ejca.2021.04.021. Online ahead of print, PMID 34214936
 108. Gide, T. N., Pires da Silva, I., Quek, C., Ferguson, P. M., Batten, M., Shang, P., Ahmed, T., Menzies, A. M., Carlino, M. S., Saw, R. P. M., Thompson, J. F., Scolyer, R. A., **Long, G. V.**, Wilmott, J. S., Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets, *Cancers (Basel)*. **2021 Jun 25**; 13(13):3186. doi: 10.3390/cancers13133186. PMID 34202352
 109. Pires da Silva, I., Ahmed, T., Reijers, I. L. M., Wepler, A. M., Betof Warner, A., Patrinely, J. R., Serra-Bellver, P., Allayous, C., Mangana, J., Nguyen, K., Zimmer, L., Trojaniello, C., Stout, D., Lyle, M., Klein, O., Gerard, C. L., Michielin, O., Haydon, A., Ascierto, P. A., Carlino, M. S., Lebbe, C. Lorigan, P., Johnson, D. B., Sandhu, S., Lo, S. N., Blank, C. U., Menzies, A. M., **Long, G. V.**, Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study, *Lancet Oncol*. **2021 Jun;22** (6):836-847. doi: 10.1016/S1470-2045(21)00097-8. Epub 2021 May 11. PMID: 33989557
 110. Li, A. T., Maw, A. M., Hsiao, E., Ch'ng, S., **Long, G. V.**, Shannon, K. F., Morrison, E. J., Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma, *ANZ J Surg*. **2021 Jun 14**. doi: 10.1111/ans.16992. Online ahead of print. PMID 34124833
 111. Ch'ng, S., Uyulmaz, S., Carlino, M. S., Pennington, T. E., Shannon, K. F., Rtshiladze, M., Stretch, J. R., Nieweg, O. E., Varey, A. H. R., Hsiao, E., Kapoor, R., Pires da Silva, I., Lo, S. N., Spillane, A. J., Scolyer, R. A., **Long, G. V.**, Hong, A. M., Saw, R. P. M., Thompson, J. F., Menzies, A. M., Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies, *Eur J Cancer*. **2021 Jun 11**; 153:8-15. doi: 10.1016/j.ejca.2021.04.037. Online ahead of print. PMID 34126335
 112. Parakh, S., MUSAFA, A., Paessler, S., Witkowski, T., Suen, Csnlw, Tutuka, C. S. A., Carlino, M. S., Menzies, A. M., Scolyer, R. A., Cebon, J., Dobrovic, A., **Long, G. V.**, Klein, O., Behren, A., PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma, *Front Immunol*, **2021 Jun 9**; 12:672521. doi: 10.3389/fimmu.2021.672521. eCollection 2021, PMID 34177913
 113. Brase, J. C., Walter, R. F. H., Savchenko, A., Gusenleitner, D., Garrett, J., Schimming, T. T., Varaljai, R., Castelletti, D., Kim, J. Y., Dakappagari, N. K., Schultz, K., Robert, C., **Long, G. V.**, Nathan, P. D., Ribas, A., Flaherty, K. T., Karaszewska, B., Schachter, J., Sucker, A., Schmid, K. W., Zimmer, L., Livingstone, E., Gasal, E., Schadendorf, D., Roesch, A., Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib, *Clin Cancer Res*. **2021 Jun 9**; clincanres.3586.2020. doi: 10.1158/1078-0432.CCR-20-3586. Online ahead of print, PMID 34108180
 114. Menzies, A. M., Scolyer, R. A., **Long, G. V.**, Neoadjuvant immunotherapy in melanoma - the new frontier, *Clin Cancer Res*. **2021 Jun 3**; clincanres.1236.2021. doi: 10.1158/1078-0432.CCR-21-1236. Online ahead of print, PMID 34083235

115. Rawson, R. V., Adhikari, C., Bierman, C., Lo, S. N., Shklovskaya, E., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Shannon, K. F., Gonzalez, M., Guminski, A. D., Tetzlaff, M. T., Stretch, J. R., Eriksson, H., van Thienen, J. V., Wouters, M. W., Haanen, Jbag, Klop, W. M. C., Zuur, C. L., van Houdt, W. J., Nieweg, O. E., Ch'ng, S., Rizos, H., Saw, R. P. M., Spillane, A. J., Wilmott, J. S., Blank, C. U., **Long, G. V.**, van de Wiel, B. A., Scolyer, R. A., Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma, *Ann Oncol.* **2021 Jun**;3 2(6):766-777. doi: 10.1016/j.annonc.2021.03.006. Epub 2021 Mar 17, PMID: 33744385
116. Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandal, M., **Long, G. V.**, Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Puig, S., Ascierto, P. A., Larkin, J., Lorigan, P. C., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J. M., Grob, J. J., Gutzmer, R., Jamal, R., van Akkooi, A. C. J., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S., Robert, C., Eggermont, A. M. M., EORTC Melanoma Group, Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial, *Lancet Oncol*, **2021 May 22** (5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12. PMID 33857414
117. Knispel, S., Gassenmaier, M., Menzies, A. M., Loquai, C., Johnson, D. B., Franklin, C., Gutzmer, R., Hassel, J. C., Weishaupt, C., Eigentler, T., Schilling, B., Schummer, P., Sirokay, J., Kiecker, F., Owen, C. N., Fleischer, M. I., Cann, C., Kahler, K. C., Mohr, P., Bluhm, L., Niebel, D., Thoms, K. M., Goldinger, S. M., Reinhardt, L., Meier, F., Berking, C., Reinhard, R., Susok, L., Ascierto, P. A., Drexler, K., Pföhler, C., Tietze, J., Heinzerling, L., Livingstone, E., Ugurel, S., **Long, G. V.**, Stang, A., Schadendorf, D., Zimmer, L., Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition, *Eur J Cancer*. **2021 May**;14 8:61-75. doi: 10.1016/j.ejca.2021.01.034. Epub 2021 Mar 15, PMID 33735811
118. Wu, S. Z., Roden, D. L., Al-Eryani, G., Bartonicek, N., Harvey, K., Cazet, A. S., Chan, C. L., Junankar, S., Hui, M. N., Millar, E. A., Beretov, J., Horvath, L., Joshua, A. M., Stricker, P., Wilmott, J. S., Quek, C., **Long, G. V.**, Scolyer, R. A., Yeung, B. Z., Segara, D., Mak, C., Warrier, S., Powell, J. E., O'Toole, S., Lim, E., Swarbrick, A., Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis, *Genome Med.* **2021 May 10**;13(1):81. doi: 10.1186/s13073-021-00885-z, PMID 33971952
119. Brown, L. J., Weppler, A., Bhawe, P., Allayous, C., Patrinely, J. R., Jr., Ott, P., Sandhu, S., Haydon, A., Lebbe, C., Johnson, D. B., **Long, G. V.**, Menzies, A. A., Carlino, M. S., Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders, *J Immunother Cancer*. **2021 May**;9 (5):e002121. doi: 10.1136/jitc-2020-002121, PMID 33963010
120. Versluis, J. M., Hendriks, A. M., Weppler, A. M., Brown, L. J., de Joode, K., Suijkerbuijk, K. P. M., Zimmer, L., Kapiteijn, E. W., Allayous, C., Johnson, D. B., Hepner, A., Mangana, J., Bhawe, P., Jansen, Y. J. L., Trojaniello, C., Atkinson, V., Storey, L., Lorigan, P., Ascierto, P. A., Neyns, B., Haydon, A., Menzies, A. M., **Long, G. V.**, Lebbe, C., van der Veldt, A. A. M., Carlino, M. S., Sandhu, S., van Tinteren, H., de Vries, E. G. E., Blank, C. U., Jalving, M., The Role of Local Therapy in the Treatment of Solitary Melanoma Progression upon Immune Checkpoint Inhibition: A Multicenter Retrospective Analysis; *Eur J Cancer*. **2021 May 7**;151:72-83. doi: 10.1016/j.ejca.2021.04.003. Online ahead of print. PMID 33971447
121. Muir, C. A., Clifton-Bligh, R. J., **Long, G. V.**, Scolyer, R. A., Lo, S. N., Carlino, M. S., Tsang, V. H. M., Menzies, A. M., Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment, *J Clin Endocrinol Metab*. **2021 Apr 20**; dgab263. doi: 10.1210/clinem/dgab263. Online ahead of print. PMID 33878162
122. Park, J. J., Diefenbach, R. J., Byrne, N., **Long, G. V.**, Scolyer, R. A., Gray, E. S., Carlino, M. S., Rizos, H., Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition, *Cancers (Basel)*. **2021 Apr 6**; 13(7):1740. doi: 10.3390/cancers13071740, PMID 33917514
123. Owen, C. N., Bai, X., Quah, T., Lo, S. N., Allayous, C., Callaghan, S., Martinez-Vila, C., Wallace, R., Bhawe, P., Reijers, I. L. M., Thompson, N., Vanella, V., Gerard, C. L., Aspeslagh, S., Labianca, A.,

- Khattak, A., Mandala, M., Xu, W., Neyns, B., Michielin, O., Blank, C. U., Welsh, S. J., Haydon, A., Sandhu, S., Mangana, J., McQuade, J. L., Ascierto, P. A., Zimmer, L., Johnson, D. B., Arance, A., Lorigan, P., Lebbe, C., Carlino, M. S., Sullivan, R. J., **Long, G. V.**, Menzies, A. M., Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma, *Ann Oncol.* **2021 Mar 30**; S0923-7534(21)01101-7. doi: 10.1016/j.annonc.2021.03.204. Online ahead of print, PMID 33798657
124. Patrinely, J. R., Jr., Johnson, R., Lawless, A. R., Bhave, P., Sawyers, A., Dimitrova, M., Yeoh, H. L., Palmeri, M., Ye, F., Fan, R., Davis, E. J., Rapisuwon, S., **Long, G. V.**, Haydon, A., Osman, I., Mehnert, J. M., Carlino, M. S., Sullivan, R. J., Menzies, A. M., Johnson, D. B., Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma, *JAMA Oncol.* **2021 Mar 25**. doi: 10.1001/jamaoncol.2021.0051. Online ahead of print. PMID: 33764387
 125. F. Dimitriou, **G.V. Long**, A.M. Menzies, Novel adjuvant options for cutaneous melanoma, *Ann Oncol.* **2021 Mar 24**; S0923-7534(21)01077-2. doi: 10.1016/j.annonc.2021.03.198. Online ahead of print, PMID: 33771664
 126. Lee, H., Da Silva, I. P., Palendira, U., Scolyer, R. A., **Long, G. V.**, Wilmott, J. S., Targeting NK Cells to Enhance Melanoma Response to Immunotherapies, *Cancers (Basel).* **2021 Mar 17**; 13(6):1363. doi: 10.3390/cancers13061363. PMID 33802954
 127. Versluis, J. M., Reijers, I. L. M., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Wouters, M. W., Ch'ng, S., Saw, R. P. M., Scolyer, R. A., van de Wiel, B. A., Schilling, B., **Long, G. V.**, Blank, C. U., Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma, *Eur J Cancer.* **2021 Mar 15**;148:51-57. doi: 10.1016/j.ejca.2021.02.012. Online ahead of print, PMID: 33735809
 128. Kramer, R., Zaremba, A., Moreira, A., Ugurel, S., Johnson, D. B., Hassel, J. C., Salzmann, M., Gesierich, A., Weppner, A., Spain, L., Loquai, C., Dudda, M., Pfohler, C., Hepner, A., **Long, G. V.**, Menzies, A. M., Carlino, M. S., Sachse, M. M., Lebbe, C., Baroudjian, B., Enokida, T., Tahara, M., Schlaak, M., Hayani, K., Brockelmann, P. J., Meier, F., Reinhardt, L., Friedlander, P., Eigentler, T., Kahler, K. C., Berking, C., Zimmer, L., Heinzerling, L., Hematological immune related adverse events after treatment with immune checkpoint inhibitors, *Eur J Cancer.* **2021 Mar 8**;147:170-181. doi: 10.1016/j.ejca.2021.01.013. Online ahead of print. PMID: 33706206
 129. Menzies, A. M., Amaria, R. N., Rozeman, E. A., Huang, A. C., Tetzlaff, M. T., van de Wiel, B. A., Lo, S., Tarhini, A. A., Burton, E. M., Pennington, T. E., Saw, R. P. M., Xu, X., Karakousis, G. C., Ascierto, P. A., Spillane, A. J., van Akkooi, A. C. J., Davies, M. A., Mitchell, T. C., Tawbi, H. A., Scolyer, R. A., Wargo, J. A., Blank, C. U., **Long, G. V.**, Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) *Nat Med.* **2021 Feb**;27(2):301-309. doi: 10.1038/s41591-020-01188-3. Epub 2021 Feb 8. PMID 33558722
 130. Garg, M., Couturier, D. L., Nsengimana, J., Fonseca, N. A., Wongchenko, M., Yan, Y., Lauss, M., Jonsson, G. B., Newton-Bishop, J., Parkinson, C., Middleton, M. R., Bishop, D. T., McDonald, S., Stefanos, N., Tadross, J., Vergara, I. A., Lo, S., Newell, F., Wilmott, J. S., Thompson, J. F., **Long, G. V.**, Scolyer, R. A., Corrie, P., Adams, D. J., Brazza, A., Rabbie, R, Tumour gene expression signature in primary melanoma predicts long-term outcomes, *Nat Commun.* **2021 Feb 18**;12(1):1137. doi: 10.1038/s41467-021-21207-2. PMID 33602918
 131. Olofsson Bagge, R., Ny, L., Ascierto, P. A., Hodi, F. S., Larkin, J., Robert, C., Schachter, J., Weber, J. S., **Long, G. V.**, van Akkooi, A. C. J., The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials, *Melanoma Res.* **2021 Feb 18**. doi: 10.1097/CMR.0000000000000719. Online ahead of print, PMID: 33625104
 132. Kelly, G. M., Al-Ejeh, F., McCuaig, R., Casciello, F., Ahmad Kamal, N., Ferguson, B., Pritchard, A. L., Ali, S., Silva, I. P., Wilmott, J. S., **Long, G. V.**, Scolyer, R. A., Rao, S., Hayward, N. K., Gannon, F., Lee, J. S., G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma, *Clin Cancer Res.* **2021 Feb 15**. doi: 10.1158/1078-0432.CCR-20-3463. Online ahead of print. PMID: 33589432
 133. Syeda, M. M., Wiggins, J. M., Corless, B. C., **Long, G. V.**, Flaherty, K. T., Schadendorf, D., Nathan, P. D., Robert, C., Ribas, A., Davies, M. A., Grob, J. J., Gasal, E., Squires, M., Marker, M., Garrett, J., Brase, J. C., & Polsky, D. (2021). Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study, *Lancet Oncol.* **2021 Feb 12**;S1470-2045(20)30726-9. doi: 10.1016/S1470-2045(20)30726-9. Online ahead of print, PMID: 33587894
 134. Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., Gonzalez, M., Torres Acosta, A.,

- Grijpink-Ongering, L. G., Shannon, K., Haanen, J., Stretch, J., Ch'ng, S., Nieweg, O. E., Mallo, H. A., Adriaansz, S., Kerkhoven, R. M., Cornelissen, S., Broeks, A., Klop, W. M. C., Zuur, C. L., van Houdt, W. J., Peeper, D. S., Spillane, A. J., van Akkooi, A. C. J., Scolyer, R. A., Schumacher, T. N. M., Menzies, A. M., **Long, G. V.**, & Blank, C. U. (2021). Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma, *Nat Med.* **2021 Feb 8**. doi: 10.1038/s41591-020-01211-7. Online ahead of print. PMID 33558721
135. Patrinely, J. R., Jr., McGuigan, B., Chandra, S., Fenton, S. E., Chowdhary, A., Kennedy, L. B., Mooradian, M. J., Palmeri, M., Portal, D., Horst, S. N., Scoville, E. A., **Long, G. V.**, Shi, C., Mehnert, J. M., Sullivan, R. J., Salama, A. K., Sosman, J. A., Menzies, A. M., Johnson, D. B., A multicenter characterization of hepatitis associated with immune checkpoint inhibitors, *Oncoimmunology*, . **2021 Feb 8**;10(1):1875639. doi: 10.1080/2162402X.2021.1875639. PMID 33628621
 136. Simpson, R. C., Shanahan, E., Scolyer, R. A., & **Long, G. V.** Targeting the Microbiome to Overcome Resistance, *Cancer Cell.* **2021 Feb 8**;39(2):151-153. doi: 10.1016/j.ccell.2021.01.016 PMID 33561397
 137. Vergara, I. A., Wilmott, J. S., **Long, G. V.**, Scolyer, R. A. Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape, *Exp Dermatol.* **2021 Jan 17**. doi: 10.1111/exd.14287. Online ahead of print. PMID: 33455025
 138. Rabbie, R., Ferguson, P., Wong, K., Couturier, D. L., Moran, U., Turner, C., Emanuel, P., Haas, K., Saunus, J. M., Davidson, M. R., Lakhani, S. R., Shivalingam, B., **Long, G. V.**, Parkinson, C., Osman, I., Scolyer, R. A., Corrie, P., & Adams, D. J. (2020). The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence, *Br J Cancer.* **2021 Jan**;124(1):156-160. doi: 10.1038/s41416-020-01090-2. Epub 2020 Oct 7 PMID 33024263
 139. Rogiers, A., Pires da Silva, I., Tentori, C., Tondini, C. A., Grimes, J. M., Trager, M. H., Nahm, S., Zubiri, L., Manos, M., Bowling, P., Elkrief, A., Papneja, N., Vitale, M. G., Rose, A. A. N., Borgers, J. S. W., Roy, S., Mangana, J., Pimentel Muniz, T., Cooksley, T., Lupu, J., Vaisman, A., Saibil, S. D., Butler, M. O., Menzies, A. M., Carlino, M. S., Erdmann, M., Berking, C., Zimmer, L., Schadendorf, D., Pala, L., Queirolo, P., Posch, C., Hauschild, A., Dummer, R., Haanen, J., Blank, C. U., Robert, C., Sullivan, R. J., Ascierto, P. A., Miller, W. H., Jr., Stephen Hodi, F., Suijkerbuijk, K. P. M., Reynolds, K. L., Rahma, O. E., Lorigan, P. C., Carvajal, R. D., Lo, S., Mandala, M., & **Long, G. V.** (2021). Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition, *J Immunother Cancer.* **2021 Jan**;9(1):e001931. doi: 10.1136/jitc-2020-001931, PMID 33468556
 140. Mangantig, E., MacGregor, S., Iles, M. M., Scolyer, R. A., Cust, A. E., Hayward, N. K., Montgomery, G. W., Duffy, D. L., Thompson, J. F., Henders, A., Bowdler, L., Rowe, C., Cadby, G., Mann, G. J., Whiteman, D. C., **Long, G. V.**, Ward, S. V., Khosrotehrani, K., Barrett, J. H., & Law, M. H. (2021). Germline variants are associated with increased primary melanoma tumor thickness at diagnosis. *Hum Mol Genet.* **2021 Jan 6**;29(21):3578-3587. doi: 10.1093/hmg/ddaa222, PMID 33410475
 141. Robert, C., Hwu, W. J., Hamid, O., Ribas, A., Weber, J. S., Daud, A. I., Hodi, F. S., Wolchok, J. D., Mitchell, T. C., Hersey, P., Dronca, R., Joseph, R. W., Boutros, C., Min, L., **Long, G. V.**, Schachter, J., Puzanov, I., Dummer, R., Lin, J., Ibrahim, N., Diede, S. J., Carlino, M. S., & Joshua, A. M. (2020). Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma, *Eur J Cancer.* **2020 Dec 23**;144:182-191. doi: 10.1016/j.ejca.2020.11.010. Online ahead of print. PMID 33360855
 142. Papadopoulos, K. P., Autio, K. A., Golan, T., Dobrenkov, K., Chartash, E., Chen, Q., Wnek, R., & **Long, G. V.** (2020). Phase I Study of MK-4166, an Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody, Alone or With Pembrolizumab in Advanced Solid Tumors, *Clin Cancer Res.* **2020 Dec 21**;clincanres.2886.2020. doi: 10.1158/1078-0432.CCR-20-2886. Online ahead of print, PMID 33355238
 143. Ferrucci, P. F., Di Giacomo, A. M., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., **Long, G. V.**, Stephens, R., Svane, I. M., Lotem, M., Abu-Amna, M., Gasal, E., Ghorri, R., Diede, S. J., Croydon, E. S., Ribas, A., Ascierto, P. A., & team, K.-i. (2020). KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. *J Immunother Cancer.* **2020 Dec**;8(2):e001806. doi: 10.1136/jitc-2020-001806 PMID: 33361337
 144. Hoefsmit EP, Rozeman EA, Van TM, Dimitriadis P, Krijgsman O, Conway JW, Pires da Silva I, van der Wal JE, Ketelaars SLC, Bresser K, Broeks A, Kerkhoven RM, Reeves JW, Warren S, Kvistborg P,

- Scolyer RA, Kapiteijn EW, Peeper DS, **Long GV**, Schumacher TNM, Blank CU, Comprehensive analysis of cutaneous and uveal melanoma live metastases, *J Immunother Cancer*. **2020 Dec**;8(2):e001501. doi: 10.1136/jitc-2020-00150, PMID: 33262254
145. Smith AL, Watts CG, Robinson S, Schmid H, Goumas C, Mar VJ, Thompson JF, Rapport F, Australian Melanoma Centre of Research Excellence Study Group*, *Braithwaite J, *Gyorki DE, *Henderson M *Hong AM, *Kelly JW, ***Long GV**, *Menzies A, *Morton RL, *Saw RPM, *Scolyer RA, *Spillane AJ, *Mann GJ Cust AE, Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study, *Australas J Dermatol*. **2020 Dec 5**. doi: 10.1111/ajd.13518. Online ahead of print. PMID: 33277693
 146. Tetzlaff, M. T., Adhikari, C., Lo, S., Rawson, R. V., Amaria, R. N., Menzies, A. M., Wilmott, J. S., Ferguson, P. M., Ross, M. I., Spillane, A. J., Vu, K. A., Ma, J., Ning, J., Haydu, L. E., Saw, R. P. M., Wargo, J. A., Tawbi, H. A., Gershenwald, J. E., **Long, G. V.**, Davies, M. A., & Scolyer, R. A. Histopathologic features of complete pathologic response predict recurrence free survival following neoadjuvant targeted therapy for metastatic melanoma, *Ann Oncol*. **2020 Nov**;30(11):1569-1579. doi: 10.1016/j.annonc.2020.07.016. Epub 2020 Jul 31 PMID: 32739408
 147. Eggermont AMM, Blank CU, Mandala M, **Long GV**, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: new results from the EORTC1325-MG/Keynote 054 trial, *J Clin Oncol*. **2020 Nov 20**;38(33):3925-3936. doi: 10.1200/JCO.20.02110. Epub 2020 Sep 18, PMID32946353
 148. Hong, A. M., Waldstein, C., Shivalingam, B., Carlino, M. S., Atkinson, V., Kefford, R. F., McArthur, G. A., Menzies, A. M., Thompson, J. F., & **Long, G. V.** (2020). Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia, *Eur J Cancer*, **2020 Nov 15**;142:10-17. doi: 10.1016/j.ejca.2020.10.013. Online ahead of print PMID: 33207293
 149. Geva, R., Voskoboynik, M., Dobrenkov, K., Mayawala, K., Gwo, J., Wnek, R., Chartash, E., & **Long, G. V.** (2020). First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors, *Cancer*. **2020 Nov 15**; 126(22):4926-4935. doi: 10.1002/cncr.33133. Epub 2020 Aug 18, PMID 32809217
 150. Marsavela, G. Lee, J., Calapre, L., Wong, S. Q., Pereira, M. R., McEvoy, A. C., Reid, A. L., Robinson, C., Warburton, L., Abed, A., Khattak, M. A., Meniawy, T. M., Dawson, S. J., Sandhu, S., Carlino, M. S., Menzies, A. M., Scolyer, R. A., **Long, G. V.**, Amanuel, B., Millward, M., Ziman, M. R., Rizos, H., Gray, E. S., Circulating Tumor DNA Predicts Outcome from First, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy, *Clin Cancer Res*. **2020 Nov 15**; 26(22):5926-5933. doi: 10.1158/1078-0432.CCR-20-2251. Epub 2020 Oct 16. PMID 33067256
 151. Shklovskaya, E., Lee, J. H., Lim, S. Y., Stewart, A., Pedersen, B., Ferguson, P., Saw, R. P., Thompson, J. F., Shivalingam, B., Carlino, M. S., Scolyer, R. A., Menzies, A. M., **Long, G. V.**, Kefford, R. F., & Rizos, H. (2020). Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma, *Cancers*, **2020 Nov 14**, doi.org/10.3390/cancers12113374 PMID 33202676
 152. Nahar KJ, Rawson RV, Ahmed T, Tattersall S, Sandanayake N, Kiely CJ, Lo S, Carlino, Palendira U, Scolyer RA, **Long GV**, Menzies AM, Clinicopathological characteristics and management of colitis with anti- PD1 immunotherapy alone or in combination with ipilimumab, *J Immunother Cancer*. **2020 Nov**;8(2):e001488. doi: 10.1136/jitc-2020-001488 PMID 33234603
 153. Clarke ME, Rizos H, Pereira MR, McEvoy AC, Marsavela G, Calapre L, Mehan K, Ruhen O, Khattak MA, Meiniawy TM, **Long GV**, Carlino MS, Menzies AM, Millward M, Ziman M, Gray ES, Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies, *Oncotarget* **2020 Nov 3**;11(44):4016-4027. doi: 10.18632/oncotarget.27790, PMID: 33216826

154. Dey, A., Manolios, N., **Long, G. V.**, Carlino, M. S., Kefford, R., & Schrieber, L. (2020). Musculoskeletal immune-related adverse events with use of checkpoint inhibitors in malignancy, *Intern Med J.* **2020 Nov 2**. doi: 10.1111/imj.15123. Online ahead of print. PMID: 33135853
155. Dummer, R., Lebbe, C., Atkinson, V., Mandala, M., Nathan, P. D., Arance, A., Richtig, E., Yamazaki, N., Robert, C., Schadendorf, D., Tawbi, H. A., Ascierto, P. A., Ribas, A., Flaherty, K. T., Pakhle, N., Campbell, C. D., Gusenleitner, D., Masood, A., Brase, J. C., Gasal, E., & **Long, G. V.** (2020). Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i, *Nat Med.* **2020 Oct;26**(10):1557-1563. doi: 10.1038/s41591-020-1082-2. Epub 2020 Oct 5. PMID 33020648
156. Bhave, P., Pallan, L., **Long, G. V.**, Menzies, A. M., Atkinson, V., Cohen, J. V., Sullivan, R. J., Chiarion-Sileni, V., Nyakas, M., Kahler, K., Hauschild, A., Plummer, R., Trojaniello, C., Ascierto, P. A., Zimmer, L., Schadendorf, D., Allayous, C., Lebbe, C., Maurichi, A., Santinami, M., Roy, S., Robert, C., Lesimple, T., Patel, S., Versluis, J. M., Blank, C. U., Khattak, A., Van der Westhuizen, A., Carlino, M. S., Shackleton, M., & Haydon, A. (2020). Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis, *Br J Cancer*, **2020 Oct 22**. doi: 10.1038/s41416-020-01121-y. Online ahead of print. PMID 33087895
157. Newell, F., Wilmott, J. S., Johansson, P. A., Nones, K., Addala, V., Mukhopadhyay, P., Broit, N., Amato, C. M., Van Gulick, R., Kazakoff, S. H., Patch, A. M., Koufariotis, L. T., Lakis, V., Leonard, C., Wood, S., Holmes, O., Xu, Q., Lewis, K., Medina, T., Gonzalez, R., Saw, R. P. M., Spillane, A. J., Stretch, J. R., Rawson, R. V., Ferguson, P. M., Dodds, T. J., Thompson, J. F., **Long, G. V.**, Levesque, M. P., Robinson, W. A., Pearson, J. V., Mann, G. J., Scolyer, R. A., Waddell, N., & Hayward, N. K. (2020). Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. *Nat Commun.* **2020 Oct 16**;11(1):5259. doi: 10.1038/s41467-020-18988-3. PMID: 33067454
158. Braun, M., Aguilera, A. R., Sundarajan, A., Corvino, D., Stannard, K., Krumeich, S., Das, I., Lima, L. G., Meza Guzman, L. G., Li, K., Li, R., Salim, N., Jorge, M. V., Ham, S., Kelly, G., Vari, F., Lepletier, A., Raghavendra, A., Pearson, S., Madore, J., Jacquelin, S., Effern, M., Quine, B., Koufariotis, L. T., Casey, M., Nakamura, K., Seo, E. Y., Holzel, M., Geyer, M., Kristiansen, G., Taheri, T., Ahern, E., Hughes, B. G. M., Wilmott, J. S., **Long, G. V.**, Scolyer, R. A., Batstone, M. D., Landsberg, J., Dietrich, D., Pop, O. T., Flatz, L., Dougall, W. C., Veillette, A., Nicholson, S. E., Moller, A., Johnston, R. J., Martinet, L., Smyth, M. J., & Bald, T. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells, *Immunity*, **2020 Oct 13**, 53(4):805-823.e15. doi: 10.1016/j.immuni.2020.09.010 PMID33053330
159. Fischer, G. M., Carapeto, F. C. L., Joon, A. Y., Haydu, L. E., Chen, H., Wang, F., Van Arnham, J. S., McQuade, J. L., Wani, K., Kirkwood, J. M., Thompson, J. F., Tetzlaff, M. T., Lazar, A. J., Tawbi, H. A., Gershenwald, J. E., Scolyer, R. A., **Long, G. V.**, & Davies, M. A. (2020). Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker, *Cancer Med.* **2020 Oct 5**. doi: 10.1002/cam4.3474. Online ahead of print. PMID 33016647
160. Carlino, M. S., Menzies, A. M., Atkinson, V., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., Hwu, W. J., Hodi, F. S., Guminiski, A. D., Kefford, R., Wu, H., Ibrahim, N., Homet Moreno, B., & **Long, G. V.** (2020). Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B *Clin Cancer Res.* **2020 Oct 1;26**(19):5086-5091. doi: 10.1158/1078-0432.CCR-20-0177. Epub 2020 Jun 30.
161. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, **Long GV**. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. *J Clin Oncol.* **2020 Sep 30**;JCO2000995. doi: 10.1200/JCO.20.00995. Online ahead of print. PMID 32997575
162. Dummer, R., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Kirkwood, J. M., Chiarion Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Lesimple, T., Plummer, R., Dasgupta, K., Gasal, E., Tan, M., **Long, G. V***, & Schadendorf, D*. (2020). Five-Year

- Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma., *N Engl J Med.* **2020 Sep 17**;383(12):1139-1148. doi: 10.1056/NEJMoa2005493. Epub 2020 Sep 2. PMID: 32877599
163. Attrill, G. H., Ferguson, P. M., Palendira, U., **Long, G. V.**, Wilmott, J. S., & Scolyer, R. A. (2020). The tumour immune landscape and its implications in cutaneous melanoma a, *Pigment Cell Melanoma Res.* **2020 Sep 16**. doi: 0.1111/pcmr.12926 Online ahead of print. PMID 32939993
 164. Edwards, J., Ferguson, P. M., Lo, S. N., Pires da Silva, I., Colebatch, A. J., Lee, H., Saw, R. P. M., Thompson, J. F., Menzies, A. M., **Long, G. V.**, Newell, F., Pearson, J. V., Waddell, N., Hayward, N. K., Johansson, P. A., Mann, G. J., Scolyer, R. A., Palendira, U., & Wilmott, J. S. (2020). Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas, *Cancer Immunol Res.* **2020 Sep 11**; canimm.0835.2019. doi: 10.1158/2326-6066.CIR-19-0835. Online ahead of print PMID: 32917657
 165. Ascierto, P. A., Puzanov, I., Agarwala, S. S., Blank, C., Carvajal, R. D., Demaria, S., Dummer, R., Ernstoff, M., Ferrone, S., Fox, B. A., Gajewski, T. F., Garbe, C., Hwu, P., Lo, R. S., **Long, G. V.**, Luke, J. J., Osman, I., Postow, M. A., Sullivan, R. J., Taube, J. M., Trinchieri, G., Zarour, H. M., Caraco, C., & Thurin, M. (2020). Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy), **7 Sept 2020**, published, DOI: 10.1186/s12967-020-02482-x, PMID: 32894202
 166. Hultin, S., Nahar, K., Menzies, A. M., **Long, G. V.**, Fernando, S. L., Atkinson, V., Cebon, J., & Wong, M. G. (2020). Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report, *BMC Nephrology*, **7 Sept 2020**, DOI: 10.1186/s12882-020-02044-9, PMID: 32894101
 167. Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, Mangana J, Atkinson V, Zaman F, Young A, Hoeller C, Hersey P, Dummer R, Khattak MA, Millward M, Patel SP, Haydon A, Johnson DB, Lo S, Blank CU, Sandhu S, Carlino MS, Larkin JMG, Menzies AM*, **Long GV*** Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy, *Ann Oncol* **2020 Aug**;31(8):1075-1082. doi: 10.1016/j.annonc.2020.04.471. Epub 2020 May 6. PMID: 32387454
 168. Diefenbach, R. J., Lee, J. H., Menzies, A. M., Carlino, M. S., **Long, G. V.**, Saw, R. P. M., Howle, J. R., Spillane, A. J., Scolyer, R. A., Kefford, R. F., & Rizos, H. (2020). Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA, *Cancers (Basel)* **2020 Aug 10**;12(8):E2228. doi: 10.3390/cancers12082228, PMID 32785074
 169. Puzanov I, Ribas A, Robert C, Schachter J, Nyakas N, Daud A, Blank CU, Arance A, Carlino MS, O'Day SJ, **Long GV**, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Moreno BH, Ibrahim N. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. *JAMA Oncol.* **2020 Aug 1**;6(8):1256-1264. doi: 10.1001/jamaoncol.2020.2288. PMID 32672795
 170. Menzies AM, Carlino MS, McEvoy AC, Sandhu A, Wepler AM, Diefenbach RJ, Dawson SJ, Kefford RF, Millward MJ, Al-Ogaili S, Tra T, Gray ES, Wong SQ, Scolyer RA, **Long GV**, Rizos H. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. *Clin Cancer Res.* **2020 Aug 1**;26(15):4064-4071. doi: 10.1158/1078-0432.CCR-19-3926. Epub 2020 Apr 22. PMID 3231716
 171. Puzanov, I., Ribas, A., Robert, C., Schachter, J., Nyakas, M., Daud, A., Arance, A., Carlino, M. S., O'Day, S. J., **Long, G. V.**, Margolin, K. A., Dummer, R., Schadendorf, D., Lutzky, J., Ascierto, P. A., Tarhini, A., Lin, J., Mogg, R., Homet Moreno, B., Ibrahim, N., & Hamid, O. (2020). Association of BRAFV600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of Three Clinical Trials *JAMA Oncol.* **2020 Aug 1**;6(8):1256-1264. doi: 10.1001/jamaoncol.2020.2288, PMID: 32672795
 172. SC. Sasson*, JJ. Zaunders, K. Nahar, C. Mee-Ling Munier, BP. Fairfax, S. Danielli, A. Olsson-Brown, Cc Jolly, SA. Read, G. Ahlenstiel, U. Palendira, RA. Scolyer, MS. Carlino, MJ. Payne, VTF. Cheung, T. Gupta, P Klenerman, **GV. Long**, O. Brain#, AM. Menzies, AD. Kelleher# Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis, *Clin Exp Immunol.* **2020 Jul 31**. doi: 10.1111/cei.13502. Online ahead of print PMID: 32734627

173. Khushalani, N. I., Diab, A., Ascierto, P. A., Larkin, J., Sandhu, S., Sznol, M., Koon, H. B., Jarkowski, A., Zhou, M., Statkevich, P., Geese, W. J., & **Long, G. V.** (2020). Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design, Future Oncol. **2020 Jul 29**. doi: 10.2217/fon-2020-0351. Online ahead of print. PMID: 32723187
174. Grossman D, Bar-Eli M, Bartlett EK, Berry E, Berwick M, Bowen GM, Bowles T, Buchbinder EI, Burton E, Chu EY, Coit DG, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon D, Ferris LK, Gershenwald JE, Grossmann KF, Hartman RI, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres R, Karakousis GC, Kendra KL, Korde L, Lawson DH, Leachman SA, Lee S, Leming PD, **Long GV**, Kim CC, Kirkwood JM, Marchetti MA, Mehnert JM, Ming ME, Nelson KC, Okwundu N, Othus M, Polsky D, Scolyer RA, Smith EA, Sondak V, Stark M, Thompson JA, Thompson JF, Wei ML, Swetter SM. Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit. *JAMA Dermatology* **29 July 2020** DOI: 10.1001/jamadermatol.2020.1729 PMID: 32725204
175. MH Law, LG Aoude, DL Duffy, **GV Long**, PA Johannson, AL Pritchard, K Khosrotehiani, GJ Mann, GW Montgomery, MM Iles, AE Cust, J Palmer, Melanoma GWAS Consortium, KF Shannon, AJ Spillane, JR Stretch, JF Thompson, RPM Saw, RA Scolyer, NG Martin, NK Hayward, S MacGregor Multiplex melanoma families are enriched for polygenic risk colour figures : Yes, Hum Mol Genet. **2020 Jul 27**;ddaa156. doi: 10.1093/hmg/ddaa156. Online ahead of print
176. Barnhill R, van Dam PJ, Vermeulen P, Champenois G, Nicolas A, Rawson RV, Wilmott JS, Thompson JF, **Long GV**, Cassoux N, Roman-Roman S, Busam KJ, Scolyer RA, Lazar AJ, Lugassy C. Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value, *J Pathol Clin Research*, **2020 Jul;6** (3):195-206. doi: 10.1002/cjp.2.161. Epub 2020 Apr 18, PMID: 32304183
177. Gide T, Silva IP, Quek C, Ahmed T, Menzies AM, Carlino MS, Saw RPM, Thompson JF, Batten M, **Long GV**, Scolyer RA, Wilmott JS. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. *Oncoimmunology*. **2019 Oct 16**;9(1):1659093. doi: 10.1080/2162402X.2019.1659093. PMID32002281
178. **GV Long** and RA Scolyer. Translating Basic Cancer Discoveries to the Clinic. Feature Article: A Critical Nexus. *Cancer cell*, **8 June 2020**, Vol.37(6), pp.735-737. DOI:https://doi.org/10.1016/j.ccell.2020.05.017. PMID: 32516583
179. Cipponi A, Goode DL, Bedo J, Croucher DR, McCabe MJ, Rajal AG, Saunders DN, Lobachevsky P, Junanakar SR, Papenfuss AT, Pajic M, Nessen D, Nobis M, Warren SC, Timpson P, Cowley M, Vargas AC, Qiu MR, Generali DG, Keerthikumar S, Nguyen U, Corcoran NM, **Long GV**, Blay LY, Thomas DM. MTOR Signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancers. *Science*. **2020 Jun 5**;368(6495):1127-1131. doi: 10.1126/science.aau8768. PMID 32499442
180. Watts, C. G., Smith, A. L., Robinson, S., Chang, C. S., Goumas, C., Schmid, H., Kelly, J. W., Hong, A. M., Scolyer, R. A., **Long, G. V.**, Spillane, A. J., Henderson, M., Gyorki, D. E., Mar, V. J., Morton, R. L., Saw, R. P., Varey, A. H., Mann, G. J., Thompson, J. F., Cust, A. E., Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management, *Aust J Gen Pract*, **2020 Jun;4** 9(6):355-362. doi: 10.31128/AJGP-10-19-5138. PMID: 32464734
181. Tsang V, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, **Long GV**, Menzies AM, Response to Letter to the Editor for "Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes". *J Clin Endocrinol Metab*. **2020 Jun 1**;105(6). pii: dgaa144. doi: 10.1210/clinem/dgaa144. PMID 32188993.
182. Tsang VHM, McGrath RT, Clifton-Bligh RJ, Jakrot V, Scolyer RA, Guminski AD, **Long GV**, Menzies AM. Response to Letter to the Editor: "Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes".. *J Clin Endocrinol Metab*. **2020 Jun 1**;105(6). pii: dgaa144. doi: 10.1210/clinem/dgaa144. PMID32188993
183. Johansson, P. A., Brooks, K., Newell, F., Palmer, J. M., Wilmott, J. S., Pritchard, A. L., Broit, N., Wood, S., Carlino, M. S., Leonard, C., Koufariotis, L. T., Nathan, V., Beasley, A. B., Howlie, M., Dawson, R., Rizos, H., Schmidt, C. W., **Long, G. V.**, Hamilton, H., Kiilgaard, J. F., Isaacs, T., Gray, E. S., Rolfe, O. J., Park, J. J., Stark, A., Mann, G. J., Scolyer, R. A., Pearson, J. V., van Baren, N., Waddell, N., Wadt, K. W., McGrath, L. A., Warrier, S. K., Glasson, W., & Hayward, N. K. (2020). Whole genome landscapes

- of uveal melanoma show a role for ultraviolet radiation in iris tumours, *Nature Communications*, **2020 May 15**;11(1):2408. doi: 10.1038/s41467-020-16276-8, PMID: 32415113
184. Siemys A, Kim MS, Menzies A, Willmott J, **Long GV**, Scolyer RA, Kwong LN, Holder AM, Boland GM. Integration of Digital Pathologic and Transcriptomic Analyses Connect Tumor-Infiltrating Lymphocyte Spatial Density with Clinical Response to BRAF Inhibitors. *Frontiers in Oncology* **2020 May 14**;10:757. doi: 10.3389/fonc.2020.00757. eCollection 2020, PMID: 32528881
 185. Ugurel S, Röhm J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Livingstone E, **Long GV**, Lorigan P, McArthur GA, Ribas A, Robert C, Zimmer L, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition – Update 2019 - *Eur J Cancer*. **2020 May**;13 0:126-138. doi: 10.1016/j.ejca.2020.02.021. Epub 2020 Mar 13, PMID 32179447
 186. Landi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, Brossard M, Calista D, Choi J, Fargnoli MC, Zhang T, Rodolfo M, Trower AJ, Menin C, Martinez J, Hadjisavvas A, Song L, Stefanaki I, Scolyer R, Yang R, Goldstein AM, Potrony M, Kypreou KP, Pastorino L, Queirolo P, Pellegrini C, Cattaneo L, Zawistowski M, Gimenez-Xavier P, Rodriguez A, Elefanti L, Manoukian S, Rivoltini L, Smith BH, Loizidou MA, Del Regno L, Massi D, Mandala M, Khosrotehrani K, Akslen LA, Amos CI, Andresen PA, Avril MF, Azizi E, Soyer HP, Bataille V, Dalmasso B, Bowdler LM, Burdon KP, Chen WV, Codd V, Craig JE, Dębniak T, Falchi M, Fang S, Friedman E, Simi S, Galan P, Garcia-Casado Z, Gillanders EM, Gordon S, Green A, Gruis NA, Hansson J, Harland M, Harris J, Helsing P, Henders A, Hočvar M, Höiom V, Hunter D, Ingvar C, Kumar R, Lang J, Lathrop GM, Lee JE, Li X, Lubiński J, Mackie RM, Malt M, Malvehy J, McAloney K, Mohamdi H, Molven A, Moses EK, Neale RE, Novaković S, Nyholt DR, Olsson H, Orr N, Fritsche LG, Puig-Butlle JA, Qureshi AA, Radford-Smith GL, Randerson-Moor J, Requena C, Rowe C, Samani NJ, Sanna M, Schadendorf D, Schulze HJ, Simms LA, Smithers M, Song F, Swerdlow AJ, van der Stoep N, Kukutsch NA, Visconti A, Wallace L, Ward SV, Wheeler L, Sturm RA, Hutchinson A, Jones K, Malasky M, Vogt A, Zhou W, Pooley KA, Elder DE, Han J, Hicks B, Hayward NK, Kanetsky PA, Brummett C, Montgomery GW, Olsen CM, Hayward C, Dunning AM, Martin NG, Evangelou E, Mann GJ, **Long GV**, Pharoah PDP, Easton DF, Barrett JH, Cust AE, Abecasis G, Duffy DL, Whiteman DC, Gogas H, De Nicolo A, Tucker MA, Newton-Bishop JA; GenoMEL Consortium; Q-MEGA and QTWIN Investigators; ATHENS Melanoma Study Group; 23andMe; SDH Study Group; IBD Investigators; Essen-Heidelberg Investigators; AMFS Investigators; MelaNostrum Consortium, Peris K, Chanock SJ, Demenais F, Brown KM, Puig S, Nagore E, Shi J, Iles MM, Law MH. Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility. *Nat Genet*. **2020 May**;52(5):494-504. doi: 10.1038/s41588-020-0611-8. Epub 2020 Apr 27 PMID:32341527
 187. Haydu LE, Lo S, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza I, Tawbi H, Carlino MS, Menzies AM, **Long GV**, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma *J Clin Oncol*. **2020 May 1**;38(13):1429-1441. doi: 10.1200/JCO.19.01508. Epub 2020 Jan 28, PMID31990608
 188. Lepletier A, Madore J, O'Donnell JS, Johnston RL, Li XY, McDonald E, Ahern E, Kuchel A, Eastgate M, Pearson SA, Mallardo D, Ascierto PA, Massi D, Merelli B, Mandala M, Willmott JS, Menzies AM, Leduc C, Stagg J, Routy B, **Long GV**, Scolyer RA, Bald T, Waddell N, Dougall WC, Teng MWL. Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. *Clin Cancer Res*. **28 Apr 2020**. pii: clincanres.3925.2019. doi: 10.1158/1078-0432.CCR-19-3925. PMID: 32345648
 189. Versluis JM, **Long GV**, Blank CU. Learning from Clinical Trials of neoadjuvant checkpoint blockade. *Nature Medicine* Published **26 April 2020**. 10.1038/s41591-020-0829-0. PMID 32273608
 190. Lee JH, Menzies AM, Carlino MS, Mcevoy AC, Sandhu S, Wepler AM, Diefenbach RJ, Dawson SJ, Kefford RF, Millward MJ, Al-Ogaili S, Tra T, Gray ES, Wong SQ, Scolyer RS, **Long GV**, Rizos H. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. **22 April 2020** *Clin Cancer Res*. doi: 10.1158/1078-0432.CCR-19-3926 PMID 32321716

191. Lee J, Shklovskaya E, Yin Lim S, Carlino M, Menzies A, Stewart A, Pedersen B, Irvine M, Alavi S, Yang J, Strbenac D, Saw R, Thompson J, Wilmott J, Scolyer R, **Long GV**, Kefford R, Rizos H. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. *Nat Commun.* **2020 Apr 20**;11(1):1897. doi: 10.1038/s41467-020-15726-7. PMID 32312968
192. McKelvey, K. J., Hudson, A. L., Prasanna Kumar, R., Wilmott, J. S., Attrill, G. H., **Long, G. V.**, Scolyer, R. A., Clarke, S. J., Wheeler, H. R., Diakos, C. I., & Howell, V. M. (2020). Temporal and spatial modulation of the tumor and systemic immune response in the murine G1261 glioma model. *PLoS One*, **2020 Apr 2**;15(4):e0226444. doi: 10.1371/journal.pone.0226444. PMID 32240177
193. Wang DY, McQuade JL; Rai RR, Park JJ, Zhao S, Ye F, Beckermann KE, Rubinstein SM; Johnpulle RA, **Long GV**, Carlino MS, Menzies AM, Davies MA, Johnson DB. The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. *The Oncologist* **2020 Mar**;25(3):e602-e605. doi: 10.1634/theoncologist.2019-0518. Epub 2019 Nov 29 PMID: 32162820
194. Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood JM, Hauschild A, Schadendorf D, **Long GV**. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. *Lancet Onc. Lancet Oncol.* **2020 Mar**;21(3):358-372. doi: 10.1016/S1470-2045(20)30062-0. PMID32007138
195. Pirozyan MR, McGuire HM, Al Emran A, Tseng H, Tiffen JC, Lee JH, Carlino MS, Menzies AM, **Long GV**, Scolyer RA, Fazekas de St Groth B, Hersey P. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. *Front Immunol.* **2020 Mar 10**; 11:372. doi: 10.3389/fimmu.2020.00372. PMID 32210968
196. Rapport F, Smith AL, Cust AE, Mann GJ, Watts CG, Gyorki DE, Henderson M, Hong AM, Kelly JW, **Long GV**, Mar VJ, Morton RL, Saw RP, Scolyer RA, Spillane AJ, Thompson JF, Braithwaite J. Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. **27 Feb 2020** *BMJ Open*. doi: 10.1136/bmjopen-2019-032636. PMID 32111612
197. Eggermont AMM; Kicinski M; Blank CU; Mandalà M; **Long GV** Atkinson V, Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial, *JAMA Oncol*, **2 Jan 2020** doi: 10.1001/jamaoncol.2019.5570. PMID 31895407
198. Luke J, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, **Long GV**, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, Eggermont AMM. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. *Future Oncol.* E-published **24 December 2019**, 16(3), 4429–4438. DOI: 10.2217/fon-2019-0666, PMID: 31870188
199. Diefenbach, R. J., Lee, J. H., Strbenac, D., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., **Long, G. V.**, Spillane, A. J., Stretch, J. R., Saw, R. P. M., Thompson, J. F., Ch'ng, S., Scolyer, R. A., Kefford, R. F., & Rizos, H. (2019). Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. *Cancers (Basel)*. **2019 Nov 29**;11(12). pii: E1905. doi: 10.3390/cancers11121905. PMID 31795494
200. Atkinson V, Sandhu S, Hospers G, **Long GV**, Aglietta M, Ferrucci PF, Tulyte S, Cappellini GCA, Soriano V, Sayed Ali, Poprach A, Cesas A, Rodriguez-Abreu D, Lau M, de Jong E, Legenne P, Stein D, King B, van Thienen JV. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). *EPub ahead of print. Melanoma Res.* **2020 Jun**;30, doi: 10.1097/CMR.0000000000000654. PMID31895752
201. Diefenbach RJ, Lee JH, Chandler D, Wang Y, Pflueger C, **Long GV**, Scolyer RA, Carlino MS, Menzies AMM, Kefford RF, Rizos H. Hypermethylation of Circulating Free DNA in Cutaneous Melanoma. *Applied sciences.* **2019**,

202. Hong AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, Lo SN, Haydu LE, Vardy JL, Nowak AK, Dhillion HM, Ahmed T, Shivalingam B, **Long GV**, Menzies AM, Hruby G, Drummond KJ, Mandel C, Middleton MR, Reisse CH, Paton EJ, Steel V, Williams NC, Scolyer RA, Morton RL, Thompson JF. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. *J Clin Oncol.* **2019 Nov 20**;37(33):3132-3141. doi: 10.1200/JCO.19.01414. PMID31553661
203. Silva I, Lo S, Quek C, Gonzalez M, Carlino MS, **Long GV**, Menzies AM. Site-Specific Response Patterns, Pseudoprogression, and Acquired Resistance in Patients With Melanoma Treated With Ipilimumab Combined With Anti-PD-1 Therapy. *Cancer.* **2020 Jan 1**;126(1):86-97. doi: 10.1002/cncr.32522. PMID31584722
204. House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, Sek K, Mardiana S, Gide TN, Quek C, Scolyer RA, **Long GV**, Wilmott JS, Loi S, Darcy PK, Beavis PA. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. *Clin Cancer Res.* **2020 Jan 15**;26(2):487-504. doi: 10.1158/1078-0432.CCR-19-1868. PMID31636098
205. Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms K, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, **Long GV**, Kefford R, Enk A, Blank CU, Hassel JC. Targeted therapy in advanced melanoma with rare BRAF mutations. *J Clin Oncol.* **2019 Nov 20**;37(33):3142-3151. doi: 10.1200/JCO.19.0048. PMID31580757.
206. Mason R, Dearden HC, Nguyen B, Oon JS, Smith JL, Randhawa M, Mant A, Warburton L, Lo S, Meniawy T, Guminski A, Parente P, Ali S, Haydon A, **Long GV**, Carlino MS, Millward M, Atkinson VG, Menzies AM. Combined ipilimumab and nivolumab first-line and after BRAF targeted therapy in advanced melanoma. *Pigment Cell Melanoma Res.* **2020 Mar**;33(2):358-365. doi: 10.1111/pcmr.12831. PMID31587511.
207. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao CD, Cowey L, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, **Long GV**, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi S, Wolchok JD. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med.* **2019 Oct 17**;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. PMID31562797.
208. **Long GV**, Saw RPM, Lo S, Nieweg OE, Shannon KF, Gonzalez M, Guminski A, Lee JH, Lee H, Ferguson PM, Rawson RV, Wilmott JS, Thompson JF, Kefford RF, Ch'ng S, Stretch JR, Emmett L, Kapoor R, Rizos H, Spillane AJ, Scolyer RA, Menzies AM. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. *Lancet Oncol.* **2019 Jul**;20(7):961-971. doi: 10.1016/S1470-2045(19)30331-6. PMID31171444
209. **Long GV**, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. *Lancet Oncol.* **2019 Aug**;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. PMID31221619
210. Robert C, Grob J. J., Stroyakovskiy D., Karaszewska B., Hauschild A., Levchenko E., Chiarion Sileni V., Schachter J., Garbe C., Bondarenko I., Gogas H., Mandala M., Haanen J., Lebbe C., Mackiewicz A., Rutkowski P., Nathan P. D., Ribas A., Davies M. A., Flaherty K. T., Burgess P., Tan M., Gasal E., Voi M., Schadendorf D., & **Long, G. V.** (2019). Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma, *N Engl J Med.* **2019 Aug 15**;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4, PMID: 31166680
211. Colebatch AJ, Ferguson P, Newell F, Kazakoff S, Witkowski T, Dobrovic A, Johansson PA, Menzies AM, Saw R, Stretch J, McArthur G, **Long GV**, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Waddell N, Scolyer RA, Wilmott JS. Molecular genomic profiling of melanocytic nevi. *J Invest Dermatol.* **2019 Aug**;13. doi: 10.1016/j.jid.2018.12.033. Epub 2019 Feb 14. PMID 30772300

212. Newel F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Liang Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, Jönsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane A, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. *Nat Commun.* 2019 Jul 18;10(1):3163. doi: 10.1038/s41467-019-11107. PMID31320640
213. Zhang X, Zhong Tang J, Vergara I, Fang Zhang Y, Szeto P, Yang L, Mintoff C, Colebatch A, McIntosh L, Mitchell K, Shaw E, Rizos H, **Long GV**, Hayward N, McArthur G, Papenfuss A, Harvey K, Shackleton M. Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma. *Mol Cancer Res* 2018. *Mol Cancer Res.* 2019 Jul;17(7):1435-1449. doi: 10.1158/1541-7786.MCR-18-0407. Epub 2019 Mar 4. PMID 30833299
214. Eggermont AMM, Blank CU, Mandala M, **Long GV**, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. *Eur J Cancer.* 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. PMID31200321
215. Ascierto PA, Ferrucci PF, Fisher R Del Vecchio, M, Atkinson V, Schmidt H, Schachter J, Queirolo P, **Long GV**, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. *Nat Med.* 2019 Jun;25(6):941-946. doi: 10.1038/s41591-019-0448-9. Epub 2019 Jun 6 PMID: 31171878
216. Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, **Long GV**. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. *Lancet Oncol* 2019; 20(9):1239-1251
217. Johnson DB, McDonnell WJ, Ericsson-Gonzalez PI, Al-Rohil R, Mobley BC, Salem J-E, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem J, Menzies AM, Tio M, **Long GV**, Cohen JV, Guidon AC, O'Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger S, Rushing E, Buchbinder E, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. *Nature Med* 2019; 25(8):1243-1250.
218. Ipenburg NA, Nieweg O, Ahmed T, van Doorn R, Scolyer RA, **Long GV**, Thompson JF, Lo S. External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. *Br J Surg.* 2019 Sep;106(10):1319-1326. doi: 10.1002/bjs.11262. Epub 2019 Jul 16, PMID: 31310333
219. Amaria RN, Menzies A, Burton EM, Van Akooi A, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty K, Gershenwald JE, Hamid O, Hong A, Kirkwood J, Lo S, Margolin K, Messina J, Postow M, Rizos H, Ross MI, Rozeman L, Saw R, Scolyer R, Sondak V, Spillane A, Sullivan RJ, Taube J, Tetzlaff MT, Thompson J, Van de Weil B, Davies JMA, Wargo JA, Blank CU, Tawbi H, Long GV. Shaping the Future of Neoadjuvant Systemic Therapy in Melanoma: Recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncol.* 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8 PMID 31267972
220. **Long GV**, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Hauschild A. Reply to E. Hindié and K.R. Hess. *J Clin Oncol.* 2019 May 20;37(15):1356-1358. doi: 10.1200/JCO.19.00004. Epub 2019 Apr 2. PMID 30939092

221. Gide, T. N., Allanson, B. M., Menzies, A. M., Ferguson, P. M., Madore, J., Saw, R. P. M., Thompson, J. F., **Long, G. V.**, Wilmott, J. S., & Scolyer, R. A. (2019). Inter- and inpatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. *Histopathology*. **2019 May**;74(6):817-828. doi: 10.1111/his.13814, PMID: 30589949
222. **Long GV.** Making a difference to many. *Nat Med*. March **2019**;25(3):356.
223. **Long GV**, Gasal E, Hauschild A. Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. Reply. *N Engl J Med*. April **2019**;380(14):1376-7.
224. Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Højberg L, Schmidt H, van Thiene JV, Haanen Jbag, Tiaïnen L, Svane IM, Makela S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, **Long GV**, Atkinson V, Blank CU, Neyns B. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. *Ann Oncol*. March **2019**.
225. Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall, V L J, Liu C, Bettington M. L, Takeda K, **Long GV**, Scolyer R. A, Lan R, Siemers N, Korman A, Teng MWL, Johnston R. J, Dougall WC, Smyth, M J. CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. *Cancer Immunol Res*. **2019 Apr**;7(4):559-571. doi: 10.1158/2326-6066.CIR-18-0637. Epub 2019 Mar 20. PMID: 30894377
226. Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., Broeks, A., van Thienen, J. V., Guminski, A. D., Acosta, A. T., Ter Meulen, S., Koenen, A. M., Bosch, L. J. W., Shannon, K., Pronk, L. M., Gonzalez, M., Ch'ng, S., Grijpink-Ongering, L. G., Stretch, J., Heijmink, S., van Tinteren, H., Haanen, J., Nieweg, O. E., Klop, W. M. C., Zuur, C. L., Saw, R. P. M., van Houdt, W. J., Peeper, D. S., Spillane, A. J., Hansson, J., Schumacher, T. N., **Long, G. V.**, & Blank, C. U. (2019). Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. *Lancet Oncol*. **2019 Jul**;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31. PMID: 31160251
227. Quek C, Rawson RV, Ferguson PM, Shang P, Silva I, Saw RPM, Shannon K, Thompson JF, Hayward NK, **Long GV**, Mann GJ, Scolyer RA, Wilmott JS. Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. *Oncotarget*. Jan **2019**;10(9):930-41.
228. Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SM, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM., **Long GV**, Johnson DB, Menzies AM. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. *Pigment Cell Melanoma Res*. **2019**. 32(4):553-563
229. Heinzerling L, Ascierto PA; Dummer R, Gogas H, Grob JJ, Lebbe C, **Long GV**, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A. Adverse events 2.0- Let's get SERIOs New reporting for adverse event outcomes needed in the era of immuno-oncology. *Eur J Cancer*. **2019 May**;112:29-31. doi: 10.1016/j.ejca.2019.01.015. Epub 2019 Mar 21. PMID: 30903870
230. Edwards J, Batten M, Ferguson A, Palendira U, Wilmott JS, **Long GV**, Scolyer RA. Novel immune targets in melanoma – Response. *Clin Cancer Res* Sept **2019**. 25:5254-5425.
231. Edwards JJ, Tasker A, Silva I, Quek C, Batten M, Ferguson AL, Allen R, Allanson BM, Saw RP, Thompson JF, Menzies AM, Palendira U, Wilmott JS, **Long GV**, Scolyer RA. Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naïve melanoma: implications for clinical trials. *Clin Cancer Res*. June **2019**. 25:3247-3258.
232. Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH, Jr, Carlino MS, Fisher R, **Long GV**, Hodi SF, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghorri R, Homet Moreno B, Ibrahim N, Hamid O. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. **2019** *Nature Medicine*. 25:936-940

233. Lee JH, Saw RPM, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch J, Howle J, Menzies AM, Carlino MS, Kefford RF, **Long GV**, Scolyer RA, Rizos. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients *Annals of Oncology*. **2018** 30:815-822.
234. Kim H, Duong JK, Gonzalez M, **Long GV**, Menzies AM, Rizos H, Yin Lim S, Lee J, Boddy AV. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. *Cancer Chemother Pharmacol* April **2019**. 83:693-704.
235. Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Lesimple, T., Plummer, R., Schachter, J., Dasgupta, K., Manson, S., Koruth, R., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M., & **Long, G. V.** (2019). Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. *Lancet Oncol*. **2019 May**;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27, PMID: 30928620
236. Gide T, Quek C, Menzies A, Tasker A, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RP, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva I, Batten M, Scolyer RA, Wilmott JS* **Long GV***,. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. *Cancer Cell* Feb **2019**. 35: 238-255.
237. Ascierto PA, **Long GV**, Robert C, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles , Mihalciou C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Marie Svane I, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V. Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. *JAMA Onc* **2018**. [Epub ahead of print].
238. Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood J, **Long GV**. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. *J Clin Oncol* **2018**. [Epub ahead of print].
239. Arasaratnam M, Hong A, Shivalingam B, Wheeler H, Guminski A, **Long GV**, Menzies AM. Leptomeningeal melanoma-A case series in the era of modern systemic therapy. *Pigment Cell Melanoma Res* **2018**; 31: 120-124.
240. Lim S, Lee J, Gide T, Menzies A, Guminski A, Carlino M, Breen E, Yang J, Ghazanfar S, Kefford R, Scolyer R, **Long GV**, Rizos H. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. *Clin Cancer Res*. **2019 Mar** 1;25(5):1557-1563. doi: 10.1158/1078-0432.CCR-18-2795. Epub 2018 Nov 8. 3, PMID: 30409824
241. Pires da Silva I, Wang K, Wilmott J, Holst J, Carlino M, Park J, Quek C, Wongchenko M, Yan Y, Mann G, Johnson D, McQuade J, Rai R, Kefford R, Rizos H, Scolyer R, Yang J, **Long GV**, Menzies A. Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma. *Clin Cancer Res* **2019**; 25: 1272-1279
242. Lee H, Quek C, Edwards J, Madore J, Palendira M, Menzies A, Carlino M, Guminski A, Saw R, Thompson J, Silva I, Ferguson P, **Long GV**, Scolyer R, Wilmott J. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. *Oncoimmunology* **2019**, 8: e1537581
243. Tio M, Rai R, Ezeoke OM, McQuade J, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson B, Rizvi H, Joshua AM, Hellmann MD, **Long GV**, Menzies AM. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. *Eur J Cancer* **2018**; 104: 137-144.
244. Orozco J, Knijnenburg J, Manughian-Peter A, Salomon M, Barkhoudarian G, Jalas J, Wilmott J, Hothi, Xiaowen Wang R, Takasumi Y, Buckland M, Thompson J, **Long GV**, Cobbs C, Shmulevich I, Kelly

- D, Scolyer R, Hoon D, Marzese D. Epigenetic profiling for the molecular classification of metastatic brain tumors. *Nature Communications* **2018**; 9: 4627.
245. Wang D, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell K, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, **Long GV**, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan R, Moslehi JJ, Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis *JAMA Oncol.* **2018 Dec 1**;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923, PMID: 30242316
 246. Dodds T, Wilmott J, Jackett L, Lo S, **Long GV**, Thompson J, Scolyer R. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. *Pathology* **2019**. Epub; 51: 39-45.
 247. Silva da I, Battem M, **Long GV**. Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas. *Br J Cancer* **2018**; 119: 661-662.
 248. **Long GV**, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. *Ann Oncol* **2018**. 29:2208-2213.
 249. Wang K, Menzies AM, Silva IP, Wilmott J, Yan Y, Wongchenko M, Kefford R, Scolyer RA, **Long GV**, Tarr G, Mueller S, Yang JYH. bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. *Bioinformatics.* **2019 Apr 15**;35(8):1350-1357. doi: 10.1093/bioinformatics/bty783. PMID: 30215668
 250. Allanson B, Weber M, Jackett L, Chan C, Lau L, Ziegler D, Warby M, **Long GV**, Maher A, Tucker K, Anazodo A, Scolyer RA. Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. *Pathology* **2018**. 50: 648-653.
 251. Wilmott J, Johansson P, Newell F, Waddell N, Ferguson P, Quek C, Patch AM, Nones K, Shang P, Pritchard A, Kazakoff S, Holmes O, Leonard C, Wood S, Xu Q, Saw RP, Spillane AJ, Stretch JR, Shannon KF, Kefford RF, Menzies AM, **Long GV**, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA. Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. *Int J Cancer* **2019**; 144: 1049-1060.
 252. Strub T, Ghiraldini F, Carcamo S, Wroblewska A, Li M, Wang Z, Singh R, Goldberg M, Hasson D, Gallagher S, Hersey P, Ma'ayan A, **Long GV**, Scolyer R, Zheng B, Brown B, Bernstein E. SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signaling. *Nat Commun* **2018**; 9:3440.
 253. Krisp C, Parker R, Pascovici D, Hayward NK, Wilmott JS, Thompson JF, Mann G, **Long GV**, Scolyer R, Molloy M. Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. *Br J Cancer* **2018**; 119: 713-723.
 254. Tetzlaff M, Messina J, Stein J, Xu X, Amaria R, Blank C, Van De Wiel B, Ferguson P, Rawson R, Ross M, Spillane A, Gershenwald J, Saw R, Mitchell T, Menzies A, **Long GV**, Wargo J, Davies M, Prieto V, Taube J, Scolyer R. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. *Ann Oncol* **2018**; 29: 1861-1868.
 255. Carlino MS, **Long GV**, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blan C, Hoeller C, Bar-Selat G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomized clinical trial. *Eur J Cancer* **2018**; 101: 236-243.
 256. **Long GV**, Atkinson V, Hong A, McArthur G, Menzies AM. Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - Authors' reply. *Lancet Oncol* **2018**; 19: e367.
 257. Eggermont A, Blank C, Mandala M, **Long GV**, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto P, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh A, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi A, Suci S, Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. *N Engl J Med* **2018**; 378: 1789-1801.

258. Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss S, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea G, Ecker BL, Allegranza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich DI, Stone EL, Nowicki TS, Sosman JA, Rai R, Carlino MS, **Long GV**, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling MA, Schadendorf D, Menzies AM, McQuade JL, Johnson DB, Osman, Weeraratna AT. Age correlates with response to anti-PD1, reflecting age-related differences in intra-tumoral effector and regulatory T cell populations. *Clinical Cancer Res.* **2018**; 24: 5347-5356.
259. **Long GV**, Hauschild A, Kirkwood M. Adjuvant Therapy in Resected Melanoma. *N Engl J Med* **2018**; 19:1813-1823.
260. Edwards J, Wilmott J, Madore J, Gide T, Quek C, Chen J, Hewavisenti R, Hersey P, Gebhardt T, Weninger W, Britton W, Saw R, Thompson J, Menzies A, **Long GV**, Scolyer R, Palendira U. CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy naive melanoma patients and response to anti-PD1 immunotherapy. *Clin Cancer Res* **2018**; 24: 3036-3045.
261. Borcoman E, Nandikolla A, **Long GV**, Goel S, Le Tourneau C. Patterns of response and progression to immunotherapy. *American Society for Clinical Oncology Education Book* **2018**. 38:169-178.
262. **Long GV**, Atkinson V, Lo S, Guminski AS, Sandhu S, Brown MP, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncol* **2018**; 19:672-681.
263. De Sousa SMC, Sheriff N, Tran CH, Menzies AM, Tsang VHM, Guminski AD, **Long GV**, Tonks KTT. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. *Pituitary* **2018**; 21: 274-282.
264. Star P, Goodwin A, Kapoor R, Conway RM, **Long GV**, Scolyer R, Guitera P. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. *Eur J Cancer* **2018**; 92: 48-53.
265. Tio M, Xuan W, Carlino, Shivalingam B, Fogarty G, Guminski A, Lo S, Hong A, Menzies A, **Long GV**. Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. *Pig Cell Mel Res* **2017**; 31:509-515.
266. Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger S, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, **Long GV**, Lorigan P. Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" *Eur J Cancer* **2018**; 91: 116-124.
267. Lee J, **Long GV**, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford K, Rizos H, Carlino M. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. *JAMA Oncol* **2018**; 4: 717-721.
268. Scott E, **Long GV**, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang V. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma *Eur J Endocrinol* **2018**; 178: 175-182.
269. Tan A, Emmett L, Lo S, Liu V, Kapoor R, Carlino M, Guminski A, **Long GV**, Menzies A. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. *Ann Oncol* **2018**; 29: 2115-2120.
270. McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JP, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki T, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, **Long GV**, Johnson DB, Menzies AM, Davies MA. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. *Lancet Oncol* **2018**; 19: 310-322.

271. Lee J, Lyle M, Menzies A, Chan M, Lo S, Clements A, Carlino M, Kefford R, **Long GV**. Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. *Pigment Cell Melanoma Res* **2018**; 31: 404-410.
272. **Long GV**. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma. *Clin Adv Hematol Oncol* **2018**; 16(1):25-27.
273. Ferguson P, **Long GV**, Scolyer RA, Thompson JF. Impact of genomics on the surgical management of melanoma. *Br J Surg* **2018**; 105: e31-e47.
274. Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, **Long GV**, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. *Ann Oncol* **2018**; 29: 250-255.
275. Liang R, Meiser B, Smith S, Kasparian N, Lewis C, Chin M, **Long GV**, Ward R, Menzies A, Harris-Wai J, Kaur R. Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study. *Eur J Cancer Care (Engl)*. **2017 Nov**;26(6). doi: 10.1111/ecc.12600. Epub 2016 Oct 11
276. Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., **Long, G. V.**, Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., Haydu, L. E., Eggermont, A. M. M., Flaherty, K. T., Balch, C. M., Thompson, J. F. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual, *CA Cancer J Clin*. **2017 Nov**;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13, PMID: 29028110
277. Arasaratnam M, Hong A, Shivalingam B, Wheeler H, Guminski A, **Long GV**, Menzies AM. Leptomeningeal melanoma – a case series in the era of modern systemic therapy. *Pig Cell Mel Res* **2017**. 31:120-124.
278. Davies MA, Saiag P, **Long GV**. Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough? - Authors' reply. *Lancet Oncol* **2017**; 18:509.
279. Gu YF, Menzies AM, **Long GV**, Fernando SL, Herkes G. Immune mediated neuropathy following combined checkpoint immunotherapy. *J Clin Neurosci* **2017**; 45:14-17.
280. Gide TN, Wilmott J, Scolyer R, **Long GV**. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. *Clin Cancer Res* **2018**; 24: 1260-1270.
281. Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Won Kim D, Algazi A, Johnson DB, Liniker E, Kong B, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku P, Wei C, Sosman JA, Joseph R, Postow MA, Carlino MS, Hwu W-J, Scolyer RA, Messina J, Cochran AJ, **Long GV**, Ribas A. High response rate to PD-1 blockade in desmoplastic melanomas. *Nature* **2018**; 553: 347-350.
282. **Long GV**, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. *J Clin Oncol* **2018**; 36: 667-673.
283. **Long GV**, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood J. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. *N Engl J Med* **2017**; 19:1813-1823.
284. Lim SY, Lee J, Welsh S, Ahn SB, Breen E, Khan A, Carlino M, Menzies A, Kefford R, Scolyer RA, **Long GV**, Rizos H. Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. *Biomark Res*. **2017 Nov** 10;5:32. doi: 10.1186/s40364-017-0112-9. eCollection 2017, PMID 29152306
285. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AN, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, **Long GV**, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Min Kim T, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA., Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III or IV melanoma. *N Engl J Med* **2017**. 377(19):1824-1835.

286. Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey L, Lao C, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino M, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, **Long GV**, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi S, Larkin J. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med* **2017**; 377:1345-1356.
287. Glodde N, Bald T, Boorn-Konijnenberg D, Nakamura K, O'Donnell J, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, Van der Sluis T, Ruotsalainen J, Gaffal E, Landsberg J, Ludwig K, Wilhelm C, Riek-Burchardt M, Müller A, Gebhardt C, Scolyer R, **Long GV**, Janzen V, Teng M, Kastenmüller W, Mazzone M, Smyth M, Tüting T, Hölzel M. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. *Immunity* **2017**; 47:789-802.
288. Sidhu P, Menzies AM, Carlino MS, **Long GV**, Kapoor R. Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy. *J Med Imaging Radiat Oncol* **2017**. 61(6):759-766.
289. Gershenwald J, Scolyer RA, Hess K, Sondak V, **Long GV**, Ross M, Lazar A, Faries M, Kirkwood J, McArthur G, Haydu L, Eggermont A, Flaherty K, Balch C, Thompson J, and members of the AJCC Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA* **2017**. 67(6):472-492.
290. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka R, Michielin O, Olszanski AJ, Malvey J, Cebon J, Fernandez E, Kirkwood J, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman M, Gansert J, Hodi FS, **Long GV**. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. *Cell* **2018**; 174: 1031-1032.
291. Aivazian K, **Long GV**, Sinclair E, Kench JG, McKenzie CA. Histopathology of Pembrolizumab-Induced Hepatitis: a case report. *Pathology* **2017**. 49(7): 789-792 [Epub ahead of print].
292. Rawson R, Robbins E, Kapoor R, Scolyer RA, **Long GV**. Recurrent bowel obstruction: unusual presentation of Pembrolizumab-induced pancreatitis in annular pancreas. *Eur J Cancer* **2017**; 82:167-170.
293. Silvam IP, **Long GV**. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. *Curr Opin Oncol*. **2017 Nov**;29(6):484-492. doi: 10.1097/CCO.0000000000000405.
294. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, **Long GV**, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of novel therapies – Update 2017. *Eur J Cancer* **2017**; 83:247-257.
295. Somasundaram R, Wagner SN, Zhang G, Perego M, Wagner C, Hristova D, Garg K, Hards R, Wei Z, Wu L, Frederick DT, Flaherty K, Scolyer RA, **Long GV**, Maurer M, Fukunaga-Kalabis M, Krepler C, Damle M, Ellingsworth C, Grinman L, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Liu Q, Bennett K, Griss J, Schaidler H, Czerniecki BJ, Schuchter L, Herlyn D, Herlyn M. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. *Nat Commun* **2017**; 8:607.
296. Reinhardt J, Landsberg J, Schmid-Burgk JL, Bibiloni Ramis B, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, **Long GV**, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M. MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. *Cancer Res* **2017**; 77:4697-4709.
297. Mar VJ, Scolyer RA, **Long GV**. Computer-assisted diagnosis for skin cancer: have we been outsmarted? *Lancet* **2017**; 389:1962-1964.
298. Kakavand H, Rawson R, Pupo G, Yang J, Menzies A, Carlino M, Kefford R, Howle J, Saw R, Thompson J, Wilmott J, **Long GV**, Scolyer R, Rizos H. PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. *Clin Can Res* **2017**; 23:6054-6061.

299. Kakavand H, Jakkett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, **Long GV**, Scolyer RA. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. *Mod Pathol* **2017**; 30(12): 1666-1676.
300. Schadendorf D, Larkin J, Wolchok J, Hodi S, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey L, Lao C, Wagstaff J, Callahan M, Postow M, Smylie M, Ferrucci P, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, **Long GV**. Health-related quality of life results from the phase III CheckMate 067 Study. *Eur J Cancer* **2017**; 82: 80-91.
301. Schadendorf D, **Long GV**, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen J, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies M, Zhang Y, Kaper M, Mookerjee B, Legos J, Flaherty K, Robert C. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. *Eur J Cancer* **2017**; 82: 45-55.
302. Young A, Ngiew SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas D, Ahern E, Huntington N, Schadendorf D, **Long GV**, Boyle G, Hölzel M, Scolyer RA, Smyth MJ. Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. *Cancer Res* **2017**; 77:4684-4696.
303. **Long GV**, Atkinson V, Cebon J, Jameson M, Fitzharris B, McNeil C, Hill A, Ribas A, Atkins M, Thompson J, Hwu W-J, Hodi S, Menzies A, Guminski A, Kefford R, Kong B, Tamjid B, Srivastava A, Lomax A, Islam Shu X, Ebbinghaus S, Ibrahim N, Carlino M. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma: the open-label, phase 1b KEYNOTE-029 study. *Lancet Onc* **2017**; 18:1202-1210.
304. Vilain R, Menzies A, Wilmott J, Kakavand H, Madore J, Guminski A, Liniker E, Kong B, Cooper A, Howle J, Saw R, Jakrot V, Lo S, Thompson J, Carlino M, Kefford R, **Long GV** (shared senior author), Scolyer R. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. *Clin Cancer Res* **2017**; 23:5024-33.
305. Schachter J, Ribas A, **Long GV**, Arance A, Grob J-J, Mortier L, Daud A, Carlino M, Catriona McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella T, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet* **2017**; 390:1853-1862.
306. **Long GV**, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Ann Oncol* **2017**; 28:1631-1639.
307. Davies M, Saiag P, Robert C, Grob J-J, Flaherty K, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos S, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, MD, Zhang Y, Huang Y, Mookerjee B, **Long GV**. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. *Lancet Oncol* **2017**; 18(7):863-873.
308. Wilmott J, Rizos H, Scolyer RA, **Long GV**. The "tricky business" of identifying mechanisms of resistance to anti-PD-1. *Clin Cancer Res* **2017**; 23:2921-2923.
309. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch A-M, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, de Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm S-J, Pritchard A, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, **Long GV**, Cebon J, Shackleton M, Spillane AJ, Saw RPM, Lopez-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ. Whole-genome landscapes of major melanoma subtypes. *Nature* **2017**; 545:175-180.

310. **Long GV**, Weber JS, Larkin J, Atkinson V, Grob J-J, Schadendorf D, Dummer R, Robert C, Marquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain J-F, Hodi FS, Wolchok JD. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials. *JAMA Onc* **2017**; 3:1511-1519.
311. Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozon V, **Long GV**, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* **2017**; 18:435-445.
312. Hendrix MJ, Kandela I, Mazar AP, Seftor EA, Seftor RE, Margaryan NV, Strizzi L, Murphy GF, **Long GV**, Scolyer RA. Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. *Lab Invest*. **2017 Feb**;97(2):176-186. doi: 10.1038/labinvest.2016.107. Epub 2016 Oct 24 PMID 27775961
313. Lee JH, **Long GV**, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. *Ann Oncol* **2017**; 28:1130-1136.
314. Pupo G, Boyd SC, Fung C, Carlino MS, Menzies AM, Pedersen B, Johansson P, Hayward NK, Kefford RF, Scolyer RA, **Long GV**, Rizos H. Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. *Biomark Res* **2017**; 5:17.
315. Luke JJ, Flaherty KT, Ribas A, **Long GV**. Targeted agents and immunotherapies: optimizing outcomes in melanoma. *Nat Rev Clin Oncol*. **2017**;14:463-482.
316. Menzies AM, **Long GV**. Optimum dosing of ipilimumab in melanoma: too little, too late? *Lancet Oncol* **2017**; 18:558-559.
317. Eskiocak B, McMillan E, Mendiratta S, Kollipara R, Zhang H, Humphries C, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales T, Eskiocak U, Smith MP, Sudderth J, Komurov K, DeBerardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, **Long GV**, Kittler R, White M. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. *Cancer Discov* **2017**; 7(8); 832–51.
318. Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaff JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, **Long GV** (shared senior author), Hellmann MD. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. *J Clin Oncol*. **2017 Mar**;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30 PMID: 27646942
319. O'Donnell JS, **Long GV**, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. *Cancer treatment reviews* **2017**; 52:71-81.
320. Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, **Long GV**, Menzies AM, Klein O, Carlino MS. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. *Br J Cancer*, **2017**; 116:1558-1563.
321. Choong ES, Lo S, Drummond M, Fogarty GB, Menzies AM, Guminski A, Shivalingam B, Clarke K, **Long GV**, Hong AM. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. *Eur J Cancer* **2017**; 75:169-178.
322. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoustari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, **Long GV**. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. *Ann Oncol* **2017**; 28:368-376.
323. Atkinson V, **Long GV**, Menzies AM, McArthur G, Carlino MS, Millward M, Roberts-Thomson R, Brady B, Kefford R, Haydon A, Cebon J. Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. *Asia Pac J Clin Oncol* **2016**; 7:5-12

324. **Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 2016; 17:1743-1754.**
325. Carlino MS, Vanella V, Girgis C, Giannarelli D, Guminski A, Festino L, Kefford RF, Menzies AM, **Long GV**, Ascierto PA. Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. Br J Cancer **2016**; 115:1280-1284.
326. Arnheiter H, **Long G**, Aplin A, Harris J, Kelsh R. Triple jeopardy for people with albinism. Pigment Cell Melanoma Res **2016**; 29(5):48.
327. Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song JY, Verbrugge I, Hoeller C, Dummer R, Haanen JB, **Long GV**, Blank CU. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology **2016**. [Epub ahead of print]5(12): e1238557.
328. Menzies AM, **Long GV**. Recent Developments in Melanoma Therapy. JAMA Oncol **2016**; 2:1259-1260.
329. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, **Long GV**, Li H, Waxman IM, Jiang J, Caroline Robert C. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients with Advanced Melanoma. J Clin Oncol **2017**; 35:785-792.
330. **Long G**, Hoadley A, Sandanayake N. Atrophic Exocrine Pancreatic Insufficiency Associated with Anti-PD1 Therapy. Ann Oncol **2017**; 28(2):434-435.
331. Thompson, JF, Shivalingam, B, Hong AM, Lyle, M, **Long, GV**, Chapter 5 – Brain Metastases from Melanoma, Brain Metastases from Primary Tumours, Volume 3, **2016 October 21**
332. Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, Carlino MS, Hong A, **Long GV**. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology **2016**. 5(9): e1214788.
333. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, **Long GV**, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res **2016**; 29:404-416.
334. **Long GV**, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau I, Dastani HB, Waxman IM, Abernethy AP. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol **2016**; 27:1940-1946.
335. Kong BY, Menzies AM, Saunders CA, Liniker E, Ramanujam S, Guminski A, Kefford RF, **Long GV**, Carlino MS. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell Melanoma Res **2016**; 29:572-577.
336. Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E, Saw RP, Yu B, Cooper WA, **Long GV**, O'Toole SA, Scolyer RA. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology **2016**; 69:680-686.
337. Carlino MS, **Long GV**. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma? Clin Cancer Res **2016**; 22:3992-3998.
338. Ascierto PA, **Long GV**. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. Lancet Oncol **2016**; 17:1037-1039
339. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkova AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA,

- Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, **Long GV**, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. *Nature* **2016**; 537:254.
340. De Paoli-Iseppi R, Johansson PA, Menzies AM, Dias KR, Pupo GM, Kakavand H, Wilmott JS, Mann GJ, Hayward NK, Dinger ME, **Long GV**, Scolyer RA. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. *Pathology* **2016**; 48:261-266.
 341. Welsh SJ, Rizos H, Scolyer RA, **Long GV**. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? *Eur J Cancer* **2016**; 62:76-85.
 342. Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, **Long GV**, Carlino MS, Klein O. Reply to Comment on Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. *Br J Cancer* **2017**; 116:e15.
 343. Madore J, Strbenac D, Vilain R, Menzies AM, Yang JY, Thompson JF, **Long GV**, Mann GJ, Scolyer RA, Wilmott JS. PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. *Clin Cancer Res* **2016**; 22:3915-3923.
 344. Lyle M, Haydu LE, Menzies AM, Thompson JF, Saw RP, Spillane AJ, Kefford RF, Mann GJ, Cooper WA, Yu B, Scolyer RA, O'Toole SA, **Long GV**. The molecular profile of metastatic melanoma in Australia. *Pathology* **2016**; 48:188-193.
 345. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, **Long GV**, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. *Eur J Cancer* **2016**; 53:125-134.
 346. Pulvirenti T, Hong A, Clements A, Forstner D, Suchowersky A, Guminski A, McNeil C, Hersey P, Fogarty G, Kefford R, **Long GV**, Wang W. Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. *J Clin Oncol* **2016 Jan 20**;34(3):e17-20. doi: 10.1200/JCO.2013.49.0565. Epub 2014 May 2.
 347. Kakavand H, Wilmott JS, **Long GV**, Scolyer RA. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. *Pathology* **2016**; 48:194-202.
 348. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, **Long GV**, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. *JAMA Oncol* **2016**; 2:234-240.
 349. **Long GV**, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. *J Clin Oncol* **2016**; 34:871-878.
 350. Menzies AM, Atkinson VG, Brown MP, Carlino MS, Cebon J, Guminski A, Kefford RF, **Long GV**, McArthur G, McNeil CM, Millward M, Sandhu S. Sentinel node biopsy for melanoma: The medical oncology perspective. *Aust Fam Physician* **2015**; 44(12):875-876.
 351. Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, **Long GV**, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, Haney P, OHagan A, Carver J, Goodman V, Legos J, Martin AM. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. *Clin Cancer Res* **2016**; 22:567-574.
 352. Liang R, Meiser B, Smith S, Kasparian N, Lewis C, Chin M, **Long GV**, Ward R, Menzies AM, Guminski A, Harris-Wai J, Kaur R. Oncology patients attitudes toward, and experiences with, somatic mutation tumour testing. *Asia Pac J Clin Oncol* **2015**; 11:144.

353. Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, **Long GV**, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, Opatt McDowell D, Mookerjee B, Schadendorf D, Robert C. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. *Lancet Oncol* **2015**; Oct: 16(13):1389-1398.
354. Grob JJ, **Long GV**, Schadendorf D, Flaherty K. Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. *Lancet Oncol* **2015**; Oct: 16(13):e522–e526.
355. Carlino MS, **Long GV**, Kefford RF, Rizos H. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. *Crit Rev Oncol Hematol* **2015**; Dec: 96(3):385-398.
356. Gray, E. S., Rizos, H., Reid, A. L., Boyd, S. C., Pereira, M. R., Lo, J., Tembe, V., Freeman, J., Lee, J. H., Scolyer, R. A., Siew, K., Lomma, C., Cooper, A., Khattak, M. A., Meniawy, T. M., **Long, G. V.**, Carlino, M. S., Millward, M., & Ziman, M. (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma, *Oncotarget*. **2015 Dec 8**;6(39):42008-18. doi: 10.18632/oncotarget.5788, PMID: 26524482
357. Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, Hersey P, **Long GV**, Scolyer RA. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. *Mod Pathol* **2015**; Dec: 28:1535-1544.
358. Arnheiter H, **Long GV**, Aplin A, Harris J, Kelsh, Welcome to the New Year!, (Editorial) *Pigment Cell & Melanoma Research*, **2015 Dec 15**, doi.org/10.1111/pcmr.12446
359. Johnson DB, Menzies AM, Zimmer L, Eroglud Z, Yea F, Zhaoa S, Rizos H, Sucker A, Scolyer RA, Gutzmerj R, Gogas H, Kefford RF, Thompson JT, Becker JC, Berking C, Egbertsn F, Loquai C, Goldinger S, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, **Long GV**, Schadendorf D. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behavior, and phenotypic associations of resistance mechanisms. *Eur J Cancer* **2015**; Dec: 51(18):2792-2799.
360. Carlino MS, **Long GV**. Is chemotherapy still an option in the treatment of melanoma? *Ann Oncol* **2015**; Nov: 26(11):2203-4.
361. Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, **Long GV**, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferrao PT. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. *Sci Signal* **2015**; Aug: 18:8(390):ra82.
362. **Long GV**, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet* **2015**; Aug; 1:386(9992):444-51.
363. Theodosakis N, Meeth K, Micevic G, Scolyer RA, **Long GV**, Marzuka A, Stern D, Bosenberg M. BRAF inhibition decreases cellular glucose uptake in melanoma in association with reduction in cell volume. *Mol Cancer Ther* **2015**; Jul: 14(7):1680-92.
364. Amaravadi RK, Hamilton KE, Ma X, Piao S, Del Portillo A, Nathanson KL, Carlino MS, **Long GV**, Puzanov I, Xu X, Morrisette JJD, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR. Multiple gastrointestinal polyps in patients treated with BRAF inhibitors. *Clin Cancer Res* **2015**; Dec: 21(23):5215-21
365. Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MMK, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, **Long GV**. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. *Cancer* **2015**; Nov: 121(21):3826-35.

366. Ramanujam S, Schadendorf D, **Long GV**. Systemic therapies for melanoma brain metastases: which drug for whom and when? *Chin Clin Oncol* **2015**; Jun; 4(2):25. doi: 10.3978/j.issn.2304-3865.2015.06.06.
367. Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, Arachchi H, Arora A, Auman JT, Ayala B, Baboud J, Balasundaram M, Balu S, Barnabas N, Bartlett J, Bartlett P, Bastian BC, Baylin SB, Behera M, Belyaev D, Benz C, Bernard B, Beroukhi R, Bir N, Black AD, Bodenheimer T, Boice L, Boland G, Bono R, Bootwalla MS, Bosenberg M, Bowen J, Bowlby R, Bristow CA, Brockway-Lunardi L, Brooks D, Brzezinski J, Bshara W, Buda E, Burns WR, Butterfield YSN, Button M, Calderone T, Cappellini GA, Carter C, Carter SL, Cherney L, Cherniack AD, Chevalier A, Chin L, Cho J, Cho RJ, Choi YL, Chu A, Chudamani S, Cibulskis K, Ciriello G, Clarke A, Coons S, Cope L, Crain D, Curley E, Danilova L, D'Atri S, Davidsen T, Davies MA, Delman KA, Demchok JA, Deng QA, Deribe YL, Dhalla N, Dhir R, DiCara D, Dinikin M, Dubina M, Ebrom JS, Egea S, Eley G, Engel J, Eschbacher JM, Fedosenko KV, Felau I, Fennell T, Ferguson ML, Fisher S, Flaherty KT, Frazer S, Frick J, Fulidou V, Gabriel SB, Gao J, Gardner J, Garraway LA, Gastier-Foster JM, Gaudioso C, Gehlenborg N, Genovese G, Gerken M, Gershenwald JE, Getz G, Gomez-Fernandez C, Gribbin T, Grimsby J, Gross B, Guin R, Gutschner T, Hadjipanayis A, Halaban R, Hanf B, Haussler D, Haydu LE, Hayes DN, Hayward NK, Heiman DI, Herbert L, Herman JG, Hersey P, Hoadley KA, Hodis E, Holt RA, Hoon DSB, Hoppough S, Hoyle AP, Huang FW, Huang M, Huang S, Hutter CM, Ibbes M, Iype L, Jacobsen A, Jakrot A, Janning A, Jeck WR, Jefferys SR, Jensen MA, Jones CD, Jones SJM, Ju Z, Kakavand H, Kang H, Kefford RF, Khuri FR, Kim J, Kirkwood JM, Klode J, Korkut A, Korski K, Krauthammer M, Kucherlapati R, Kwong LN, Kyczer W, Ladanyi M, Lai PH, Laird PW, Lander E, Lawrence MS, Lazar AJ, Łażniak R, Lee D, Lee JE, Lee J, Lee K, Lee S, Lee S, Leporowska E, Leraas KM, Li HI, Lichtenberg TM, Lichtenstein L, Lin P, Ling S, Liu J, Liu O, Liu W, Long GV, Lu Y, Ma S, Ma Y, Mackiewicz A, Mahadeshwar HS, Malke J, Mallery D, Manikhas GM, Mann GJ, Marra MA, Matejka B, Mayo M, Mehrabi S, Meng S, Meyerson M, Mieczkowski PA, Miller JP, Miller ML, Mills GB, Moiseenko F, Moore RA, Morris S, Morrison C, Morton D, Moschos S, Mose LE, Muller FL, Mungall AJ, Murawa D, Murawa P, Murray PA, Nezi L, Ng S, Nicholson D, Noble MS, Osunkoya A, Owonikoko TK, Ozenberger BA, Pagani E, Paklina OV, Pantazi A, Parfenov M, Parfitt J, Park PJ, Park WY, Parker JS, Passarelli F, Penny R, Perou CM, Pihl TD, Potapova O, Prieto VG, Protopopov A, Quinn MJ, Radenbaugh A, Rai K, Ramalingam SS, Raman AT, Ramirez NC, Ramirez R, Rao U, Rathmell WK, Ren X, Reynolds SM, Roach J, Robertson AG, Ross MI, Roszik J, Russo G, Saksena G, Saller C, Samuels Y, Sander C, Sander C, Sandusky G, Santoso N, Saul M, Saw RPM, Schadendorf D, Schein JE, Schultz N, Schumacher SE, Schwallier C, Scolyer RA, Seidman J, Sekhar PC, Sekhon HS, Senbabaoglu Y, Seth S, Shannon KF, Sharpe S, Sharpless NE, Mills Shaw KR, Shelton C, Shelton T, Shen R, Sheth M, Shi Y, Shiao YJ, Shmulevich I, Sica GL, Simons JV, Sinha R, Sipahimalani P, Sofia HJ, Soloway MG, Song X, Sougnez C, Spillane AJ, Spychala A, Stretch JR, Stuart J, Suchorska WM, Sucker A, Sumer So, Sun Y, Synott M, Tabak B, Tabler TR, Tam A, Tan D, Tang J, Tarnuzzer R, Tarvin K, Tatka H, Taylor BS, Teresiak M, Thiessen N, Thompson JF, Thorne L, Thorsson V, Trent JM, Triche Jr TJ, Tsai KY, Tsou P, Van Den Berg DJ, Van Allen Em, Veluvolu U, Verhaak RG, Voet D, Voronina O, Walter V, Walton JS, Wan Y, Wang Y, Wang Z, Waring S, Watson IR, Weinhold N, Weinstein JN, Weisenberger DJ, White P, Wilkerson MD, Wilmott JS, Wise L, Wiznerowicz M, Woodman SE, Wu CJ, Wu CC, Wu J, Wu Y, Xi R, Xu AW, Yang D, Yang L, Yang L, Zack TI, Zenklusen JC, Zhang H, Zhang J, Zhang W, Zhao X, Zhu J, Zhu K, Zimmer L, Zmuda E, Zou L Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. *2015 Jun* 18;161(7):1681-96. doi: 10.1016/j.cell.2015.05.044 PMID: 26091043
368. Menzies AM, Yeh I, Botton T, Bastian BC, Scolyer RA, **Long GV**. Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. *Pigment Cell Melanoma Res* **2015**; Sep; 28(5):607-10.
369. Stark M, Klein K, Weide B, Haydu L, Pflugfelder A, Tang YH, Palmer J, Whiteman D, Scolyer RA, Mann GJ, Thompson JF, **Long GV**, Barbour A, Soyer HP, Garbe C, Herington A, Pollock P, Hayward N. The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis. *EBioMedicine* **2015**; May; 12;2(7):671-80.

370. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Cowey L, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, **Long GV**, Callahan MK, Postow MA, Grossman K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* **2015**; Jul; 2;373(1):23-34.
371. Lam T, Chan MMK, Sweeting AN, De Sousa SMC, Clements A, Carlino MS, **Long GV**, Tonks K, Chua E, Kefford RF, Chipps DR. Ipilimumab-induced hypophysitis in melanoma patients: An Australian case series. *Intern Med J* **2015**; Oct; 45(10):1066-73.
372. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, **Long GV**. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. *Eur J Cancer* **2015**; May; 51(7):833-40.
373. **Robert C, Schachter J, Long GV, Arance A, Grob J-J, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; Jun; 25;372(26):2521-32**
374. Anforth R, Menzies AM, Byth K, Carlos G, Chou S, Sharma R, Scolyer RA, Kefford RF, **Long GV**, Fernandez-Penas P. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. *J Am Acad Dermatol* **2015**; May; 72(5):809-15.e1.
375. Wilmott JS, Hersey P, **Long GV**, Scolyer RA. Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? *Melanoma Manag* **2015**; 2(1):15-19.
376. Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, **Long GV**, Scolyer RA. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. *Clin Cancer Res* **2015**; 21(14):3140-48.
377. Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, **Long GV**, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. Expanded access programmes: patient interests versus clinical trial integrity. *Lancet Oncol* **2015**; Jan; 16(1):15-17.
378. Phan TG, **Long GV**, Scolyer RA. Multiple checkpoints on the long road towards cancer immunotherapy. *Immunol Cell Biol* **2015**; Apr; 93(4):323-5.
379. Wilmott JS, Colebatch A, Kakavand H, Shang P, Carlino MS, Thompson JF, **Long GV**, Scolyer RA, Hersey P. Expression of the Class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. *Mod Pathol* **2015**; Jul; 28(7):884-94.
380. Madore J, Vilain R, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, **Long GV**, Hersey P, Scolyer RA. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. *Pigment Cell Melanoma Res* **2015**; May; 28(3):245-53.
381. Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, **Long GV**, Daud A. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. *Ann Oncol* **2015**; Feb; 26(2):415-21.
382. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, **Long GV**, Flaherty K, Nathan P, Ribas A, Martin A-M, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. *N Engl J Med* **2015**; Jan; 1;372(1):30-9.
383. **Long GV, Fung C, Menzies AM, Pupo G, Carlino M, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward N, Johansson P, Scolyer RA, Kefford RF, Rizos H.**

- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma. Nat Commun 2014; Dec: 2:5:5694**
384. Carlino MS, Fung C, Shahheydari H, Todd JR, Nagrial AM, Scolyer RA, Kefford RF, **Long GV**, Rizos H. Pre-existing MEK1 ^{P124} mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Clin Cancer Res **2015**; Jan: 1;21(1):98-105
 385. **Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassell JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in Previously Untreated Melanoma without BRAF mutation. N Engl J Med 2015; Jan: 22;372(4):320-30**
 386. **Long GV.** From dismal prognosis to rising star: melanoma leading the way with new generation cancer therapies. Med J Aust **2015**; Feb: 16:202(3):115-6.
 387. Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, **Long GV**, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients with BRAFV600-Mutant Melanoma Experiencing Progression with Single-Agent BRAF Inhibitor. J Clin Oncol **2014**; Nov: 20:32(33):3697-704.
 388. Gopal VNV, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, **Long GV**, Davies MA. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1 α and Oxidative Phosphorylation in melanoma. Cancer Res **2014**; Dec: 1:74(23):7037-47.
 389. Sutton SK, Koach J, Tan O, Liu B, Carter DR, Wilmott JS, Yosufi B, Haydu LE, Mann GJ, Thompson JF, **Long GV**, Liu T, McArthur G, Zhang XD, Scolyer RA, Cheung BB, Marshall GM. TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget **2014**; Oct: 30:5(20):10127-39.
 390. **Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi, V.; Kovalenko, N.; Mohr, P.; Probachai, V.; Schadendorf, D.; Nathan, P.; Robert, C.; Ribas, A.; DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin A-M, Le N, Patel K, Flaherty K. Combined BRAF and MEK Inhibition Versus BRAF Inhibition Alone in Melanoma. N Engl J Med 2014; Nov: 13:371(20):1877-88.**
 391. Wang, J., Huang, S. K., Marzese, D. M., Hsu, S. C., Kawas, N. P., Chong, K. K., **Long, G. V.**, Menzies, A. M., Scolyer, R. A., Izraely, S., Sagi-Assif, O., Witz, I. P., & Hoon, D. S. B. (2015). Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol . **2015 Feb**;135(2):532-541. doi: 10.1038/jid.2014.418. Epub 2014 Sep 22 PMID: 25243790
 392. De Sousa, S, **Long GV**, Tonks K. Ipilimumab-induced hypophysitis: early Australian experience. Med J Aust **2014**; Aug: 18:201(4):198-9.
 393. **Long GV**, Falchook GS, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin M, ODay SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436). Clin Cancer Res **2014**; Sept: 1:20(17):4449-58.
 394. Lee CI, Menzies AM, Haydu LE, Azer M, Clements A, Kefford RF, **Long GV.** Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Mel Res **2014**; Oct: 24(5):468-74.
 395. Zimmer L, Haydu LE, Menzies AM, Scolyer RA, Kefford RF, Thompson JF, Schadendorf D, **Long GV.** Reply to M. Perier-Muzet et al. J Clin Oncol **2014**; Oct: 1:32(28):3203-4.

396. Bowyer SE, Rao A, Lyle M, Sandhu S, **Long GV**, McArthur G, Raleigh J, Hicks R, Millward M Activity of Trametinib in K601E and L597Q BRAF Mutation-Positive Metastatic Melanoma. *Mel Res* **2014**; Oct: 24(5):504-8.
397. Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, NG CC, Cooper W, Thompson JF, Kefford RF, O'Toole SO, Scolyer RA, **Long GV**. Correlation of BRAF and NRAS mutation status with outcome, organ involvement and response to chemotherapy in metastatic melanoma. *Br J Cancer* **2014**; Jul: 15:111(2):292-9.
398. Chan, M. M., Haydu, L. E., Menzies, A. M., Azer, M. W., Klein, O., Lyle, M., Clements, A., Guminski, A., Kefford, R. F., & **Long, G. V.** (2014). The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition, *Cancer*. **2014 Oct 15**;120(20):3142-53. doi: 10.1002/cncr.28851. Epub 2014 Jul 1, PMID: 24985732
399. Chien A, Haydu LE, Biechele TL, Kulikauskas RM, Rizos H, Kefford RF, Scolyer RA, Moon RT, **Long GV**. Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/beta-catenin signaling. *PlosOne* **2014**; Apr: 14:9(4):e94748.
400. Brown MP, **Long GV**. The Use of Vemurafenib in Australian Patients with Unresectable or Metastatic Melanoma Containing the V600 *BRAF* Gene Mutation. *Asia-Pac J Clin Oncol* **2014**; Apr: (10):suppl S3:1-15.
401. Menzies AM, **Long GV**. Systemic treatment for BRAF-mutant melanoma: Where do we go next? Invited Review. *Lancet Oncol* **2014**; Aug: 15(9):e371-81.
402. Menzies AM, **Long GV**. Dabrafenib and Trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Invited review. *Clin Cancer Res* **2014**; Apr: 15:20(8):2035-43.
403. Flaherty KT, Hennis M, Lee SJ, Ascierto PA, Dummer R, Eggermont AMM, Hauschild A, Kefford R, Kirkwood JM, **Long GV**, Lorigan P, Mackensen A, McArthur G, O'Day S, Patel PM, Robert C, Schadendorf D. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. *Lancet Oncol*. **2014**; Mar: 15(3):297-304.
404. Wilmott JS, Haydu LE, Menzies AM, Lum T, Hyman J, Thompson JF, Hersey P, Kefford RF, Scolyer RA, **Long GV**. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF- mutant melanoma patients during BRAF inhibitor treatment. *Journal Immun* **2014**; Mar: 1:192(5):2505-2513.
405. **Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, Scolyer RA, Long GV. BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact. Clin Cancer Res** **2014**; Apr: 1:20(7):1965-77.
406. Carlino M, Todd J, Gowrishankar K, Mijatov B, Pupo G, Snoyman S, Hersey P, **Long GV**, Kefford RF, Rizos H. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. *Mol Oncol* **2014**; May: 8(3):544-54.
407. Anastas JN, Tamir T, Kulikauskas RM, Rizos H, **Long GV**, Euv EM, Chen H-W, Haydu L, Yang P-T, Toroni RA, Lucero OM, Chien AJ, Moon RT. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors and promotes cell growth and survival through activation of AKT signaling. *J Clin Inv* **2014**; Jul: 1:124(7):2877-90.
408. Parmenter T, Kleinschmidt M, Kinross K, Bond S, Li J, Kaadige M, Sheppard K, Hugo W, Pupo G, Pearson R, McGee S, **Long GV**, Scolyer R, Rizos H, Lo R, Cullinane C, Ayer D, Ribas A, Johnstone R, Hicks R, McArthur G. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. *Cancer Discov* **2014**; Apr: 4(4):423-33.
409. Shi H, Hong A, Kong X, Koya R, Song C, Moriceau G, Hugo W, Yu C, Ng C, Chodon T, Scolyer R, Kefford R, Ribas A, **Long GV**, Lo R, A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. *Cancer Discov* **2014**; 4(1):69-79.
410. Shi H, Willy H, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson D, Dahlman KB, Kelley M, Kefford RF, Chmielowski B, Glaspy J, Sosman JA, **Long GV**, Ribas A, Lo R, Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. *Cancer Discov* **2014**; 4(1):80-93.

411. Lyle M, **Long GV**. The Role of Systemic Therapies in the Management of Melanoma Brain Metastases. *Current Opin Onc* **2014**; 26(2):222-9.
412. Menzies AM, Haydu LE, Carlino M, Azer MF, Carr PJA, Kefford RF, **Long GV**. Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. *PlosOne* **2014**; 9(1):e85004.
413. Carlino MS, Kwan V, Miller DK, Saunders CAB, Yip D, Nagrial AM, Tomlinson J, Grimmond SM, Scolyer RA, Kefford RF, Biankin AV, **Long GV**. New *RAS*-mutant Pancreatic Adenocarcinoma with Combined BRAF and MEK inhibition for Metastatic Melanoma. *J Clin Oncol* **2014**; Apr: 10:33(11).
414. Kakavand H, Crainic O, O'Toole S, Kefford RF, Thompson JF, Wilmott JS, **Long GV**, Scolyer RA. Concordant BRAF^{V600E} mutation status in primary melanomas and associated nevi: implications for mutation testing of primary melanomas. *Pathol* **2014**; 46(3):193-198.
415. Lezcano C, Lee C-W, Larson AR, Menzies AM, Kefford RF, Thompson JF, Mihm MC, Ogino S, **Long GV**, Scolyer RA, Murphy GF Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. *Mod Pathol* **2014**; Sep: 27(9):1193-202.
416. Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi SF, Kefford RF, Menzies AM, Atkins MB, Cho DC, Sullivan RJ, **Long GV** (shared senior author). Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after targeted therapy. *Cancer* **2014**; Jun: 1:120(11):1695-1701
417. Azer MWF, Menzies AM, Haydu LE, Kefford RF, **Long GV**. Patterns of Response and Progression in Patients with BRAF-mutant Melanoma Metastatic to the Brain treated with Dabrafenib. *Cancer* **2014**; 120:530-6.
418. Zimmer L, Haydu LE, Menzies AM, Scolyer RA, Richard F. Kefford RF, John F. Thompson JF, Schadendorf D, **Long GV**. Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. *J Clin Oncol* **2014**; Mar: 10;32(8):816-23.
419. Menzies AM, Wilmott JS, **Long GV**, Scolyer RA. Intra-patient heterogeneity of BRAF mutation status: fact or fiction? *Br J Cancer* **2014**; Mar: 38(3):377-82.
420. Menzies AM, Lum T, Wilmott JS, Hyman J, Kefford RF, Thompson JF, O'Toole S, **Long GV**, Scolyer RA. Intrapatient homogeneity of BRAFV600E expression in melanoma. *Am J Surg Path* **2014**; Mar: 38(3):377-82.
421. Hu W, Jin L, Jiang CC, **Long GV**, Scolyer RA, Wu Q, Zhang XD, Mei Y, Wu M. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. *Cell Death Dis.* **2013**; 4:e914.
422. Lyle M, **Long GV**. Diagnosis and Treatment of KIT-Mutant Metastatic Melanoma. Invited review *J Clin Oncol* **2013**; 31:3176-81.
423. Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, **Long GV**, Fernandez-Peñas P. Acneiform Eruptions: A Common Cutaneous Toxicity of the MEK Inhibitor Trametinib. *Australas J Derm* **2014**; Nov: 55(4):250-4 .
424. Menzies AM, **Long GV**. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. *Eur J Cancer* **2013**; 49(15):3229-41.
425. Anforth R, Blumetti TCMP, Clements A, Kefford R, **Long GV**, Fernandez-Peñas P. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. *Br J Dermatol.* **2013**; 169:1310-3.
426. Menzies AM, Kefford RF, **Long GV**. Paradoxical oncogenesis: are all BRAF inhibitors equal? *Pigment Cell Melanoma Res* **2013**; 26(5):611-5.
427. Nathanson KL, Martin A-M, Wubbenhorst B, Greshock J, Letrero R, DAndrea K, ODay S, Infante JR, Falchook GS, Arkenau H-T, Millward M, Brown MP, Pavlick A, Davies MA, Ma B, Gagnon R, Curtis M, Lebowitz PF, Kefford RF, **Long GV**. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). *Clinical Cancer Res* **2013**; 19(17):4868-4878.

428. Menzies AM, **Long GV**. New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Invited review *Ther Adv Med Oncol* **2013**; 5:278-85.
429. Ascierto PA, Minor D, Ribas A, Lebbe C, OHagan A, Arya N, Guckert M, Schadendorf D, Kefford R, Grob J-J, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, **Long GV**, Martin A-M, Mazumdar J, V Goodman V, Trefzer U. A Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. *J Clin Oncol* **2013**; 31:3205-3211.
430. **Long, G. V.**, Wilmott, J. S., Haydu, L. E., Tembe, V., Sharma, R., Rizos, H., Thompson, J. F., Howle, J., Scolyer, R. A., & Kefford, R. F. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. *Pigment Cell Melanoma Res.* **2013 Jul**;26(4):499-508. doi: 10.1111/pcmr.12098. Epub 2013 May 3, PMID 23557327
431. Carlino, M. S., Gowrishankar, K., Saunders, C. A., Pupo, G. M., Snoyman, S., Zhang, X. D., Saw, R., Becker, T. M., Kefford, R. F., **Long, G. V.**, & Rizos, H. (2013). Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma, *Mol Cancer Ther.* **2013 Jul**;12(7):1332-42. doi: 10.1158/1535-7163.MCT-13-0011. Epub 2013 May 3, PMID: 23645591
432. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Peter Hersey P, **Long GV**, Lawrence D, Ott PA, Amaravadi R K, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients with Metastatic Melanoma. *J Clin Oncol* **2013**; 31:1767-74.
433. **Long GV**, Margolin KA. Multidisciplinary Approach to Brain Metastasis from Melanoma; Systemic Targeted Therapies for CNS Metastases. Invited review *American Society of Clinical Oncology Educational Book*, **2013**; 393-8.
434. Wilmott, J. S., Menzies, A. M., Haydu, L. E., Capper, D., Preusser, M., Zhang, Y. E., Thompson, J. F., Kefford, R. F., von Deimling, A., Scolyer, R. A., & **Long, G. V.** (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma, *Br J Cancer.* **2013 Mar** 5;108(4):924-31. doi: 10.1038/bjc.2013.29. Epub 2013 Feb 12 PMID 23403819.
435. Lo RS, A. Ribas A, **Long GV**, Ballotti R, Berger M, Hugo W, Gibney GT, Bosenberg M, Bernstein E, Villanueva J, Smalley KSM. Meeting report from the Society for Melanoma Research **2012** Congress, Hollywood, California. *Pigment Cell Melanoma Res* **2013**; 26:E1-7.
436. Anforth RM, Fernandez-Penas P, **Long GV**. Cutaneous Toxicities of RAF Inhibitors. Invited review *Lancet Onc* **2013**; 14:e11-8.
437. Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., McArthur, G. A., Hwu, P., Gonzalez, R., Ott, P. A., **Long, G. V.**, Gardner, O. S., Ouellet, D., Xu, Y., DeMarini, D. J., Le, N. T., Patel, K., & Lewis, K. D. (2013). Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor, *J Clin Oncol.* **2013 Feb** 1;31(4):482-9. doi: 10.1200/JCO.2012.43.5966. Epub 2012 Dec 1 PMID: 23248257
438. Klein O, Clements A, Menzies A, Kefford R, **Long GV**. BRAF inhibitor activity in V600R metastatic melanoma. *Eur J Cancer* **2013**; 49:1797-8.
439. **Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford R. Sosman JA, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi AP, Lewis KD, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber JS.** Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med* **2012**; 367:1694-703.
440. Menzies AM, **Long GV**, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Invited review *Drug Des Develop Ther* **2012**; 6:391-40.
441. Klein O, Ribas A, Chmielowski B, Walker G, Clements A, **Long GV**, Kefford K. Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. *J Clin Oncol* **2013**; 31:e215-7.

442. Carlino, M. S., Saunders, C. A., Haydu, L. E., Menzies, A. M., Martin Curtis, C., Jr., Lebowitz, P. F., Kefford, R. F., & **Long, G. V.** (2013). (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma, *Eur J Cancer*. **2013 Jan**;49(2):395-402. doi: 10.1016/j.ejca.2012.08.018. Epub 2012 Sep 1, PMID: 22981500
443. **Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA, Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. *Am J of Surg Path* 2013; 37:61-5.**
444. **Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., Mortier, L., Tawbi, H., Wilhelm, T., Zimmer, L., Switzky, J., Swann, S., Martin, A. M., Guckert, M., Goodman, V., Streit, M., Kirkwood, J. M., & Schadendorf, D. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial, *Lancet Oncol*. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub 2012 Oct 8, PMID 23051966**
445. Anforth RM, Blumetti TCMP, Kefford RF, Sharma R, Scolyer RA, Kossard S, **Long GV**, Fernandez-Penas, P. Cutaneous Manifestations of GSK2118436, A Selective Inhibitor of Mutant BRAF in patients with Metastatic Melanoma. *Br J Dermatol* **2012**; 167:1153-60.
446. Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, Lo RS, Kefford RF, Scolyer RA, **Long GV**. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. *Mole Can Therap* **2012**; 12:2704-8.
447. Murali R, Brown PT, Kefford RF, Scolyer RA, Thompson JF, Atkins MB, **Long GV**. Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. *Cancer* **2012**; 118:4519-29.
448. Menzies AM, **Long GV**. Clinicopathologic Features of V600E and V600K Melanoma—Response. *Clin Cancer Res*. **2012**; 18(24):6793.
449. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, **Long GV**. Distinguishing Clinicopathologic Correlates of BRAF mutant V600E and V600K Metastatic Melanoma. *Clin Can Res* **2012**; 18:3242-9.
450. **Long GV, Falchook G (shared first authorship), Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, ODay SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. *Lancet*, 2012; 379:1893-90.**
451. Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M. E., Busam, K., Carvajal, R. D., Egberts, F., Hauschild, A., Kashani-Sabet, M., Goldinger, S. M., Dummer, R., **Long, G. V.**, McArthur, G., Scherag, A., Sucker, A., & Schadendorf, D. (2012). Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition, *J Clin Oncol*. **2012 Jul 1**;30(19):2375-83. doi: 10.1200/JCO.2011.41.1660. Epub 2012 May 21, PMID: 22614973
452. Wilmott JS, Scolyer RA, **Long GV**, Hersey P. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. *Invited review OncoImmunology*, **2012**; 1:997-999.
453. Shi, H., Moriceau, G., Kong, X., Koya, R. C., Nazarian, R., Pupo, G. M., Bacchiocchi, A., Dahlman, K. B., Chmielowski, B., Sosman, J. A., Halaban, R., Kefford, R. F., **Long, G. V.**, Ribas, A., & Lo, R. S. (2012). Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors, *Cancer Discov*. **2012 May**;2(5):414-24. doi: 10.1158/2159-8290.CD-12-0022. Epub 2012 Apr 1, PMID 22588879
454. Carlino M S, Fogarty GB, **Long GV**. Treatment of melanoma brain metastases: A new paradigm. *Invited review The Cancer J* **2012**; 18:208-12.

455. Murali R, Haydu LE, Quinn MJ, Saw RPM, Shannon K, Spillane AJ, Stretch JR, Thompson JF, **Long GV**, Scolyer RA. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. *Ann Surg Oncol* **2012**; 19:1782-9.
456. Shi H, Moriceau G, Kong X, Lee M, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman J, Kefford R, **Long GV**, Nelson SF, Ribas A, Lo R. Melanoma exome sequencing identifies V600E BRAF amplification driving acquired resistance to vemurafenib. *Nat Commun* **2012**; 3:724.
457. **Long GV, Wilmott J (shared first authorship), Sharma RN, Howle JR, Thompson J, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce Marked T cell Infiltration into Human Melanoma. Clin Cancer Res, 2012, 18:1386-94.**
458. Scolyer R, **Long GV**, Thompson JF. Evolving Concepts in Melanoma Classification and Their Relevance to Multidisciplinary Melanoma Patient Care. Invited review *Mol Oncol* **2011**; 5:124-136.
459. **Long GV, Menzies AM, Nagrial AM, Haydu L, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford, RF. Prognostic and clinico-pathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29:1239-46.**
460. Arkenau H-T, Kefford R, **Long GV**. Targeting B-Raf for patients with melanoma. Invited review *Br J Cancer* **2011**; 104:392-398.
461. **Long GV**. Book Review of The molecular biology of the cell Eds. Pelengaris and Khan, **2007**. *Cancer Forum* **2007**; 31:121.
462. **Long GV**, Tattersall MH. Lung encasement by metastatic osteoblastic sarcoma. *Med J Aust* **2007**; 186:100.
463. Fernandez-Lopez S, Kim H-S, Choi E, Delgado M, Granja J, Khasanov K, **Long GV**, Weinberger D, Wilcoxon K, Ghadiri MR. Antibacterial Agents based on the Cyclic D,L- α -Peptide Architecture. *Nature* **2001**; 412:452-55.
464. **Long GV**, Harding MM, Turner P. X-ray Structure of the Zinc Complex of the Central Metal Chelation site of the Antitumour Drug Streptonigrin. *Polyhedron* **2000**; 19:1067-1071.
465. Harding MM, **Long GV**. Interaction of the Antitumour Antibiotic Streptonigrin with Metal Ions and DNA. *Curr Med Chem* **1997**; 4:405-420.
466. **Long GV**, Harding MM, Fan J-Y, Denny WA. Interaction of the Antitumour Antibiotic Streptonigrin with DNA and Oligonucleotides. *Anti-cancer Drug Des* **1997**; 12:453-472.
467. **Long, G.V.**, Harding, M.M., A proton nuclear magnetic resonance study of the interaction of zinc(II) with the antitumour drug streptonigrin, *Journal of Chemical Society*, **1996**
468. **Long GV**, Harding MM, Turner P, Hambley TW. Copper(II) Bipyridyl and Iminopyridyl Analogues of Streptonigrin. *J Chem Soc, Dalton Trans* **1995**; 3905-3910.
469. **Long GV**, Harding MM, Xie MCL, Buys IE, Hambley TW. 3- Amino-6,6-bis(methoxycarbonyl)-2,2-bipyridine, a Model for the Central Chelation Unit of Streptonigrin. *J Chem Soc, Dalton Trans* **1995**; 951-955.
470. **Long GV**, Boyd SE, Harding MM, Buys IE, Hambley TW. Synthesis, Properties and Complexation Studies of 3-Amino-6,6-dimethyl-2,2-bipyridine. *J Chem Soc, Dalton Trans* **1993**; 3175-3180.
471. Harding MM, **Long GV**, Brown CL. Solution Conformation of the Antitumour Drug Streptonigrin. *J Med Chem* **1993**; 36:3056-3060.

TEACHING, MENTORSHIP AND SUPERVISION

Post-Graduate Degree Supervision, University of Sydney

From 2011

University of Sydney, co-supervision of post-graduate students

Primary supervisor for four PhD students and co-supervisor of seven PhD students

Name	Year completed /Awarded PhD	Thesis Title	Primary/ Co-supervisor
Dr James Wilmott	2013	Biomarkers and biology of BRAF inhibitor treated metastatic melanoma	Co-supervisor
Dr Alexander Menzies	2015	Determining the Molecular mechanisms of BRAF/MEK inhibitor resistance in Melanoma	Primary
Dr Matteo Carlino	2015	Determining the Molecular mechanisms of BRAF/MEK inhibitor resistance in Melanoma	Co-supervisor
Mr Hansol Lee	2021	NK cells in the microenvironment of anti-PD1 treated melanoma	Co-supervisor
Dr Hojabr Kakavand	2017	Molecular determinants of melanoma progression and susceptibility to current treatment strategies	Co-supervisor
Dr Louise Jackett	Current commenced 2017	Clinical and histopathological associations of melanocytic lesions in the molecular era	Co-supervisor
Dr Jarem Edwards	Current commenced 2018	Improving immunotherapy in the clinic: The cells underlying response and resistance to drug immunotherapy	Co-supervisor
Ms Tuba Nur Gide	2019	Biomarkers of response and resistance to anti-PD1 immunotherapy in melanoma	Primary
Dr Jordan Conway	Current commenced 2019	Mechanisms of resistance to PD-1 based immunotherapy in melanoma liver metastases	Co-supervisor
Rebecca Simpson	Current commenced 2020	Assessing the mechanistic links between the intestinal microbiota and the immune system during cancer immunotherapy	Co-supervisor
Dr Jorja Braden	Current commenced 2021	Determining optimal neoadjuvant sequencing of anti-PD1 and BRAF – targeting therapy in resectable BRAF mutant stage IIIB/C/D melanoma	Primary
Dr Kazi Nahar	2021	Mechanisms of immune checkpoint inhibitor-induced gastrointestinal toxicities	Mentor – Lab PI
Xinyu Catherine Bai	2020	Immunogenomic features of adolescent and young adult melanoma and their implications for response to checkpoint inhibitor immunotherapy	Mentor – Lab PI
Eva Shteinman	Current commenced 2022	Characterising the Genomic and Immune Landscape of Melanoma Subtypes	Mentor – Lab PI
Grace Attril	Current comments 2019	Assessing the function of tumour specific and bystander T-cells in relation to clinical outcomes of melanoma patients	Mentor – Lab PI

Advanced and Basic Trainee Education and Supervision

I have mentored and trained more than 20 Advanced Trainees in medical oncology since 2009 at Westmead Hospital, Melanoma Institute Australia and Royal North Shore Hospital. Additionally, they have completed a research project, published and presented it, and many have pursued a higher post-graduate degree as a direct result of my mentorship. I lecture to basic and advanced physician trainees in formal hospital-based training programs.

Medical Oncology Fellow

The medical oncology unit at Melanoma Institute Australia has offered competitive 12-month clinical fellowships since 2013. As their primary supervisor, I:

- Oversee clinical commitments and duties; weekly 1:1 meetings for review of progress

- Educate regarding the management of patients with melanoma, and the conduct of clinical trials and research
- Provide support and mentorship for research projects (to be completed within 12 months)
- Provide guidance for writing successful publications and grant applications
- Support conference attendance
- Ensure my qualifications are sufficient for supervision e.g. completed Royal Australasian College Supervisors Training, completed University of Sydney post-graduate degree supervisor training

Fellows have published in high-impact journals as first authors (Journal of Clinical Oncology IF 44.54 CCR), presented original research at international conferences (including the prestigious American Society for Clinical Oncology, European Clinical Cancer Organisation, European Society for Medical Oncology, Clinical Oncology Society of Australia and Society for Melanoma Research).

The following Fellows have worked under my supervision since 2013

2013	Megan Lyle		
2014	Elizabeth Liniker		
2015	Sangeetha Ramanuja		
2016	Rajat Rai	Kazi Nahar	Ines Da Silva
2017	Helen Dearden	Elizabeth Liniker	
2018	Martin Tio	Carina Owen	
2019	Lalit Pallan	Adriana Hepner	
2020	Aljosja Rogiers	Florentia Dimitriou	Kay Xu
	Sarah Maloney	Tam Bui	
2021	Amelia Taylor	Julia Lai-Kwon	
2022	Rachel Woodford	Piyush Grover	
2023	Ivo Julio	Anne Zaremba	Thomas Bennett

All of the above Fellows have gone on to prestigious careers.

Supervisor Training

Royal Australasian College of Physicians, training for supervisors of advanced trainees	2013
University of Sydney, training for supervisors of USYD post-graduate students	2011
Teaching on the run, training for teaching and mentorship in clinical settings	2005

Financial Support for Teaching and Supervision

Organised PhD top-up scholarship via Melanoma Institute Australia for PhD students

Obtained Educational Grants and Sponsorship for conference travel for Advanced Trainees and Post-graduate Students

Medical Student Teaching and Supervision

University of Sydney, supervision of Graduate Medical Program Honours Students	2009-2010
University of Sydney, Graduate Medical Program;	
• Communication Skills Tutorials, Central Clinical School	2004-2006
• SCORPIO Procedural & Examination Skills Tutorials, Central Clinical School	2004,2005
• Integrated Clinical Attachments, Central Clinical School	2003-2005
• Integrated Clinical Attachments, Western Clinical School	2011

Observerships/Sabbaticals

- I host colleagues for sabbaticals (6weeks-6months) and teach international and local medical students and trainees at Melanoma Institute Australia

Other Teaching

Intern lecture series, Royal Prince Alfred Hospital, regular invited speaker **2003-2006**

University of Sydney

- Careers Evening, final year MBBS. Physician Training, whats involved **2004**
- Chemistry I laboratory Demonstrator and Tutor **1992-1995**
- Chemistry III Laboratory Demonstrator **1992-1995**
- High School Chemistry Workshops **1997, 1998**
- Workshop for the Research and Scholarships Office Grants and Scholarships – how to apply **1996**
- Mathematics and Chemistry Private Tuition, HSC and University level **1989-2002**

Curriculum Development and Training Review

Member of The Royal Australasian College of Physicians Trainee Committee **2005**

Basic Physician Trainee Representative, Network Governance Committee, RPAH Network **2005**

RMO Representative, Clinical Training Committee, Royal Prince Alfred Hospital **2002**

Student member - Yrs 3 & 4 Curriculum Committee, Sydney University Medical Program **1997, 1998**

University of Sydney, Chemistry III laboratory curriculum development **1998**

COMMUNITY AND MEDIA

Community and Patient Speaking Engagements

- Cancer Research: Melanoma Cancer Research Uncovered Talks for the Community, The University of Sydney, Australia **Nov 2015**
- The Melanoma Treatment Landscape AIM Patient Advocate Forum, Munich, Germany **June 2015**
- Multiple Media Interviews for Community Awareness of Melanoma **From 2013**
- Beating Melanoma; Targeting Genes. 21st Century Medicine, The University of Sydney, Sydney, Australia **Oct 2013**
- The BRAF story – from Target to Treatment and Beyond. Patient Symposium, 7th Annual University of North Carolina Conference on Melanoma, Chapel Hill, North Carolina, USA **Feb 2012**
- New Treatments in Melanoma. Melanoma Institute Australia, Community and Volunteers Seminar, Sydney, Australia **Dec 2012**
- Advances in the Treatment of Melanoma. Westmead Medical Research Foundation Community Seminars, Sydney, Australia **June 2011**
- Research and Clinical Trials. Advances in Melanoma Care Symposium, Melanoma Network and Melanoma Institute Australia, Sydney, Australia **Aug 2009**

Television

Show	Channel	Date	Story
7 News	7	01.03.2023	Immunotherapy PBS

			https://www.facebook.com/MelanomaInstituteAustralia/videos/706911081134399/?extid=NS-UNK-UNK-UNK-IO5_GK0T-GK1C&mibextid=1YhcI9R&ref=sharing
Weekend Today	9	04.02.2023	Ban the bake https://www.facebook.com/MelanomaInstituteAustralia/videos/587385116164536/?extid=NS-UNK-UNK-UNK-IO5_GK0T-GK1C&mibextid=1YhcI9R&ref=sharing
10 Adelaide	10	16.12.2022	Cancer vaccine breakthrough Also appeared under licence with: 10 Broken Hioll, 10 Darwin, 10 Gold Coast, 10 News First: Breakfast, 10 Perth, 10 Central Digital, 10 Canberra, 10 Central Queensland, 10 Central Victoria, 10 Gippsland, 10 Cairns, 10 Lismore, Ten Mackay, 10 Riverina, Ten Toowoomba, Ten Townsville, Ten Western Victoria, Ten Wide Bay
ABC News	ABC	15.12.2022	Moderna mRNA melanoma vaccine may be 'the penicillin moment' in cancer treatment researchers say https://www.abc.net.au/news/2022-12-15/world-first-melanoma-vaccine-may-be-the-penicillin-moment/101773886
9 News	9	15.12.2022	Melanoma vaccine could be 'penicillin moment' for cancer treatment https://www.9news.com.au/national/melanoma-vaccine-offering-hope-for-cancer-patients-moderna-trial/cdb14a51-cfe4-437f-9e06-be77beccf940
National Press Club of Australia	ABC	21.09.2022	State of the Nation – A Report into Melanoma https://iview.abc.net.au/show/national-press-club-address/series/0/video/NC2211C034S00
7NEWS Spotlight	7	20.05.2022	Skin Deep – a major new skin cancer and melanoma documentary https://www.youtube.com/watch?v=v1t9ZzNcEuI
The Morning Show	7	17.03.2022	Young Aussie mum of three raises melanoma awareness just days after having a cancerous mole removed https://7news.com.au/the-morning-show/story-info/young-aussie-mum-of-three-raises-melanoma-awareness-just-days-after-having-a-cancerous-mole-removed-c-6091412
Sunrise	7	07.12.2022	Melanoma – Early Detection – Game on Mole https://fb.watch/9NjrThNXyr/
9 News	9	03.06.2022	Breakthrough for melanoma patients with new drug that has already saved lives https://www.9news.com.au/national/melanoma-breakthrough-immunotherapy-drug-saves-lives/ef674b87-a42a-4ee9-b603-983fe4caaddb
A Current Affair	9	12.05.2021	Dangerous illegal item hiding in Aussie suburban backyard shed https://9now.nine.com.au/a-current-affair/dangerous-illegal-item-hiding-aussie-suburban-backyard-shed/6ad984ab-c050-4898-9b9b-1f9381f303a7?ocid=Social-ACA
7 News	7	09.02.2021	Biggest breakthrough in Melanoma https://www.youtube.com/watch?v=T74L45VLXN4
10 News First	10	09.02.2022	Fighting Melanoma Biggest breakthrough in melanoma treatment in a decade https://www.9news.com.au/national/melanoma-treatment-huge-advance-australia/88d16605-6f6c-4644-8a78-a2b33f482de1
9 News	9	09.02.2021	Biggest advancement in melanoma treatment in a decade https://www.msn.com/en-au/video/news/biggest-advancement-in-melanoma-treatment-in-a-decade/vi-BB1dwtlq Televised in Sydney/Adelaide/ Albury-Wodonga/Canberra/ Central Queensland/Central Victoria/Central West/Darwin/ Gippsland/Illawarra/ Mackay/Perth/Riverina/ Sunshine

			Coast/Townsville/Coffs Harbour/Gold Coast/Gosford/Lismore/Newcastle/ Port Macquarie/ Tamworth/Cairns/
7.30 Report	ABC	14.12.2020	Stuart Taylor story https://iview.abc.net.au/show/7-30/series/0/video/NC2001H197S00
7News	7	28.08.2020	MIA Calculator for skin cancer risk https://7news.com.au/lifestyle/health-wellbeing/melanoma-calculator-for-skin-cancer-risk-c-1271736
9 News	9	28.08.2020	MIA Calculator for skin cancer risk
10 News First	10	28.08.2020	MIA Calculator for skin cancer risk
Sunrise	7	08.06.2020	Queen's Birthday Honors List 2020 https://7news.com.au/sunrise/on-the-show/queens-birthday-honours-list-2020-tony-abbott-michael-clarke-among-australians-honoured-c-1084267
7 News	7	22.07.2019	Breast cancer drug may be key to beating the most deadly type of melanoma https://7news.com.au/lifestyle/health-wellbeing/breast-cancer-drug-may-be-key-to-beating-the-most-deadly-type-of-melanoma-c-359083
7.30 Report	ABC	14.02.2019	Research breakthrough to help melanoma treatment https://www.abc.net.au/7.30/research-breakthrough-to-help-melanoma-treatment/10813786
60 Minutes	9	2018	Australian mother's fight to beat incurable cancer https://9now.nine.com.au/60-minutes/allison-langdon-patient-71/e8a3fb4f-b072-4d29-9c77-41bb9115fa1b
ABC News	ABC	18.05.2012	New drug that shrinks brain tumours in melanoma patients https://www.youtube.com/watch?v=IHaGyyIeI4Q
Sunrise	7	19.07.2011	Skin cancer breakthrough – Melanoma injection gets the nod https://www.youtube.com/watch?v=S0xPkz-hQ7U

Print/online publications (including but not limited to)

Publication	Date	Story
Medical Forum	09.03.2023	Cheaper melanoma treatments https://mforum.com.au/cheaper-melanoma-treatments/
Australian Seniors News	02.03.2023	Treatment for recurrent melanoma to be subsidised https://australianseniorsnews.com.au/featured/treatment-for-recurrent-melanoma-to-be-subsidised/
The National Tribune	02.03.2023	Affordable treatment for recurrent melanoma https://www.nationaltribune.com.au/affordable-treatment-for-recurrent-melanoma/
Formulary Watch	01.03.2023	FDA sets action date for Opdivo for melanoma indication https://www.formularywatch.com/view/fda-sets-action-date-for-opdivo-for-melanoma-indication
Drug Topics	01.03.2023	FDA accepts supplemental BLA for nivolumab for melanoma https://www.drugtopics.com/view/fda-accepts-supplemental-bla-for-nivolumab-for-melanoma
SBS News	12.02.2023	Australia has the world's highest melanoma rate. What are tanning products still being advertised? https://www.sbs.com.au/news/article/australia-has-the-worlds-highest-melanoma-rate-why-are-tanning-products-still-being-advertised/2oczxmut
Your Life Choices	16.12.2022	Vaccine may be 'the penicillin moment' for cancer, says researchers https://www.yourlifechoices.com.au/health/melanoma-vaccine-may-be-the-penicillin-moment-in-cancer-treatment-say-researchers/

Beauresert Times	15.12.2022	Melanoma vaccine using mRNA technology on the horizon https://www.beaureserttimes.com.au/story/8019810/another-leap-forward-recurring-melanoma-vaccine-on-horizon-after-breakthrough-trial/
Internewscast	15.12.2022	Melanoma vaccine could be 'penicillin moment' for cancer treatment https://internewscast.com/news/au/melanoma-vaccine-could-be-penicillin-moment-for-cancer-treatment/
Starts at 60	15.12.2022	Melanoma vaccine trial shows 'highly encouraging' results in improving patient outcomes https://starts60.com/media/health/melanoma-vaccine-trial-shows-highly-encouraging-results-in-improving-patient-outcomes
Port Lincoln Times	15.12.2022	Melanoma vaccine using mRNA technology on the horizon https://www.portlincolntimes.com.au/story/8019810/another-leap-forward-recurring-melanoma-vaccine-on-horizon-after-breakthrough-trial/ The article was also published in - The Muswellbrook Chronicle, Goulburn Post, The Daily Advertiser, The Transcontinental, The Murray Valley Standard, Merimbula News Weekly, Harden Express, The Queanbeyan Age, The Scone Advocate, Blue Mountains Gazette, The Flinders News, The Standard, The Narooma News, The Jimboomba Times, Namoi Valley Independent, Cootamundra Herald, The Braidwood Times
The Daily Telegraph	14.12.2022	Vaccine nearly halves melanoma deaths https://ausprint.meltwater.com/print_clip_previewer/420427371?text=on&keyword=on&pdf=new
The Australian	14.12.2022	Vaccine cuts risk of new melanomas https://ausprint.meltwater.com/print_clip_previewer/420416555?text=on&keyword=on&pdf=new
Head Topics Australia	14.12.2022	Moderna develops melanoma vaccine https://headtopics.com/au/moderna-develops-melanoma-vaccine-32843677
Head Topics Australia	14.12.2022	Major breakthrough in skin cancer treatment https://headtopics.com/au/major-breakthrough-in-skin-cancer-treatment-32848044
Daily Telegraph	14.12.2022	Latest Aussie science victory is great for us https://ausprint.meltwater.com/print_clip_previewer/420416445?text=on&keyword=on&pdf=new
The Advertiser	14.12.2022	Hope for new skin cancer 'vaccine' https://ausprint.meltwater.com/print_clip_previewer/420415845?text=on&keyword=on&pdf=new
Daily Telegraph	14.12.2022	Drug busts melanoma https://ausprint.meltwater.com/print_clip_previewer/420419683?text=on&keyword=on&pdf=new
The Herald Sun	14.12.2022	Cancer vaccine win https://ausprint.meltwater.com/print_clip_previewer/420426269?text=on&keyword=on&pdf=new
Geelong Advertiser	14.12.2022	Cancer vaccine breakthrough https://ausprint.meltwater.com/print_clip_previewer/420436477?text=on&keyword=on&pdf=new
Brisbane Times	01.12.2022	"Australians are obsessed" : TikTok announces ban on tanning videos https://www.brisbanetimes.com.au/culture/celebrity/australians-are-obsessed-tiktok-announces-ban-on-tanning-videos-20221129-p5c28l.html
Sydney Morning Herald	01.12.2022	TikTok slaps prohibition on tanning videos https://ausprint.meltwater.com/print_clip_previewer/418721305?text=on&keyword=on&pdf=new
Canada Today	01.12.2022	TikTok bans videos promoting sunburn and tanning after alarm from medical experts

		https://canadatoday.news/ca/tiktok-bans-videos-promoting-sunburn-and-tanning-after-alarm-from-medical-experts-169402/
Indian Express	01.12.2022	As TikTok bans videos encouraging sunburn and tanning, experts share how they damage the skin https://indianexpress.com/article/lifestyle/life-style/tiktok-bans-videos-encouraging-sunburn-tanning-8300012/
The Australian	28.09.2022	Olympic star Cate Campbell reveals melanoma found after chat at brunch https://www.theaustralian.com.au/breaking-news/olympic-star-cate-campbell-reveals-devastating-diagnosis/news-story/32aff36e380b066f60d3755ed67ef5ec?btr=becc3dc7b2854e55622783a1584b101a This article was also published in – News.com.au, Bunbury Herald, North West Telegraph, PerthNow, The Herald Sun, The Courier Mail, Cairns Post, Townsville Bulletin, The Mercury
WA Today	23.09.2022	Melanoma Patients; diet patterns ‘linked to success of treatment’ https://www.watoday.com.au/lifestyle/health-and-wellness/melanoma-patients-diet-patterns-linked-to-success-of-treatment-20220923-p5bkma.html
9News	23.09.2022	Diet Patterns linked to success in immunotherapy for melanoma, research finds https://www.9news.com.au/national/australia-research-links-diet-patterns-gut-flora-to-how-patient-responds-to-immunotherapy-for-melanoma/b3c350d4-ccae-4cd2-be30-1b0ffd589c6d
The Sydney Morning Herald	22.09.2022	Sport has skin in the game: cancer experts https://ausprint.meltwater.com/print_clip_previewer/409397560?text=on&keyword=on&pdf=new
180gadgets	22.09.2022	Melanoma Prevention: calls for influencers to promote sun safety https://180gadgets.com/melanoma-prevention-calls-for-influencers-to-promote-sun-safety-sbs-news/
The Toys Matrix	21.09.2022	Olympic Star Cate Campbell reveals devastating diagnosis https://toysmatrix.com/olympic-star-cate-campbell-reveals-devastating-diagnosis/ The article was also published in – Broome Advertiser, Great Southern Herald, The West Australian, The Advertiser, Gold Coast Bulletin, The Daily Telegraph, The weekly Times, Geelong Advertiser, The Toowoomba Chronicle
The West Australian	21.09.2022	Olympic star calls for melanoma campaign https://thewest.com.au/news/health/olympic-star-calls-for-melanoma-campaign This article was also published in – Great Southern Herald, Bunbury Herald, Kimberley Echo, North West Telegraph, Daily Mail, Perth Now, The Daily Advertiser, The Cessnock Advertiser, The Northern Daily Leader, Yass Tribune, The Singleton Argus, The Inverell Times, Port Lincoln Times, Hawkesbury Gazette, Border Chronicle, Busselton-Dunsborough Mail, Milton Ulladulla Times, Namoi Valley Independent, Goulburn Post, Harden Murrumburrah Express
The Australian	21.09.2022	Melanoma Institute urges influences to stop glamorizing tanning https://www.theaustralian.com.au/the-oz/news/influencers-urged-to-stop-glamorising-sunburn/news-story/d3f721cd36f47f665b3894bbbce64eb?btr=eaf8b13f054ea10ba6d09e0ceaf038c7
WA Today	21.09.2022	Medical Experts call on sports to reduce melanoma risks https://www.watoday.com.au/lifestyle/health-and-wellness/medical-experts-call-on-sports-to-reduce-melanoma-risks-20220919-p5bj9d.html
News Azi		https://newsazi.com/medical-experts-call-on-sports-to-reduce-melanoma-risks/
Sanidad	23.06.2022	Pembrolizumab yields positive results in patients with stage IIB melanoma and IIC avoiding recurrences and distant metastases

		https://isanidad.com/219225/pembrolizumab-arroja-resultados-positivos-pacientes-melanoma-estadio-iib-iic-evitando-recurrencias-metastasis-distancia/
Nine News	23.06.2022	“Check your skin” 2GB radio personality Ray Hadley opens up about recent cancer scare https://www.9news.com.au/national/2gb-radio-personality-ray-hadley-opens-up-about-recent-cancer-scare/2b612569-d3bb-4917-af99-24bd5028017b
Health Industry Hub	08.06.2022	Australian dermatologists reveal new frontier in melanoma treatment https://www.healthindustryhub.com.au/pharmaceutical-news-trends/australian-dermatologists-reveal-new-frontier-in-melanoma-treatment/
Healio	06.07.2022	Adjuvant pembrolizumab shows benefit in patients with resected stage IIB, IIC melanoma https://www.healio.com/news/hematology-oncology/20220606/adjuvant-pembrolizumab-shows-benefit-in-patients-with-resected-stage-iib-iic-melanoma
Doctors Lounge	21.03.2022	Update shows Relatlimab+Nivolumab slows advanced Melanoma https://www.doctorslounge.com/index.php/news/pb/108133
Medical Xpress		https://medicalxpress.com/news/2022-03-relatlimab-nivolumab-advanced-melanoma.html
Cure 20	20.03.2022	FDA approves Opdualag, a new fixed-dose combination treatment, for certain patients with skin cancer https://www.curetoday.com/view/fda-approves-opdualog-a-new-fixed-dose-combination-treatment-for-certain-patients-with-skin-cancer
Globe World News Echo	17.03.2022	The minor body changes that led an Aussie mum to discover cancer diagnosis https://globeecho.com/news/australia/the-minor-body-changes-that-led-an-aussie-mum-to-discover-cancer-diagnosis/
Cure 20	17.03.2022	Opdivo-based combo continues to improve survival outcomes in previously untreated patients with metastatic or unresectable melanoma https://www.curetoday.com/view/opdivo-based-combo-continues-to-improve-survival-outcomes-in-previously-untreated-patients-with-metastatic-or-unresectable-melanoma
My Weekly Preview	03.03.2022	Melanoma March Meltwater Outside Insight
9 News	09.02.2022	Melanoma to cost Australia \$8.7 billion without “critical action” https://www.9news.com.au/national/new-report-calls-for-urgent-government-action-to-tackle-the-growing-impact-of-melanoma/a1060b3e-c468-45fb-8cbb-666630c42a1d
Franklin Women	31.01.2022	Career Blog – Georgina Long https://franklinwomen.com.au/georgina-long/
The Courier-Mail	17.12.2021	Sprint on to beat cancer Meltwater Outside Insight
My Weekly Preview	05.11.2021	Pandemic melanoma crisis https://www.myweeklypreview.com.au/news/pandemic-melanoma-crisis/
SBS News	31.10.2021	Fears of post-pandemic skin cancer crisis in Australia https://www.sbs.com.au/news/fears-of-post-pandemic-skin-cancer-crisis/aadafabb-9970-4486-a85f-583a6d3de25e
The News Network		https://timesnewsnetwork.com/news/world/australia/fears-of-post-pandemic-skin-cancer-crisis-in-australia/
Times News Express		https://timesnewsxpress.com/news/world/australia/fears-of-post-pandemic-skin-cancer-crisis-in-australia/
Australian Online News		https://australianonlinenews.com.au/2021/10/31/fears-of-post-pandemic-skin-cancer-crisis-in-australia/
Head topics		

		https://headtopics.com/au/fears-of-post-pandemic-skin-cancer-crisis-in-australia-22340551
7News	31.10.2021	Fears of post-pandemic melanoma crisis https://7news.com.au/lifestyle/health-wellbeing/fears-of-post-pandemic-melanoma-crisis-c-4376850
Jimboomba Times		https://www.jimboombatimes.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
Sound Telegraph		https://www.soundtelegraph.com.au/news/health/fears-of-post-pandemic-melanoma
Northern Rivers Review		https://www.northernriversreview.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/?cs=9676
Blue Mountains Gazette		https://www.bluemountainsgazette.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
The Young Witness		https://www.youngwitness.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
Wellington Times		https://www.wellingtontimes.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
Goondwindi Argus		https://www.goondwindiargus.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
Newcastle Herald		https://www.newcastleherald.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/
Canberra Times		https://www.canberratimes.com.au/story/7491093/fears-of-post-pandemic-melanoma-crisis/ This article was also published with the following papers under copyright The Northern Daily Leader, St George & Sutherland Shire Leader, Gloucester Advocate, Whyalla News, Liverpool City Champion, SBS, Seymour Telegraph, The Corowa Free Press, Redland City Bulletin, Daily Mail, The West Australian, Perth Now, Moree Champion, Port Lincoln Times, The Islander, Bay Post, Camden Haven Courier, Bendigo Advertiser, Tenterfield Star, Southern Cross, Inverell Times, The Advocate, Bunbury Mail, Blayney Chronicle, The Macleay Argus and Coastal Leader
Sydney News Today	31.10.2021	Fear of melanoma crisis after pandemic https://sydneynewstoday.com/fear-of-melanoma-crisis-after-pandemic/405455/
Medical Republic	11.10.2021	Treatment shift for Stage II Melanoma https://medicalrepublic.com.au/treatment-shift-for-stage-ii-melanoma/55424
Nine.com.au	26.09.2021	Terminally ill man's plea for Australians to get their skin checked https://honey.nine.com.au/latest/skin-cancer-signs-and-symptoms-terminally-ill-man-advice/e42ed2a4-beb2-423e-b973-8bba579331ea
Shepparton News	20.09.2021	Hope for melanoma patients https://ausprint.meltwater.com/print_clip_previewer/348632261
The Singapore Time	19.09.2021	Australian researchers breakthrough in melanoma treatment https://www.thesingaporetime.com/australian-researchers-breakthrough-in-melanoma-treatment/
Sydney News Today	19.09.2021	New Hope for Early Melanoma Patients https://sydneynewstoday.com/new-hope-for-early-melanoma-patients/352908/

From Press		https://pressfrom.info/au/lifestyle/health/-442795-new-hope-for-early-stage-melanoma-patients.html
Seymour Telegraph	20.09.2021	https://www.seymourtelegraph.com.au/national/2021/09/19/5206844/new-hope-for-early-stage-melanoma-patients
McIvor Times		http://www.mcivortimes.com.au/national/2021/09/19/5206800/new-hope-for-early-stage-melanoma-patients
Cowra Free Press		https://www.corowafreepress.com.au/national/2021/09/19/5206795/new-hope-for-early-stage-melanoma-patients
Daily Mail		https://www.dailymail.co.uk/wires/aap/article-10005721/New-hope-early-stage-melanoma-patients.html
Sound Telegraph		https://www.soundtelegraph.com.au/news/health/new-hope-for-early-stage-melanoma-patients-c-4005937
The West Australian		https://thewest.com.au/news/health/new-hope-for-early-stage-melanoma-patients-c-4005937
Perth Now		https://www.perthnow.com.au/news/health/new-hope-for-early-stage-melanoma-patients-c-4005934
Forbes Alert	19.09.2021	Australian researchers make melanoma treatment breakthrough https://forbesalert.com/news/world/australia/australian-researchers-make-melanoma-treatment-breakthrough/
Scienmag	18.09.2021	Immunotherapy drug benefits patients with high-risk local melanomas https://scienmag.com/immunotherapy-drug-benefits-patients-with-high-risk-local-melanomas/
Newsfallout.com	18.09.2021	New hope for early-stage melanoma sufferers https://newsfallout.com/country-news/australia/new-hope-for-early-stage-melanoma-sufferers/
Bioengineer.org	18.09.2021	Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma https://bioengineer.org/adjuvant-immunotherapy-prolongs-recurrence-free-survival-in-resected-stage-ii-b-c-melanoma/
Campus Morning Mail	17.09.2021	Georgina Long wins the Australian Academy of Health and Medical Sciences Outstanding Female Researcher Medal https://campusmorningmail.com.au/news/appointments-achievements-339/
The National Tribune	14.09.2021	Sydney awarded \$61 million for health research https://www.nationaltribune.com.au/sydney-awarded-61-million-for-health-research/
Health Industry Hub	07.06.2021	Australian researchers lead world in trial of novel melanoma treatment https://www.healthindustryhub.com.au/pharmaceutical-news-trends/australian-researchers-lead-world-in-trial-of-novel-melanoma-treatment/
Infosurhoy		https://infosurhoy.com/health/new-immunotherapy-drug-effective-for-melanoma-other-cancers.html
Medical Xpress	03.06.2021	New Immunotherapy drug effective for melanoma, other cancers https://medicalxpress.com/news/2021-06-immunotherapy-drug-effective-melanoma-cancers.html
InQueensland	03.06.2021	Melanoma “miracle” might pave the way for more cancer breakthroughs https://inql.com.au/news/2021/06/03/melanoma-miracle-might-pave-the-way-for-more-cancer-breakthroughs/

Health Times	03.06.2021	Australian researchers discovered a miracle drug for melanoma https://healthtimes.com.au/hub/oncology/4/news/aap/australian-researchers-discovered-a-miracle-drug-for-melanoma/5898/
Oncology News	03.06.2021	ASCO 2021: Australian researchers and patients lead world in successful new melanoma trial https://oncologynews.com.au/asco-2021-australian-researchers-and-patients-lead-world-in-successful-new-melanoma-trial/
Seymour Telegraph	03.06.2021	“Miracle” drug for melanoma identified https://www.seymourtelegraph.com.au/national/2021/06/03/4368027/miracle-drug-for-melanoma-identified
Jimbooma Times		https://www.jimboomatimes.com.au/story/7281734/miracle-drug-for-melanoma-identified/
The McIvor Times		http://www.mcivortimes.com.au/national/2021/06/03/4368012/miracle-drug-for-melanoma-identified
Daily Mail		https://www.dailymail.co.uk/wires/aap/article-9646577/Miracle-drug-melanoma-identified.html
This is money.co.uk		https://www.thisismoney.co.uk/wires/aap/article-9646577/Miracle-drug-melanoma-identified.html
MSN		https://www.msn.com/en-au/health/medical/miracle-drug-for-melanoma-identified/ar-AAKEdU9
7News.com		https://7news.com.au/lifestyle/health-wellbeing/miracle-drug-for-melanoma-identified-c-3003352
Perth Now		https://www.perthnow.com.au/news/health/miracle-drug-for-melanoma-identified-c-3003349
The Standard		https://www.standard.net.au/story/7281734/miracle-drug-for-melanoma-identified/
Liverpool City Champion		https://www.liverpoolchampion.com.au/story/7281734/miracle-drug-for-melanoma-identified/
Fairfield City Champion		https://www.fairfieldchampion.com.au/story/7281734/miracle-drug-for-melanoma-identified/
Cootamundra Herald		https://www.cootamundraherald.com.au/story/7281734/miracle-drug-for-melanoma-identified/
Yass Tribune		https://www.yasstribune.com.au/story/7281734/miracle-drug-for-melanoma-identified/
Coly Point Observer		https://www.colypointobserver.com.au/story/7281734/miracle-drug-for-melanoma-identified/
PressFrom		https://pressfrom.info/au/lifestyle/health/-394450-miracle-drug-for-melanoma-identified.html
Medical Republic	07.04.2021	New treatment regime saving lives in melanoma https://medicalrepublic.com.au/new-treatment-regime-saving-lives-in-melanoma/42972?utm_source=TMR%20List&utm_campaign=c1a164e14e-

		Newsletter April 07 04 21&utm_medium=email&mc_cid=c1a164e14e&mc_cid=73f9c29fe4
Port News	11.02.2021	Ryan Channells now working with Melanoma Institute Australia to raise awareness about melanoma after overcoming stage four https://www.portnews.com.au/story/7121586/ground-breaking-treatment-saves-channels-life-in-battle-with-cancer/?cs=12
Redland City Bulletin	14.02.2021	https://www.redlandcitybulletin.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/
Beauesert Times		https://www.beaueserttimes.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/
Jimboomba Times		https://www.jimboombatimes.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/
Hunter Valley News		https://www.huntervalleynews.net.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
The Canberra Times		https://www.canberratimes.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/
Western Magazine		https://www.westernmagazine.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9397
The Advocate – Hepburn		https://www.hepburnadvocate.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
The Young Witness		https://www.youngwitness.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Liverpool City Champion		https://www.liverpoolchampion.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Manning River Times		https://www.manningrivertimes.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9397
Gloucester Advocate		https://www.gloucesteradvocate.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Moree Champion		https://www.moreechampion.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Goulburn Post		https://www.goulburnpost.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Blue Mountains Gazette		https://www.bluemountainsgazette.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
Forbes Advocate		https://www.forbesadvocate.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
The Northern Daily Leader		https://www.northerndailyleader.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676
The Advertiser Lake Times		https://www.advertiserlake.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676

Barossa Herald Grenfell Record Illawarra Mercury		https://www.advertiserlaketimes.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/ https://www.barossaheald.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/ https://www.grenfellrecord.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/?cs=9676 https://www.illawarramercury.com.au/story/7123755/ground-breaking-treatment-saves-fireys-life-in-battle-with-cancer/
Archyde.com	10.02.2021	Immunotherapy before surgery limits the risk of relapse https://www.archyde.com/immunotherapy-before-surgery-limits-the-risk-of-relapse/
My Healthy Click	09.02.2021	New treatment found effective in preventing spread of Melanoma, Study https://www.myhealthyclick.com/new-treatment-found-effective-in-preventing-spread-of-melanoma-study/
Your Life Choices	09.02.2021	New melanoma treatment a game-changer in cancer therapy https://www.yourlifechoices.com.au/health/news-health/new-melanoma-treatment-a-game-changer-in-cancer-therapy/
Yerepouni News	09.02.2021	Melanoma breakthrough: New treatment saving lives https://www.yerepouni-news.com/2021/02/09/melanoma-breakthrough-new-treatment-saving-lives/
ABC Diseases	09.02.2021	Melanoma, the order of the factors does alter survival https://www.abc.es/salud/enfermedades/abci-melanoma-orden-factores-si-altera-supervivencia-202102091157_noticia.html
Nine News Up News Info	09.02.2021	Revolutionary melanoma treatment offers new lease on life https://www.9news.com.au/national/melanoma-treatment-huge-advance-australia/88d16605-6f6c-4644-8a78-a2b33f482de1 https://upnewsinfo.com/2021/02/09/revolutionary-melanoma-treatment-offers-new-lease-on-life/
Sydney Morning Herald The Age Brisbane Times WA Today Internews Cast	09.02.2021	Feeling “So lucky” to be alive after melanoma game-changer https://www.smh.com.au/national/feeling-so-lucky-to-be-alive-after-receiving-new-melanoma-treatment-20210205-p56zw0.html https://www.theage.com.au/national/feeling-so-lucky-to-be-alive-after-receiving-new-melanoma-treatment-20210205-p56zw0.html https://www.brisbanetimes.com.au/national/feeling-so-lucky-to-be-alive-after-receiving-new-melanoma-treatment-20210205-p56zw0.html https://www.watoday.com.au/national/feeling-so-lucky-to-be-alive-after-receiving-new-melanoma-treatment-20210205-p56zw0.html https://internewscast.com/feeling-so-lucky-to-be-alive-after-receiving-new-melanoma-treatment/
EXBulletin	08.02.2021	Breakthrough in Melanoma: A new Life-Saving treatment https://exbulletin.com/world/health/726474/
ABC News	15.12.2020	Melanoma patient Stuart Taylor told he is unlikely to live until Christmas https://www.abc.net.au/news/2020-12-15/melanoma-patient-told-he-is-unlikely-to-live-until-christmas/12985378
Surf Coast Times	15.12.2020	Major award for melanoma researchers

		https://timesnewsgroup.com.au/surfcoasttimes/living/major-award-for-melanoma-researchers/
Financial Review	21.12.2019	How the decade's biggest health breakthrough saved a US President https://www.afr.com/life-and-luxury/health-and-wellness/how-the-decade-s-biggest-health-breakthrough-saved-a-us-president-20191216-p53kkf
Cure Today	10.12.2019	The Future of Novel Immunotherapy Combinations in Melanoma https://www.curetoday.com/view/the-future-of-novel-immunotherapy-combinations-in-melanoma
Northshore Living	01.10.2019	On the Medical Frontier https://www.thinklocal.com.au/thmagazines/north-shore-living-october-2019 (page 32 & 33)
Retail Pharmacy	30.08.2019	Australia risks falling behind in melanoma prevention https://retailpharmacymagazine.com.au/australia-risks-falling-behind-in-melanoma-prevention/
Medical Journal of Australia	08.06.2020	Happy Birthday Honours List https://www.mja.com.au/journal/2020/213/1/happy-birthday-honours-list
Illawarra Mercury	23.02.2019	Picton mother Melissa Tague shares story of melanoma battle https://www.illawarramercury.com.au/story/5920408/melissas-shock-diagnosis-after-she-found-a-strange-lump-in-her-groin/
Women Love Tech	04.01.2019	One Generation Away from Zero Melanoma Deaths https://womenlovetech.com/one-generation-away-from-zero-melanoma-deaths/
Daily Telegraph	26.12.2018	All Aussies should have access to this life saver https://www.melanoma.org.au/news-events/news/all-aussies-should-have-access-to-this-lifesaver/
Sutherland Shire	14.11.2018	Sutherland Shire melanoma patient undergoing clinical trial for innovative treatment https://www.theleader.com.au/story/5757259/working-towards-zero-deaths-by-exposing-innovative-treatments-into-melanoma/
Sydney Morning Herald	03.11.2018	How Georgina is driving down one cancer's death rate down to zero https://www.smh.com.au/national/nsw/how-georgina-is-driving-one-cancer-s-death-rate-down-to-zero-20181102-p50dmc.html
SBS News	14.03.2018	Marching towards zero deaths from melanoma https://www.sbs.com.au/news/marching-towards-zero-deaths-from-melanoma
Victor Harbor Times		https://www.victorharbortimes.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=9397
Bega District News		https://www.begadistrictnews.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/
The Examiner		https://www.examiner.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=7
Mandurah Mail		https://www.mandurahmail.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=9676
The Standard		https://www.standard.net.au/story/5284068/marching-towards-zero-deaths-from-melanoma/
Bunbury Mail		https://www.bunburymail.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=27
The Advocate		https://www.theadvocate.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=9397

Wollondilly Advertiser		https://www.wollondillyadvertiser.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=9676
Northwest Star		https://www.northweststar.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/
Bendigo Advertiser		https://www.bendigoadvertiser.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=27
Campbelltown Macarthur Advertiser		https://www.macarthuradvertiser.com.au/story/5284068/marching-towards-zero-deaths-from-melanoma/?cs=9676
9News Health	11.09.2017	New therapies stop melanoma from spreading https://www.9news.com.au/health/melanoma-stopped-from-spreading-in-trials/4dd30d82-c1d8-41ff-a508-66230ee27814
Financial Review		https://afr.com/companies/healthcare-and-fitness/new-therapies-stop-melanoma-spreading-20170911-gyfai6
Daily Telegraph	17.06.2015	Women warriors fighting a deadly disease nominate for Pride of Australia https://www.dailytelegraph.com.au/news/pride-of-australia/women-warriors-fighting-a-deadly-disease-nominated-for-pride-of-australia/news-story/09e1694a3b579e66eb92bf1903c3c7e5
Herald Sun	04.02.2015	New drug to be trialled on melanoma patients in world first https://www.heraldsun.com.au/news/victoria/new-drug-to-be-trialled-on-melanoma-patients-in-world-first/news-story/b6a91faeac34da6477b3403b52f21281
Medical Xpress	08.10.2012	New drug shrinks brain tumours in melanoma patients https://medicalxpress.com/news/2012-10-drug-brain-tumours-melanoma-patients.html
The Health Safari	20.07.2012	Extending survival: powerful late-stage melanoma treatment to be considered for PBS http://www.thehealthsafari.com/blog2012july-extending-survival.html
AFR Boss (Financial Review)	June 2012	The scientific researcher: a team effort

Radio (including but not limited to)

Radio Show	Date	Link (if available)
2CC Talking Canberra	14.12.2022	Moderna melanoma vaccine This was also used under licence with @GB, 2PM, 2SM, 666 ABC, 720 ABC Perth, 891 ABC Adelaide, 4RO, ABC Alice Springs, ABC Broken Hill, ABC Capricornia FM, ABC Esperance, ABC Far North Queensland, ABC Goldfields, ABC Great Southern WA, ANC Kimberley, ABC Late News, ABC National News, ABC New England, ABC Darwin, ABC Hobart, ABC Melbourne, ABC North and West SA, ABC North Queensland, ABC North West WA, ABC Riverland, ABC South East SA, ABC Southern Queensland, ABC Sunshine Coast, ABC Tropical North, ABC West Coast, ABC Western Queensland, ABC Wide Bay, ABC New England, 2HD, GIVEaa, 10 Brisbane
ABC Melbourne	14.12.2022	Personalised vaccine trial for melanomas hailed a breakthrough https://www.abc.net.au/melbourne/programs/mornings/melanoma-vaccine/101770552

6PR	14.12.2022	New melanoma vaccine hailed as cancer's penicillin moment https://www.6pr.com.au/new-melanoma-vaccine-hailed-as-cancers-penicillin-moment/
Mike & Emma	30.09.2022	https://omny.fm/shows/mike-e-emma/m-e-professor-long-melanoma-institute
2GB	23.06.2022	Ray Hadley reveals recent melanoma scare as new cancer tech emerges https://www.2gb.com/ray-hadley-reveals-recent-melanoma-scare-as-new-cancer-tech-emerges/
2GB, 2CC, 4BC, 990, ABC, 2GN, 1152	01.03.2022	Melanoma March
1053	09.02.2022	State of the Nation media release This was also used under licence with following stations: 2CA Canberra, 1233 ABC Newcastle, 2BS, 2CC, 2EC, 2GB, 2UE, 3AW, 4MK, 612 ABC, 666, 702, 91.7, 981, ABC 24m ABC Centre Coast, ABC Far North Queensland, ABC Illawarra, ABC North West Queensland, ABC Radio National, ABC Southern Queensland, ABC Sunshine Coast, ABC Upper Hunter, ABC Western Queensland, ABC Wide Bay, Eagle FM, Forever Classic, Gold Central Victoria, Hot 100Fm, Mix 104.9, Power FM Bega, Power FM Nowra, Radio 2ST, River 1467, Southern Cross Port Lincoln,
WSFM,	11.11.2021	COVID restrictions deterred people from seeking treatment This was also used under licence with following stations: ABC Newcastle, 4KQ, 612 ABC Brisbane, 666 ABC Canberra, 702 ABC Sydney, 891 ABC Adelaide, 91.7 ABC Coast FM, 936 ABC Hobart, 97.3FM, ABC Alice Springs, ABC Ballarat, ABC Broken Hill, ABC Capricornia FM, ABC Central Victoria, ABC Great Southern WA, ABC Illawarra, ABC Kimberley, ABC Mid West and Wheatbelt, ABC Mildura, ABC New England, ABC North and West SA, ABC North Coast NSW, ABC Northern Tasmania, ABC North Queensland, ABC South East NSW, ABC Sunshine Coast, ABC Tropical North, ABC Upper Hunter, ABC West Coast SA, ABC Western Plains, ABC West Victoria, ABC Wide Bay, Cruise 1323, Gold 104.3, Mix 102.3
ABC Radio National Drive	10.11.2021	When was the last time you got a skin check? https://www.abc.net.au/radionational/programs/drive/when-was-the-last-time-you-got-a-skin-check/13625474
2CC Talking Canberra	20.09.2021	Breakthrough in melanoma treatment
2CA Canberra,	03.06.2021	Australian researchers discovered a miracle drug for melanoma This was also used under licence with following stations: 2BS, 2CC, 2GB, 2SM, 2UE, 3AW, 4BC, 4BU, 4CA, 4MK, 5AU, 5CC, 5CS, 5RM, 6PR, 981, 990, ABC, Forever Classic, Gold Central, Imparja Bull, NBN Coffs Harbour, Newcastle, Port Macquarie, Nine Adelaide, Cairns, Canberra, Central Queensland, Darwin, Mackay, Perth, Riverina, Sunshine Coast, Sydney, Toowoomba, Townsville, Sunshine Coast, WideBay, 2ST
ABC Radio National	09.02.2021	https://www.abc.net.au/radionational/programs/breakfast/new-study-drug-therapy-melanoma/13134858
Alan Jones Breakfast Show	03.04.2019	https://omny.fm/shows/the-alan-jones-breakfast-show/professor-georgina-long-co-medical-director-melano
Triple MMM	11.09.2019	Huge Melanoma Breakthrough Could Save Lives

		https://www.triplem.com.au/story/huge-melanoma-breakthrough-will-save-lives-56618
Other interviews (but not limited to) BBC, ABC, 2GB,		

Oncology education programs and interviews (regular invitee) & Podcasts

Channel	Date	Story/Link
Melanoma Institute Australia	13.04.2023	WA Update – The Game Changer, Neoadjuvant Therapy & Early Melanoma
Melanoma Institute Australia	14.03.2023	Neoadjuvant immunotherapy: Revolutionising melanoma treatment https://melanomaeducation.org.au/courses/melanoma183/
Melanoma Institute Australia	04.11.2022	Diagnosis and management of uveal melanoma https://melanomaeducation.org.au/courses/melanoma176/
OncLive	21.10.2022	Adjuvant Nivolumab Reduces Risk of Recurrence or Death by 58% in Select Stage IIB or IIC Melanoma https://www.onclive.com/view/adjuvant-nivolumab-reduces-risk-of-recurrence-or-death-by-58-in-select-stage-iib-or-iic-melanoma
Cancer Network	22.10.2022	Adjuvant Nivolumab demonstrates reduced risk of death or recurrence vs placebo in stage IIB/C Melanoma https://www.cancernetwork.com/view/adjuvant-nivolumab-demonstrates-reduced-risk-of-death-or-recurrence-vs-placebo-in-stage-iib-c-melanoma
The ASCO Post	13.09.2022	Findings on circulating tumor DNA, disease recurrence, and immunotherapy https://ascopost.com/videos/esmo-congress-2022/georgina-long-on-melanoma-findings-on-circulating-tumor-dna-disease-recurrence-and-immunotherapy/
Touch Oncology	13.09.2022	CheckMate 915 study – the use of ctDNA as a biomarker for predicting outcomes for adjuvant melanoma https://touchoncology.com/melanoma/conference-hub/georgina-long-esmo-2022-checkmate-915-study-the-use-of-ctdna-as-a-biomarker-for-predicting-outcomes-for-adjuvant-melanoma/
Touch Oncology	13.09.2022	Highlights in melanoma – SWOG S1801 trial investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma https://touchoncology.com/melanoma/conference-hub/prof-georgina-long-esmo-2022-highlights-in-melanoma-swog-s1801-trial-investigating-neoadjuvant-versus-adjuvant-pembrolizumab-for-resected-stage-iii-iv-melanoma/
VJ Oncology	10.09.2022	Pre-treatment ctDNA linked to increased risk of early recurrence in IO-treated melanoma https://www.vjoncology.com/video/_qc4quh1lc0-pre-treatment-ctdna-linked-to-increased-risk-of-early-recurrence-in-io-treated-melanoma/
OncLive	20.08.2022	Evaluating Adjuvant Pembrolizumab vs Placebo in Melanoma https://www.onclive.com/view/dr-long-on-evaluating-adjuvant-pembrolizumab-vs-placebo-in-melanoma
The ASCO Post	17.06.2022	Distant Metastasis–Free Survival With Adjuvant Pembrolizumab

		https://ascopost.com/videos/2022-asco-annual-meeting/georgina-long-on-melanoma-distant-metastasis-free-survival-with-adjuvant-pembrolizumab/
The ASCO Post	17.06.2022	Melanoma: New Data on Pembrolizumab, Dabrafenib, and Trametinib https://ascopost.com/videos/2022-asco-annual-meeting/georgina-long-on-melanoma-new-data-on-pembrolizumab-dabrafenib-and-trametinib/
Oncology Tube	17.06.2022	ASCO 2022: Phase 3 KEYNOTE-716 study https://oncologytube.com/video/41070/podcast-prof-georgina-long-prof-longmia-melanoma-aus-sydcancernetwork-nthsydhealth-asco22-oncotwitter-oncoalert-phase-3-keynote-716-study?channelName=AnnualCancerMeeting#gsc.tab=0
OncLive	07.06.2022	Nivolumab plus relatlimab demonstrates sustained PFS benefit in advanced melanoma https://www.onclive.com/view/nivolumab-plus-relatlimab-demonstrates-sustained-pfs-benefit-in-advanced-melanoma
OncLive	06.06.2022	Adjuvant pembrolizumab results in significant DMFS improvement over placebo in Stage II melanoma https://www.onclive.com/view/adjuvant-pembrolizumab-results-in-significant-dmfs-improvement-over-placebo-in-stage-ii-melanoma
The ASCO Post	04.06.2022	New data on pembrolizumab, dabrafenib and trametinib https://ascopost.com/videos/2022-asco-annual-meeting/georgina-long-on-melanoma-new-data-on-pembrolizumab-dabrafenib-and-trametinib/
The ASCO Post	04.06.2022	Distant metastasis-free survival with adjuvant pembrolizumab https://ascopost.com/videos/2022-asco-annual-meeting/georgina-long-on-melanoma-distant-metastasis-free-survival-with-adjuvant-pembrolizumab/
Melanoma Institute Australia	13.05.2022	Melanoma Insights for Professionals https://melanomaeducation.org.au/courses/melanoma149/
OncLive	17.03.2022	Relatlimab/Nivolumab Combo Continues to Impress in Previously Untreated Metastatic or Unresectable Melanoma https://www.onclive.com/view/relatlimab-nivolumab-combo-continues-to-impress-in-previously-untreated-metastatic-or-unresectable-melanoma
ASCO Post	16.03.2022	Immunotherapy Duo Delays Disease Progression in Previously Untreated Patients With Melanoma: RELATIVITY-047 https://ascopost.com/news/march-2022/immunotherapy-duo-delays-disease-progression-in-previously-untreated-patients-with-melanoma-relativity-047/
Melanoma Institute Australia Education portal	04.02.2022	The evolving paradigm shift in melanoma https://melanomaeducation.org.au/courses/melanoma133/
Melanoma & Skin Cancer Advocacy Network	17.12.2021	Patient stories: Diagnosed with advanced melanoma https://mscan.org.au/learning-hub/podcasts/series-2-the-patient-story/8-patient-stories-diagnosed-with-advanced-melanoma/
High5oncology	22.09.2021	MASTERKEY-265 Pembrolizumab +/- T-VEC My ESMO highlights https://high5oncology.tv/en/esmo-2021/?al=1/#c2543
Melanoma Institute Australia	12.08.2021	Early Stage Melanoma; Your questions answered https://www.youtube.com/watch?v=SaaF1Nxa2gU
Oncology News (Podcast)	30.07.2021	Melanoma update with Georgina Long https://oncologynews.com.au/the-ojc-episode-44/

ASCO Post	June 2021	ASCO annual meeting – Virtual Abstract presentation Nivolumab plus ipilimumab vs nivolumab alone https://ascopost.com/videos/aacr-annual-meeting-2021/georgina-long-on-melanoma-nivolumab-plus-ipilimumab-vs-nivolumab-alone/
Oncology News	16.04.2021	Neoadjuvant Therapy in Melanoma – podcast https://oncologynews.com.au/the-ojc-29/
Ecancer	13.04.2021	Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma https://ecancer.org/en/video/9680-adjuvant-therapy-with-nivolumab-combined-with-ipilimumab-vs-nivolumab-alone-in-patients-with-resected-stage-iiib-d-iv-melanoma
MIA & MPA Melanoma Symposium Series	21.10.2020	Melanoma treatments and clinical trials https://melanomapatients.org.au/resource/melanoma-treatments-and-clinical-trials/
The Doctor's Channel	28.07.2020	Patients in CheckMate 067 Demonstrate Durable Complete Responses https://www.thedoctorschannel.com/view/patients-in-checkmate-067-demonstrate-durable-complete-responses/
Targeted Oncology	20.05.2020	Patients in CheckMate 067 demonstrate durable complete responses https://www.youtube.com/watch?v=PQBHLcPEess
MIA & MPA Patient Information Evening	01.12.2019	Updates on drug treatments in melanoma https://www.youtube.com/watch?v=YPVxf2Dn0_M
OncoLive	14.11.2019	Rationale for Nivolumab/Ipilimumab in patients with melanoma who have brain mets https://www.onclive.com/view/dr-long-on-rationale-for-nivolumabipilimumab-in-patients-with-melanoma-who-have-brain-mets
OncoLive	05.11.2019	Including patients with melanoma who have brain mets on clinical trials https://www.onclive.com/view/dr-long-on-including-patients-with-melanoma-who-have-brain-mets-on-clinical-trials
OncoLive	22.10.2019	Sequencing local therapy patients with melanoma who have brain mets https://www.onclive.com/view/dr-long-on-sequencing-local-therapy-in-patients-with-melanoma-who-have-brain-mets
VJOncology	29.09.2019	Long-term outcomes of nivo vs nivo/ipi in melanoma brain metastases: ABC trial data https://www.youtube.com/watch?v=ujXRRV8uRD8
OncoLive	12.10.2019	Nivolumab/Ipilimumab in patients with melanoma who have brain mets https://www.onclive.com/view/dr-long-on-nivolumabipilimumab-in-patients-with-melanoma-who-have-brain-mets
OncoLive	28.08.2019	Results of the pooled analysis of the COMBI-I trial in melanoma https://www.onclive.com/view/dr-long-on-the-results-of-the-pooled-analysis-of-the-combii-trial-in-melanoma
OncoLive	26.07.2019	Dabrafenib/Trametinib in BRAF V600E-Mutant Melanoma https://www.onclive.com/view/dr-long-on-dabrafenibtrametinib-in-braf-v600emutant-melanoma
VJOncology	25.06.2019	KEYNOTE-029: pembrolizumab with ipilimumab for melanoma https://www.youtube.com/watch?v=aSeET16TTaQ

CancerNSW	05.11.2018	The most exciting development happening in melanoma research https://www.youtube.com/watch?v=zPSWqUak9e0
CancerNSW	05.11.2018	The most exciting thing I have learnt this year https://www.youtube.com/watch?v=llJIfXgpOII
OncLive	08.08.2017	IDO inhibitors in metastatic melanoma https://www.youtube.com/watch?v=j-1mcPMuySM
OncLive	08.08.2017	Metastatic Melanoma: Clinical pearls from the experts https://www.youtube.com/watch?v=T03TS75iUyk
OncLive	08.08.2017	Novel targeted therapies for metastatic melanoma https://www.youtube.com/watch?v=XGDNbJXBtX0
Sydney LHD	31.07.2018	Melanoma Institute Australia: A flagship for clinical translational research https://www.youtube.com/watch?v=qZX2NgwFI5E
OncLive	27.07.2017	Novel combinations for metastatic melanoma https://www.youtube.com/watch?v=CWXz5E9oV1U
OncLive	26.07.2017	Optimal Treatment of Melanoma at Progression https://www.youtube.com/watch?v=t_bFid7Tx7s
OncLive	14.07.2017	How are you using PD-1 testing in melanoma? https://www.youtube.com/watch?v=HvB8cZj_qeI
OncLive	14.07.2017	Options for NRAS-mutant melanoma https://www.youtube.com/watch?v=6MPeLlFlqcY
OncLive	14.07.2017	New data for immunotherapy in melanoma brain metastases https://www.youtube.com/watch?v=X5xGQpdp9OA
OncLive	14.07.2017	Long-term results for immunotherapy in melanoma https://www.youtube.com/watch?v=zaq1oMnY6sE
OncLive	06.07.2017	Emerging adjuvant and neoadjuvant options for melanoma https://www.youtube.com/watch?v=oZSdAf_u6dY
OncLive	06.07.2017	Dual targeted or immunotherapy for BRAF-Mutant Melanoma https://www.youtube.com/watch?v=KhV1Zyi6r8E
OncLive	06.07.2017	Adjuvant therapy for patients with melanoma https://www.youtube.com/watch?v=7BIXL2A1EKc
OncLive	05.07.2017	Recommendations for resectability in melanoma https://www.youtube.com/watch?v=q_GtNxxdXdU
Targeted Oncology	20.06.2017	Activity of Dabrafenib/Trametinib Combo in Patients With Melanoma Brain Metastases https://www.youtube.com/watch?v=D5dzJgK_Ck0
VJ Oncology	09.06.2017	Immunotherapy updates for melanoma from ASCO 2017 https://www.youtube.com/watch?v=BwfO_hg1H14
Targeted Oncology	05.06.2017	Five-Year OS data for Dabrafenib/Trametinib Combo in Melanoma https://www.youtube.com/watch?v=CkC4a1KhDr0
OncLive	04.02.2017	The future management of melanoma https://www.youtube.com/watch?v=6Ng8qGe-y3I
OncLive	31.01.2017	Neoadjuvant trials in high-risk melanoma https://www.youtube.com/watch?v=qIIInN7vwEOw
OncLive	31.01.2017	T-VEC data in the neoadjuvant setting in melanoma https://www.youtube.com/watch?v=bvgEN-Jxnmw
OncLive	17.01.2017	Melanoma: Nuances of BRAF/MEK Combinations in the front line https://www.youtube.com/watch?v=4nBOF6xHzc4
OncLive	16.01.2017	Post-Surgical Recurrent Melanoma https://www.youtube.com/watch?v=9cE5AuAONDM
OncLive	04.01.2017	Frontline decisions in Stage IV BRAF-mutant melanoma https://www.youtube.com/watch?v=IaIItGM4k80

OncLive	04.01.2017	Sequencing decisions and multidisciplinary care in metastatic melanoma https://www.youtube.com/watch?v=jKNESs-s_4k
OncLive	12.12.2016	Melanoma: Helping patients understand immunotherapy https://www.youtube.com/watch?v=YUjGbVJhkjc
OncLive	13.12.2016	Immunotherapy in melanoma: Managing toxicities https://www.youtube.com/watch?v=FJzuOENBpS0
OncLive	09.12.2016	The current understanding of biomarkers in melanoma https://www.youtube.com/watch?v=F1YBlp3u6NI
OncLive	16.11.2016	Treating Melanoma with Dabrafenib plus Trametinib https://www.youtube.com/watch?v=BeKQeMGgEZc
OncLive	31.08.2016	Multi-Modality Treatment in Basal Cell Carcinoma https://www.youtube.com/watch?v=jLRynjSv8G4
OncLive	25.08.2016	Managing brain metastases and side effects in melanoma https://www.youtube.com/watch?v=gzzbAgECwOQ
OncLive	18.08.2016	Melanoma: BRAF/MEK targeted therapy https://www.youtube.com/watch?v=K-Ivcf_YnNQ
OncLive	05.08.2016	Disease burden and first-line melanoma treatment https://www.youtube.com/watch?v=oL.HhaQCdEzo
OncLive	26.07.2016	Immunotherapy in advanced melanoma https://www.youtube.com/watch?v=ijP2ztMQjHk
OncLive	15.07.2016	Validity of PD-L1 testing in melanoma https://www.youtube.com/watch?v=fq3rGrFuTqM
OncLive	21.11.2015	Dabrafenib and Trametinib in BRAF-Mutated Melanoma https://www.youtube.com/watch?v=vsOwsM5v-vw
EMG-Health	16.11.2015	MASTERKEY-265: Phase 1B/3 trial of T-VEC and pembrolizumab for unresectable stage IIIB-IV melanoma https://www.youtube.com/watch?v=29O515klBtE
ecancer	28.10.2015	Long response and long responders in melanoma immunology https://ecancer.org/en/video/4203-long-response-and-long-responders-in-melanoma-immunology
EMG Health	03.07.2015	COMBI-d: Phase 3 trial of dabrafenib plus trametinib in BRAF V600E/K-mutated melanoma https://www.youtube.com/watch?v=3Z1hSxl9NH0
Targeted Oncology	17.12.2013	Treatment of Melanoma with emerging targeting therapies https://www.youtube.com/watch?v=zJU-waby6rI
The Westmead Medical Institute for Medical Research	23.08.2011	New ways to target melanoma https://www.youtube.com/watch?v=vmkjLOCp6ok

PROFESSIONAL AFFILIATIONS

ASCO Melanoma/Skin Cancers (Plenary Series Scientific Review Committee) Member	Jun 2021-Jun 2024
Scientific Board Member Melanoma World Society	From 2021
European Academy for Tumour Immunology (EATI)	From 2016
Medical Board of Australia, Registered Medical Practitioner (MED 0001186892)	From 2010
New South Wales Medical Board, Registered Medical Practitioner, MPO 338589	2002-2009
Member of the Australia and New Zealand Melanoma Trials Group (ANZMTG)	From 2010
Member of the ANZ Breast Cancer Trials Group Limited (ANZ BCTG)	From 2010
Member of the ANZ Gynaecology Oncology Group	From 2007
Society for Melanoma Research (Nominated for Steering Committee Member for 2014) (President 2018-2020)	From 2009

American Society of Clinical Oncology	From 2006
Medical Oncology Group of Australia	From 2006
European Society of Medical Oncology	From 2010
The Royal Australasian College of Physicians Trainee Committee	From 2005
Royal Prince Alfred Hospital Resident Medical Officers Association (President 2003)	2002-2006
Australian Medical Association	From 1997
Australian Fulbright Association	From 1996
United Kingdom General Medical Council, Registered Medical Practitioner	From 2004
Sydney University Medical Society	1997-2000
Royal Australian Chemical Institute (MRACI)	1992-2005
Sydney University Chemical Society	1992-1996
Sydney University Law Society	1989-1990